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Background: Weight gain, fat gain and loss of lean tissue are common among a growing 
population of breast cancer survivors. These unfavourable changes in body composition are 
distressing for many women and may lead to metabolic disturbance, increased risk of obesity-
related disorders and poorer prognosis. Although data are accumulating on the adverse health 
effects of obesity and weight gain in this population, relationships between acute and chronic 
effects of treatment, dietary change and weight gain after diagnosis are poorly understood.  
Objectives: The purpose of this thesis was to gain an appreciation of the experience of food 
intake and body weight over the treatment trajectory, from the perspective of women who have 
received chemotherapy for breast cancer. Study 1 was designed to explore the unique 
challenges associated with chemotherapy in relation to diet and weight management and to 
investigate possible relationships among psychosocial and treatment-related factors, dietary 
intake and weight gain during treatment. Study 2 was a follow-up to study 1, within the same 
study population. The purpose of study 2 was to investigate relationships among persistent side 
effects of treatment, diet and weight gain since the completion of chemotherapy treatment.  
Methods: Twenty-eight early stage breast cancer survivors, who were within 12 months of 
completing chemotherapy, were recruited from four regions in southwestern Ontario, to 
participate in comprehensive qualitative interviews, identify changes in diet since diagnosis, 
provide 3-day food records and complete validated surveys to assess current (past week) 
symptoms of physical and psychological distress. Demographic, medical, treatment and weight 
history were collected via questionnaire. Current weight was measured at the time of interview.  
Results: The mean weight change during treatment (mean = 15±4 weeks) was +0.8± 4.6 kg 




treatment, the mean weight change was + 5.1 and -5.2 kg, respectively. Based on the recalled 
experiences of women, who were on average 6.4±4.4 months from completing chemotherapy 
treatment, food intake during treatment appears to be highly responsive to treatment day, with 
most women reporting lower food intake and irregular eating patterns for the first few days 
after treatment. Women who lost weight during treatment tended to report more severe and 
persistent side effects of treatment, leading to a more prolonged reduction of food intake after 
each cycle. Increased appetite, food cravings and intake of energy dense comfort foods seemed 
to be more common among women who gained weight during treatment. In these women, 
changes in taste, nausea and emotional distress were central in promoting these dietary 
responses. Most women reported a reduction in physical activity during treatment.  
     The mean weight change from the completion of chemotherapy treatment to the time of 
interview was -0.4± 3.2 kg (range = - 6.0 - +5.2), with six women gaining (mean=3.5 kg) and 
seven women losing (mean=5.1 kg) > 2.0 kg during this time frame. Most women (84%) 
reported changes in diet after diagnosis. Dietary changes were largely consistent with current 
recommendations for cancer prevention, however some women were still above the guidelines 
for total and saturated fat and many were below recommendations for vegetables/fruit and 
milk/alternatives. Based on the EAR cut-point method, the prevalence of inadequate calcium 
and vitamin D intakes from foods was high (47-96%). Although symptoms were highly 
variable, the mean levels of physical and psychological distress in this sample were similar to 
previous reports among early stage breast cancer patients in active treatment and appear to be 
markedly higher than previous reports of distress among cancer-free adults. Fatigue duration 
(proportion of daytime) was negatively correlated with weight change after treatment 




Conclusions: While the etiology of weight change in this population is complex, findings from 
this study suggest that food intake and dietary patterns may play an important role for some 
women. A theoretical model based on qualitative analysis supports several pathways by which 
psychosocial factors and treatment-related side effects might influence diet and eating patterns 
in ways that promote weight change during treatment. Relatively high levels of physical and 
psychological distress after treatment suggest that these symptoms may persist for many breast 
cancer survivors in the first year after completing chemotherapy, and may associate with 
weight change during this time frame. Data on dietary change and current dietary habits 
highlight several possible targets for intervention in this population. Understanding the unique 
challenges related to diet and weight management after diagnosis, in the context of 
psychosocial and treatment-related factors, may serve to inform future research and to guide 
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1.1 Statement of the Problem 
 
     Weight gain is a common and persistent problem for many breast cancer survivors, both 
during treatment and in the months and years after diagnosis (Vance, Mourtzakis, McCargar & 
Hanning, 2011). Furthermore, with or without weight gain, unfavourable changes in body 
composition including fat gain and loss of lean tissue have been observed in this population; 
changes which may lead to a body composition phenotype known as sarcopenic obesity 
(Demark-Wahnefried, Peterson, Winer et al. 2001; Kutynec, McCargar, Barr, & Hislop, 1999).   
     Emerging data suggest that obesity, and weight gain associate with increased risk of disease 
recurrence and breast cancer mortality (Nichols, Trentham-Dietz, Egan et al., 2009; Ryu, Kim, 
Nam et al., 2001). Weight gain is also known to impact negatively on quality of life (Halbert, 
Weathers, Esteve et al., 2008; Knobf, 1986) and to increase the risk of developing co-morbid 
conditions (Brown, Brauner & Minnotte, 1993; Wingo, Gloeckler Ries, Parker & Heath, 1998). 
Loss of lean tissue might further exacerbate the problem of weight gain and, combined with 
gains in adipose tissue, may lead to metabolic disturbance, treatment complications and poor 
clinical outcomes (Carmichael, 2006; Prado, Baracos, McCargar et al., 2007).  
     Although data are accumulating on the adverse prognostic effects of sarcopenic obesity and 
weight gain, the underlying mechanisms of energy imbalance in the post-diagnosis period are 
not well understood. Diet and exercise patterns after diagnosis and possible treatment-related 
reductions in resting energy expenditure are areas of active research, however the extent to 
which these individual components of energy balance contribute to weight gain is not yet clear. 
Diet has clearly been implicated in weight gain among breast cancer survivors, but there are 
significant gaps in available knowledge and the limited data base suffers from important 




1.2 Study Rationale 
     Breast cancer is the most common female malignancy in the world, accounting globally for 
16% of all cancers in women and more than 500,000 deaths each year (World Health 
Organization, 2011a). In 2011, it was estimated that 23,400 Canadian women and 230,480 
American women would be diagnosed with breast cancer (Canadian Cancer Statistics, 2011; 
National Cancer Institute, 2011). Improved screening, combined with advances in treatment, 
has resulted in a decline in breast cancer mortality however, with more than 250,000 new cases 
expected in North America each year, an increasing number of women are living with a 
diagnosis of breast cancer. This growing population of breast cancer survivors, currently 
estimated to include at least 152,000 Canadian women (Canadian Breast Cancer Foundation, 
2011) and 2.6 million American women (National Cancer Institute, 2011), underscores a 
critical need to investigate modifiable risk factors that will promote overall health, disease 
remission and long-term survivorship.  
     Given the adverse health consequences of weight gain after diagnosis, further efforts to 
investigate dietary factors relating to energy imbalance are warranted. These findings will help 
to identify women who may be most at risk of weight gain, and may assist in the development 
of nutrition guidelines and diet/weight management interventions targeted towards the diet-
related issues experienced by women during or following breast cancer treatment.  
     There are several hypothesized mechanisms by which breast cancer and its treatment might 
influence diet and eating behaviours in ways that promote weight gain, but little empirical 
evidence at this time. Although nutrition-related side effects are well documented, 




after diagnosis are poorly understood. Previous research, however, is limited by imprecise 
dietary assessment methods, small sample size and limited data over the treatment trajectory. 
The timing of dietary measures in the current literature is especially problematic. Many studies 
have relied on pre-chemotherapy measures of dietary intake as the baseline, raising the 
possibility that important changes in dietary habits between diagnosis and the initiation of 
chemotherapy may have been missed. Moreover, most studies have used before and after 
chemotherapy measures only, which will not detect fluctuations in intake over the course of 
treatment and within treatment cycles. This limitation likely reflects the significant challenge 
in recruiting women in active treatment to a study of this nature, and reluctance to place 
additional burden on patients. This however, is an important component of dietary assessment 
in this population. Given the stresses of a cancer diagnosis and the known gastrointestinal side 
effects of treatment, food intake and eating patterns would be expected to be highly variable 
across treatment and within treatment cycles. Data from our pilot study (n=6) support this 
supposition, revealing a mean energy intake at baseline (onset of chemotherapy) of 1857 kcals, 
which drops to 1612 kcals at 8 weeks and returns to baseline by 16 weeks (p<0.05). When the 
data were analyzed by weeks from treatment, the mean energy intake for diet records 
completed in the first week after treatment was 1424 kcals, increasing to 1958 kcals and 2019 
kcals in the second and third weeks, respectively (Appendix A). This pilot work suggested high 
intra and inter-individual variability in intake over treatment as expected, but was limited by 
small sample size and did not specifically address factors influencing dietary intake across 
treatment. Furthermore, the precision of food records and other self-reported dietary 
assessment methods may preclude the ability to detect small changes in dietary intake over a 




     Comparison of diet and eating behaviour between women who gain weight versus those 
who remain weight stable has not been reported, suggesting that the role of dietary intake in 
post-diagnosis weight gain has not yet been adequately characterized. Lastly, there are very 
limited data on dietary changes in the post-treatment period, with no studies reporting these 
changes in relation to persistent treatment effects or in the context of dietary intake in the first 
year after diagnosis.  
     The current research was designed to explore these gaps in the literature; to gain an 
appreciation of the experience of food intake and body weight over the treatment trajectory, 
from the perspective of women who have received chemotherapy for breast cancer. Use of a 
mixed method design was based on the premise that incorporating both qualitative and 
quantitative analysis may help to circumvent some of the research gaps and methodological 
challenges and would provide important insights on food intake and weight change that have 
not been previously explored.  
     Our pilot work with patients in active treatment suggested that post-treatment interviews 
would be preferred over data collection during treatment and might allow for a larger, more 
representative sample. Furthermore, follow-up consultations suggested that most women had 
vivid recollection of the influences that affected their eating patterns during treatment 
(gastrointestinal disturbance, fatigue, family support), which might have been missed by 
midtreatment food records, but could be captured as a whole using qualitative interviews.   
1.3 Objectives and Research Questions 
1.3.1 Study 1  
     Study 1 was a qualitative analysis, based on comprehensive interviews with 28 breast 




study 1 was to describe the unique challenges associated with chemotherapy in relation to diet 
and weight management and to explore possible relationships among psychosocial and 
treatment-related factors, dietary intake and weight gain during treatment. Study 1 was based 
on the following objectives: 
Objective #1: To describe food intake and eating patterns in relation to the experience of 
chemotherapy. 
 
Objective #2: To identify common psychosocial and treatment-related factors associated with 
changes in food intake and eating patterns during treatment.  
 
Objective #3: To describe similarities and differences in food intake and eating patterns in 
relation to the experience of chemotherapy, among women who gained weight during 
treatment compared to women who did not gain weight. 
 
Objective #4: To develop a theoretical model based on grounded theory, to explain how 
psychosocial factors and treatment-related side effects might influence diet and eating patterns 
in ways that promote weight gain during treatment. This model was considered within the 




1.  Are there common themes around diet-related issues and supports/barriers to healthy eating 
and weight management among women treated with chemotherapy for early stage breast 
cancer? 
 
2.  Are there apparent differences in diet and eating patterns in relation to chemotherapy 
treatment among women who gained weight compared to women who did not gain weight?  
 
3.  Are there relationships between psychosocial factors and treatment-related side effects, diet 
and eating patterns, and weight gain during treatment? 
 
 
1.3.2 Study 2 
 
     Study 2 was a follow-up to study 1, within the same study population. The purpose of study 
2 was to investigate relationships among persistent side effects of treatment, current dietary 
intake, changes in diet and weight gain since the completion of chemotherapy treatment.  





Objective #1: To describe current (past week) symptoms of physical and psychological 
distress and global quality of life using the Rotterdam Symptom Checklist and the Distress 
Thermometer. 
 
Objective #2: To conduct a comprehensive assessment of the intensity and duration of current 
fatigue (past week) and to describe the extent to which fatigue has interfered with daily living 
(e.g., activities, concentration, relationships) using the Fatigue Symptom Inventory.  
 
Objective # 3: To investigate changes in diet after diagnosis based on self-reports of having 
“introduced, increased, reduced or eliminated” specific food groups or dietary constituents.  
 
Objective #4: To describe current dietary intakes based on 3-day food records, relative to the 
Dietary Reference Intakes (energy, macronutrients, fibre, calcium and vitamin D), and Eating 
Well with Canada’s Food Guide (recommended number of food guide servings). Mean intakes 
were also described relative to the Canadian Community Health Survey, Cycle 2.2, Nutrition 
(2004) (energy, food groups, % energy from macronutrients, calcium, vitamin D). 
 
Objective #5: To examine relationships between weight change (kg, gain vs. stable or loss) 
since the completion of treatment and composite scores for physical and psychological distress, 
intensity of fatigue, duration of fatigue, level of interference associated with fatigue, current 
dietary intake (energy, carbohydrate, protein and fat intake) and self-reported changes in diet 
(number of positive changes) after diagnosis. Small sample size may limit statistical power to 
detect significant correlations, but this objective will serve to generate hypotheses and power 




1.  Based on responses to standardized surveys, what is the level of physical and psychological 
distress in early stage breast cancer survivors after chemotherapy treatment, and how do these 
scores seem to compare to previous reports of distress (*) among early stage breast cancer 
patients in active treatment and comparison groups of cancer-free adults?  
* based on published normative data from the Rotterdam Symptom Checklist and the Fatigue 
Symptom Inventory 
 
2.  What is the nature and extent of self-reported changes in diet in early stage breast cancer 
survivors, after diagnosis?  
 
3.  How do current intakes of energy (kcals), carbohydrates (g, %), protein (g, %), total and 
saturated fat (%), fibre (g), calcium (mg), vitamin D (ug) and servings of vegetables & fruits 
and milk & alternatives, in this sample group of breast cancer survivors, compare to age and 
gender specific dietary recommendations? 
 
4.  Are there relationships between weight change since the completion of treatment and each 








1.4 Study Components  
 





     The first chapter of this thesis is a review of the literature, providing an overview of    
nutrition-related issues during chemotherapy treatment and a review of weight gain, health 
consequences and potential mechanisms of energy imbalance in breast cancer survivors. A 
conceptual model of possible and probable factors promoting energy imbalance after diagnosis 
summarizes and integrates these findings. Chapter 2 provides a comprehensive description of 
the research methods. Chapters 3-5 are presented as three manuscripts, representing the results 
of three distinct areas of the thesis. Chapter 3 is based on the qualitative analysis from study 1. 
Chapters 4 and 5 are based on the dietary change, 3-day food record and survey data (persistent 




key findings and contributions of this thesis, clinical applications and recommendations for 
future research and is followed by a list of references and appendices.   
Sections of the literature review have been published as follows: (Appendix Q) 
Vance, V., Mourtzakis, M., McCargar, L., & Hanning, R. (2011). Weight gain in breast cancer 
survivors: prevalence, pattern and health consequences. Obesity Reviews, 12, 282-294. 
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CHAPTER 1:  LITERATURE REVIEW 
 
1.1 Breast Cancer, Chemotherapy and Nutritional Status 
 
     A breast cancer diagnosis and chemotherapy treatment can profoundly impact dietary 
intake, dietary requirements and nutritional status. Normal dietary patterns may be altered by 
stress and the burdens of active treatment, changes in physical activity and by several possible 
nutrition-related side effects of chemotherapy agents.  
     Chemotherapy drugs target cancer cells that are dividing rapidly, however some normal 
cells including skin, hair, nails, blood cells and the lining of the digestive system also divide 
rapidly (Cancer Research UK, 2008). The process of killing cancer cells therefore, also 
damages healthy cells, producing “nutrition impact” symptoms that can lead to inadequate 
intake and nutritional deficiencies (Doyle, Kushi, Byers, Courneya, Demark-Wahnefried, 
Grant, McTierrnan et al., 2006). Common nutrition-related side effects of breast cancer 
chemotherapy include nausea, vomiting, anorexia, changes in sense of taste or smell and bowel 
complications including both constipation and diarrhea. Damage to the mucous membranes of 
the upper gastro-intestinal tract can also produce mucositis (mouth sores), esophagitis 
(inflammation of the esophagus) and heartburn (Doyle et al, 2006; Eldridge & Hamilton, 2004; 
Grant & Byron, 2006; National Cancer Institute, 2006). General information from the 
Canadian Cancer Society (2002) and the BC Cancer Agency (2011) suggests that individual 
responses to treatment are highly variable, however many breast cancer patients who receive 
chemotherapy experience difficulty eating for several days after treatment. In addition, fatigue, 
reported in 96% of women in active treatment (Demark-Wahnefried, Rimer & Winer, 1997b) 
and the psychological impact of cancer and cancer treatment (Halbert et al., 2008) can interfere 




Hamilton, 2004; National Cancer Institute, 2006). These common treatment effects can present 
significant challenges to healthy eating that may vary between women and across the treatment 
trajectory (BC Cancer Agency, 2011).    
     Cancer and its treatment may also produce alterations in energy, macronutrient, 
micronutrient and fluid requirements. Nutritional needs for breast cancer patients vary widely 
as a function of age, physical activity level, nutritional status at diagnosis and individual 
response to chemotherapy agents and may change significantly over the course of treatment. 
Adequate energy intake is especially important during cancer treatment to help resist fatigue 
and assist the body to withstand the effects of treatment (Canadian Cancer Society, 2002). 
Stress on the body caused by cancer may produce changes in amino acid metabolism and an 
increase in need for dietary protein. Additional protein is recommended during treatment, to 
preserve lean tissue, promote healing, re-build tissue and maintain immune function (Hurst & 
Gallagher, 2006; National Cancer Institute, 2006). Protein requirements can be determined 
using urinary urea nitrogen balance studies, but are more commonly estimated, based on grams 
of protein per kilogram of body weight. The recommendation for early stage, adult cancer 
patients is 1.2 g/kg (Hurst & Gallagher, 2006); 50% higher than the current dietary reference 
intake (0.8g/kg) for the general population (National Academy of Sciences, 2005). Adequate 
carbohydrate and fat calories are needed to spare protein and preserve lean muscle mass (Hurst 
& Gallagher, 2006). Carbohydrate and fat recommendations for cancer patients are the same as 
current guidelines for healthy individuals (carbohydrates-45-65% of total energy with an 
emphasis on fruits, vegetables and whole grains, fat-20-35% of total energy with an emphasis 
on mono and polyunsaturated sources) (National Academy of Sciences, 2005). Fibre intake 




     Cancer patients may be at risk for micronutrient deficiencies due to physiological stress, 
changes in vitamin and mineral metabolism, poor diet and gastrointestinal complications. 
While reliance on a healthy balanced diet is strongly encouraged over supplements, a low dose 
multi-vitamin supplement (≤ 100% of the Recommended Dietary Allowance) is sometimes 
recommended (BC Cancer Agency, 2011; Hurst & Gallagher, 2006). There is no scientific 
evidence to date, that supplements will help to prevent or fight cancer and in fact some 
evidence to suggest that high dose antioxidant vitamins and minerals, in particular, may be 
harmful and/or interfere with anti-cancer medications (BC Cancer Agency, 2011; Doyle et al., 
2006).  
     Lastly, hydration status may be compromised during cancer treatment by inadequate intake 
or treatment-related nausea, vomiting and diarrhea (Eldridge & Hamilton, 2004). Hydration is 
especially important during treatment, to protect the bladder and kidneys from the effects of 
chemotherapy drugs (BC Cancer Agency, 2011). Breast cancer patients are encouraged to 
drink 8-10 cups of liquids per day and to eat foods that contain significant amounts of fluids 
(soups, popsicles, jello, puddings) in order to achieve and maintain adequate hydration.  
1.2 Weight Gain in Breast Cancer Survivors 
1.2.1 Frequency and Magnitude of Weight Gain  
     Weight gain is a common problem among breast cancer survivors. First reported in the 
1970’s (Dixon, Moritz & Baker, 1978), this finding was initially unexpected given the known 
gastrointestinal-related side effects of treatment and because many forms of cancer are more 
typically associated with weight loss (Demark-Wahnefried et al., 1997b). Weight gain in this 




     Two extensive reviews of weight gain among breast cancer survivors were conducted 
during the 1990’s (Demark-Wahnefried, Winer & Rimer, 1993; Demark-Wahnefried et al., 
1997b). At this time, combined results suggested that 50-96% of early stage breast cancer 
patients experience significant weight gain during treatment. Weight gains in the range of   
2.5–6.2 kg were most commonly reported but gains of 10 kg or more were not unusual. Since 
1997, many additional studies have reported on weight gain during and after breast cancer 
treatment; 30 studies (1997-2011) are summarized in Table 1.1 (pg. 53).  
     While there appears to be a general trend toward a reduction in the magnitude of weight 
gain since the mid 1990’s (Ingram & Brown, 2004), the majority of recent investigations 
continue to show a high frequency of weight gain among women with early stage disease 
(Campbell, Lane, Martin et al., 2007; Costa, Varella & del Giglio, 2002; Cheney, Mahloch & 
Freeny, 1997; Del Rio, Zironi, Valeriani et al., 2002; Goodwin, Ennis, Pritchard et al., 1999;  
Halbert et al., 2008; Irwin, McTiernan, Baumgartner et al., 2005; Lankester, Phillips & 
Lawton, 2002;  Makari-Judson, Judson & Mertens, 2007; McInnes & Knobf, 2001; Rock, 
Flatt, Newman et al., 1999; Gordon, Hurwitz, Shapiro & LeBoff, 2011).  
     A 2002 retrospective chart review of 100, stage I-III breast cancer patients for example, 
found that 64% of women gained more than 2 kg during six cycles of adjuvant or neoadjuvant 
treatment (Lankester et al., 2002). The mean weight change across all participants was 3.78 kg 
(range = -8.4 - + 17.9), with one-third of patients gaining more than 5 kg. Del Rio et al. (2002) 
measured weight changes prospectively in stage I-II breast cancer patients during 
chemotherapy treatment and reported significant weight gain in all 30 participants, with a 
range of 2.0 - 5.5 kg and a mean gain of 2.8 kg. Defining “significant” weight change as a gain 




premenopausal women (n=76) gained weight during chemotherapy treatment. The mean 
weight change among all women was 1.4 kg (±3.4 kg), however, those who were classified as 
“gainers” (>2.5 kg) experienced a mean weight gain of 5 kg (±1.4 kg).   
     Some of the more recent investigations have not reported significant weight change during 
active treatment, possibly owing to shorter duration chemotherapy regimes (Demark-
Wahnefried, Hars, Conway et al., 1997a; Freedman, Aziz, Albanes et al., 2004; Kutynec et al., 
1999) however, longer follow-up data in these studies and others have reported progressive 
weight gain after the completion of treatment. Investigating weight, body composition and 
components of energy balance in women with early stage breast cancer, Kutynec et al. (1999) 
found that, while body weight was unchanged over 12 weeks of adjuvant chemotherapy (n=8) 
or radiation (n=10), follow-up data for 13 participants revealed that four out of seven women 
treated with chemotherapy (mean follow-up 66 weeks) and four out of six women treated with 
radiation (mean follow-up 103 weeks) had gained an average of 4.7 kg (range = 3.0 - 7.5 kg) 
and 4.1 kg (range = 1.9 - 8.2 kg), respectively. Likewise, Demark-Wahnefried et al. (1997a) 
found no significant difference in mean body weight among 18 premenopausal women before 
and after treatment, however at a one year follow-up found that 14 of the 18 women for whom 
weight data were available had gained an average of 3.8 kg (±0.75 kg) since the completion of 
treatment.  
     Recent longitudinal data confirms that weight gain after treatment is a problem for many 
breast cancer survivors. Irwin and colleagues (2005) recruited 514 pre and postmenopausal 
women within one year of diagnosis in order to assess changes in weight and body fat after a 
diagnosis of stage I-IIIA disease. By the third year after diagnosis, 68% of the women had 




that among 185 women diagnosed with stage I-III breast cancer, 71% had gained an average of      
3.7 kg one year after diagnosis (Makari-Judson et al., 2007). The mean weight change across 
all women was 1.5 kg at year one, 2.7 kg at year two and 2.8 kg at year three, suggesting that 
weight gain is progressive and persistent after diagnosis. Furthermore, only 15% of women 
who had gained weight at year one had lost the weight at year two and of those who did not 
gain weight in year one, 32% gained an average of 1.8 kg in the following year.  
     While post diagnosis weight gain is common, it is not universal. Limited data show that 
some women maintain a stable weight, while a smaller percentage of women (~10-29%) may 
lose weight after diagnosis (Foltz, 1985; Rock et al., 1999; Ingram & Brown, 2004; Makari-
Judson et al., 2007; Tredan, Bajard, Meunier et al., 2010; Gu, Chen, Zheng et al., 2010; Nissen, 
Shapiro & Swenson, 2011). Among those who gain weight, the amount of weight that is 
gained, at different time points in the cancer trajectory, is highly variable. Moreover, it is 
possible that there are ethnic differences in the pattern of weight gain after a breast cancer 
diagnosis. A study of 260 Korean women diagnosed with early stage disease, reported a mean 
weight gain of 0.30 kg (p<0.5) at 3 months but no significant weight change at 6, 12 and 24 
month follow-ups (Han, Lee, Kim et al, 2009). In this study, 47% of patients experienced a 
mean gain of 1.93 kg (±1.91 kg) at 12 months, though only 10% were reported to have gained 
a “significant amount of weight” (≥ 5% vs. baseline) during this time frame. The Shanghai 
Breast Cancer Survival Study (Gu et al., 2010), a larger prospective study of Chinese women 
(n=5014) however, found that 26%, 37% and 33% of women gained ≥5% of initial body 
weight at 6, 18 and 36 months, respectively.  
     Estimating average weight gain in this population is confounded by the fact that weight 




change”, % change/day, median vs mean). In addition, some studies have reported mean 
weight change across all participants (e.g., including those who are weight stable or lose 
weight after diagnosis) and by treatment group or menopause status without providing separate 
data for a sizeable proportion of women who experience weight gain (Campbell et al., 2007; 
Freedman et al., 2004; Rock et al., 1999). While this provides an estimate of overall weight 
change among breast cancer survivors and is critical in comparing weight change by specific 
sub-categories of women, it may dilute the true magnitude of the problem for some women.  
     Regardless of how the data are presented, based on more than 30 years of research, it is 
clear that among breast cancer survivors, weight gain is a common and persistent problem. The 
amount of weight gain that has been reported in the months and years after diagnosis is larger 
than would be expected in the general population and occurs at an accelerated rate compared to 
age-matched healthy women (Williamson, Kahn & Byers, 1991; Guo, Zeller, Chumlea et al., 
1999).  
1.2.2 Patterns of Weight Gain and Body Composition Changes 
     Weight gain in otherwise healthy women is typically characterized by a gain in both 
adipose tissue and lean tissue (Demark-Wahnefried et al., 2001; Harvie, Campell, Baildam & 
Howell, 2004). A growing body of research however, suggests that the pattern of weight gain 
typical of breast cancer patients is unique in that it generally occurs in combination with no 
associated gains or perhaps even losses in lean tissue: changes which may lead to a body 
composition phenotype known as “sarcopenic obesity” (Rock & Demark-Wahnefried, 2002; 
Visovsky, 2006).  
     Using several modalities of body composition assessment, including skin-folds (Goodwin et 




2004), dual energy x-ray absorptiometry (DXA) (Campbell et al., 2007; Demark-Wahnefried et 
al., 2001; Freedman et al., 2004; Kutynec et al., 1999; Irwin et al., 2005; Nissen et al., 2011; 
Gordon et al., 2011) and computed tomography (CT) (Cheney et al., 1997), increases in fat 
mass after diagnosis are well documented.  
     Using DXA, Demark-Wahnefried et al. (2001) reported changes in body composition in 36 
premenopausal breast cancer patients (stages 0-III) during the year after diagnosis. At six and 
twelve months respectively, women treated with adjuvant chemotherapy had gained an average 
of 2.2 kg and 2.1 kg in body weight and 2.0 kg and 2.3 kg of fat mass (FM), representing a 
relative gain in body fat of 1.8% and 2.2%. During the same time frame, a small but non-
significant decrease in fat free mass (FFM) and leg lean body mass in particular was noted. 
Based on a sub-sample of women from the Healthy Eating, Activity and Lifestyle Study 
(n=132), Irwin et al. (2005) found that 74% of early stage breast cancer survivors had gained 
an average of 3.6% body fat within two-three years after diagnosis.  
     Others have reported an increase in FM, accompanied by a significant loss (Cheney et al., 
1997; Kutynec et al., 1999) or no change (Campbell et al., 2007; Freedman et al., 2004, 
Gordon et al., 2011) in FFM during treatment. Based on CT images, Cheney et al. (1997) 
found that, regardless of weight change, seven out of eight early stage breast cancer patients 
gained body fat and lost lean tissue over six months of adjuvant treatment. Similarly, in the 
absence of significant weight gain, Kutynec et al. (1999) reported a significant increase in 
percent body fat and a significant loss of lean body mass in 18 premenopausal women, over 12 
weeks of chemotherapy or radiation. Once again, loss of lean tissue was especially pronounced 




     Using DXA at baseline (within one month of starting chemotherapy) and 12 months, Nissen 
et al. (2011) found that women who were normal weight at baseline (n=26) gained an average 
of 2.0 kg and experienced an increase in fat mass in the torso and arms. Conversely, women 
who were overweight or obese (n=23) lost weight (1.4 and 1.9 kg, respectively), with no 
increase in body fat, however greater BMI at baseline was associated with a larger decrease in 
lean mass in the arms. These findings suggest that, with or without weight gain, changes in 
body composition consistent with the development of sarcopenic obesity occur in some breast 
cancer survivors, during and after treatment.   
            1.2.3 Factors Associated with Weight Gain and Body Composition Changes 
1.2.3.1 Treatment Effects 
     There is considerable evidence that post diagnosis weight gain among breast cancer 
survivors is highly correlated with the type and duration of treatment (Demark-Wahnefried et 
al., 1997b). Early research in this area suggested that systemic treatment (chemotherapy) 
produced significantly more weight gain than localized treatment (surgery and/or radiation 
only) and that weight gain was higher among women treated with multi-agent regimes over 
longer periods of time (Demark-Wahnefried et al. 1993). Findings from more recent 
investigations confirm an association between chemotherapy and weight gain. A summary of 
common chemotherapy protocols and their abbreviations (e.g. AC, CEF), used in subsequent 
sections of this paper, are provided in Appendix B. 
     A large prospective study of pre and postmenopausal women (n=535) with early stage 
breast cancer (Goodwin et al., 1999) demonstrated that weight gain in the first year after 
diagnosis was significantly greater in women treated with any form of chemotherapy (2.5 kg ± 




p<0.001). Similarly in 2001, Demark-Wahnefried et al. reported a mean weight gain of 2.2 kg 
at six months and 2.1 kg at one year among premenopausal women treated with adjuvant 
chemotherapy (n=36) versus corresponding weight gains of 0.5 kg and 1.0 kg in women 
receiving localized treatment only (surgery, with/without radiation, n=17). Adjusting for 
known confounders, data from the Women’s Healthy Eating and Living (WHEL) study 
(n=3088), revealed that women treated with chemotherapy were 65% more likely to gain 
weight during treatment (OR = 1.65, CI: 1.12, 2.43) compared to women who did not receive 
systemic treatment (Saquib, Flatt, Natarjan et al., 2007). In this sample, the type of 
chemotherapy did not impact on the amount of weight that was gained.   
     There is some suggestion in the literature that the newer chemotherapy regimes containing 
anthracyclines (Doxyrubicin and Epirubicin) are associated with less weight gain (Ingram & 
Brown, 2004) however, this has not been a consistent finding (Costa et al., 2002; Goodwin et 
al., 1999; Irwin et al., 2005; Makari-Judson et al., 2007; Saquib et al., 2007; Tredan et al., 
2010). Current evidence suggests that the duration of adjuvant treatment may be the more 
important predictive indicator. A general trend towards shorter duration treatments since the 
mid 1990’s may explain a reduction in the magnitude of weight gain observed in some of the 
subsequent research (Goodwin et al., 1999; Ingram & Brown, 2004). Furthermore, Harvie et al. 
(2004) reported a mean weight gain 3.3 kg (range = 1.4 – 5.3 kg) among pre and 
postmenopausal women (n=17) treated with six months of FEC or CMF adjuvant therapy; a 
finding that is consistent with studies in which patients were treated with similar protocols 
(Aslani, Smith, Allen et al., 1999; Del Rio et al., 2002; Lankester et al., 2002). Others have 
reported that, when only four cycles of AC was the dominant therapy, weight gain during 




Freedman et al., 2004; Ingram & Brown, 2004; Kutynec et al., 1999). The use of oral agents 
versus intravenous administration within these and other chemotherapy regimes is associated 
with higher weight gain (Demark-Wahnefried et al., 1993). 
     Earlier suggestion that tamoxifen therapy may contribute to weight gain (Demark-
Wahnefried et al., 1993) is not supported by later investigations (Goodwin et al., 1999; Kumar, 
Allen, Cantor et al., 1997; Lankester et al., 2002; Makari-Judson et al., 2007; Saquib et al., 
2007; Gu et al., 2010). The largest of these studies (Saquib et al., 2007) found that among 3088 
breast cancer survivors over a six year follow-up, tamoxifen alone was not associated with 
significant weight gain, nor did the addition of tamoxifen to chemotherapy treatment modify 
the effect of chemotherapy use on weight gain. The use of corticosteroids (Dexamethasone, 
Prednisone) for the treatment of nausea and vomiting associated with some chemotherapy 
agents and the use of Megestrol Acetate for advanced stage disease are known to produce 
significant weight gain during treatment (Faber-Langendoen, 1996; Goodwin, Panzarella & 
Boyd, 1988). The wide range of chemotherapy protocols and other medications that are 
currently used in breast cancer treatment may explain some of the variability in weight gain 
that has been observed.  
1.2.3.2 Menopause Status 
     Studies conducted before the mid 1990’s, suggested that weight gain after diagnosis seemed 
to be more pronounced among premenopausal women (Demark-Wahnefried et al., 1993, 
1997b): a finding that is supported by some (Caan, Edmond, Natarajan et al., 2006; Caan, 
Kwan, Hartzell et al., 2008; Campbell et al., 2007; Cheney et al., 1997; Freedman et al., 2004; 




al., 2010) but not all later investigations (Aslani et al., 1999; Costa et al., 2002; Lankester et 
al., 2002; Kumar, Allen, Riccardi et al., 2004; Irwin et al., 2005; Tredan et al., 2010). 
     Heideman et al., (2009) reported a mean weight gain of 2.0 kg (±4.9 kg) and 2.4 kg (±5.6 
kg), among women treated for stage 0-III disease (n=217), one year and five years after 
diagnosis, respectively. Stratification by menopause status however, demonstrated that weight 
gain in this sample was largely limited to premenopausal women who gained an average of 3.9 
kg (±5.8 kg) at five years versus 1.1 kg (±5.0 kg) in postmenopausal women (p<0.05). Data 
from the Life After Cancer Epidemiology (LACE) and WHEL studies (Caan, et al., 2006; 
Caan et al., 2008), two large observational cohort studies of women previously treated for 
breast cancer (n=3214), revealed that women who were premenopausal at diagnosis gained 
significantly more weight (5.6±10.2 kg vs. 3.0±9.3 kg, p<0.001) and were significantly more 
likely to gain at least 5% of their body weight (47.2% vs. 30.3%, p<0.001) between pre-
diagnosis (~1 year) and study entry (mean = 23 months after diagnosis) compared to women 
who were postmenopausal at diagnosis. 
     Higher weight gain in premenopausal women may correlate with treatment-induced 
menopause. This effect is thought to be mediated by alterations in ovarian function and sex 
hormone concentrations which may produce an acceleration of the normal physiological 
changes associated with menopause including fat accumulation, changes in fat distribution and 
a decrease in lean body mass (Messier, Karelis, Lavoie et al., 2009; Tremollieries, Pouilles & 
Ribot, 1996). Current findings however, do not support a consistent association between 
ovarian failure and weight gain after diagnosis. Among 535 women treated for early stage 
disease, Goodwin et al. (1999) found that premenopausal women who experienced treatment-




follow-up, compared to women who remained pre or peri-menopausal (1.07±3.54 kg) or who 
were postmenopausal (1.05±3.58 kg, p<0.01) at diagnosis. Controlling for age, initial body 
weight and adjuvant treatment, a multivariate analysis revealed that onset of menopause was a 
significant predictor of weight gain (p<0.05) in the first year after diagnosis.   
     In a small sample of women with early stage disease (n=20), Freedman et al. (2004) found 
that while menopause status was not associated with weight gain during treatment, women who 
were premenopausal at diagnosis gained significantly more weight than postmenopausal 
women in the six month period after the completion of chemotherapy (+2.43±2.1 kg vs. -
0.24±2.1 kg, p<0.01). It is noteworthy that in this study, all but one of the women became 
amenorrheic within 6 months of treatment. Conversely, Gordon et al. (2011) reported a median 
weight gain of 2.7 kg (range = -6.7 - + 10.5 kg) and fat gain of 3.2 kg (range = -6.0 - + 10.2 kg) 
in premenopausal women treated for early stage disease (n=43); changes in body weight and 
body fat that were not significantly different among those who developed chemotherapy 
induced ovarian failure, compared to those who retained ovarian function at 12 months.   
     Small sample size may have been a methodological barrier for some recent studies in which 
a relationship between menopause status and weight gain after diagnosis was not evident 
(Aslani et al., 1999; Campbell et al., 2007; Lankester et al., 2002). Other explanations for 
discordant findings include variation in timing of recruitment (Rock et al., 1999), length of 
follow-up (Aslani et al., 1999) and the degree of control for potential confounding variables 
(e.g., diet, physical activity, resting energy expenditure). Although it appears that 
premenopausal women may experience greater risk during and after treatment, it is important 





1.2.3.3 Weight Status at Diagnosis  
     There is some evidence to suggest that weight gain during and after treatment may be 
influenced by weight status at diagnosis, however findings here are inconsistent. In a large 
prospective cohort study (n=5014), Gu et al. (2010) reported significantly higher weight gain 
over 36 months among women who had a lower BMI at diagnosis (p<0.001). The median 
weight gain for women who were underweight at diagnosis was 2.0, 3.0 and 3.0 kg at 6, 18 and 
36 months, respectively compared to 1.0, 2.0 and 2.0 kg for those who were normal weight. No 
significant weight change was observed among women who were overweight. Those who were 
classified as obese lost a small amount of weight over 36 months (0.5 -1.0 kg). Similarly, in a 
smaller study (n=49), Nissen et al. (2011) found that baseline BMI (onset of chemotherapy) 
was inversely associated with weight gain over 12 months. Women who were normal weight at 
diagnosis gained an average of 2.0 kg, while those who were overweight or obese lost an 
average of 1.4 kg and 1.9 kg, respectively (p<0.05). Based on data from the WHEL study 
(n=1,116),  Rock et al., (1999) reported significant weight gain, over an average of 26 months, 
in women who were underweight (3.6 kg), normal weight (3.1 kg) or overweight  (3.3 kg) 
before diagnosis. It should be noted that classification of overweight in this sample was based 
on a BMI of 27.3-32.1 kg/m2. Women with a BMI ≥32.2 kg/m2 lost an average of 0.2 kg 
during the same time frame. These findings are consistent with Yaw, Kandiah, Shariff et al., 
(2010). 
     Despite a tendency for obese women in these studies to lose a small amount of weight on 
average, a wide range of weight change is reported in most studies. For example, Gu et al., 
(2010) reported weight change ranging from -12 kg to + 18 kg, -12.5 kg to + 20 kg and -25 kg 




overweight (n=1525) or obese (n=575), respectively. This suggests that some women who are 
normal weight at diagnosis may move into the overweight or obese categories (Yaw et al., 
2011) and some who are overweight or obese will gain additional weight after diagnosis. 
Furthermore, several studies have found no association between baseline BMI and weight gain 
after diagnosis (Goodwin et al., 1988; Costa et al., 2002; Lankester et al., 2002; Ingram & 
Brown, 2004; Irwin et al. 2005; Heideman et al., 2009; Tredan et al., 2010; Gordon et al., 
2011), and one study (Camoriano, Loprinizi, Ingle et al., 1990) found that weight gain was 
significantly higher among premenopausal women who were heavier at diagnosis (8.2 kg vs. 
4.9 kg, p<0.01), suggesting that further research is needed.  
1.3 Health Consequences of Pre-Diagnosis Weight and Post-Diagnosis Weight Gain 
     The results of several studies suggest that obesity at diagnosis associates with an increase 
risk of disease recurrence (Chlebowski, Aiello & McTiernan , 2002; Majed, Moreau, Senouci 
et al., 2008), breast cancer death (Rock & Demark-Wahnefried, 2002; DalMaso, Zuccheto, 
Talamini, et al., 2008) and all-cause mortality (Carmichael, 2006; Dawood, Broglio, Gonzalez-
Anguloro et al., 2008). This effect was evident in both pre and postmenopausal women 
(Chlebowski et al., 2002; Carmichael & Bates, 2004). A meta-analysis, incorporating more 
than 8000 women, found that obesity at diagnosis was associated with poor prognosis, with a 
combined effect size of 1.56 (CI: 1.22, 2.00) for all-cause mortality (Ryu et al., 2001).  
     More recently, Kwan, Chen, Kroenke et al, (2012) investigated associations between weight 
status at diagnosis and disease recurrence and survival, based on data from the After Breast 
Cancer Pooling Project (ABCPP). The ABCPP includes data from a large cohort of breast 
cancer survivors (n=14,948), pooled from three prospective studies in the US (LACE, WHEL, 




follow-up period of 7.8 years. This study, the first to stratify breast cancer outcomes by degree 
of obesity, suggests that severe or morbid obesity at diagnosis confers the greatest risk of poor 
prognosis. Adjusting for several known prognostic indicators, a significant increased risk of 
all-cause mortality among women who were morbidly obese (BMI >40 kg/m2) at diagnosis 
(HR=1.81, CI:1.42, 2.32) and a small but non-significant increased risk among women who 
were categorized as obese or severely obese (BMI 30-34.9 and 35-39.9 kg/m2, respectively) 
was reported. Greater risk was also seen among women who were underweight (BMI < 18.5 
kg/m2) at diagnosis (HR=1.59, CI: 1.18, 2.13). Similar associations were found for breast 
cancer mortality and non-breast cancer mortality, however associations between weight status 
at diagnosis and disease recurrence were non-significant. Compared to women who were 
normal weight at diagnosis, overweight was not associated with increased risk of all-cause 
mortality, breast cancer mortality or non-breast cancer mortality. The capacity to evaluate 
obesity sub-categories (obese, severely obese, morbidly obese) in this large cohort of breast 
cancer survivors emphasizes the strong prognostic effect of morbid obesity on breast cancer 
outcomes and may suggest that the relationship between body weight and breast cancer 
prognosis is U-shaped, with normal or even high normal pre-diagnosis body weight predicting 
the best outcomes (Kwan et al., 2011). However, given the well established, time dependent 
relationships between obesity and adverse health outcomes (Abdullah, Wolfe, Stoelwinder et 
al., 2011), it will be important to observe if these associations modify over a longer follow-up 
period. Ewertz, Jensen, Gunnarsdottir et al., (2011) reported a 46% increased risk of distant 
metastases (HR = 1.46, CI: 1.11, 1.92) after 10 years and a 38% increased risk of breast cancer 
death (HR = 1.38, CI: 1.11, 1.71) after 30 years, among early stage breast cancer survivors 




Similar risk was apparent for all-cause mortality (HR = 1.31, CI: 1.05, 1.63); an effect that was 
evident after 10 years among women who were obese at diagnosis. Moreover, in this study, a 
BMI of 25-29 at diagnosis was also associated with a significantly increased risk of distant 
metastases (HR = 1.42, CI: 1.17, 1.73) and breast cancer death (HR = 1.26, CI: 1.09, 1.46) 
after 10 years. These findings are supported by Majed, Dozol, Ribassin-Majed et al., (2011) 
who reported a time-dependant increased risk of contralateral breast cancers (HR = 1.5, CI: 
1.21, 1.86) among overweight and obese women; an association that reached statistical 
significance after 10 years of follow-up. It will also be important to evaluate relationships 
between body weight status and breast cancer specific and non breast cancer outcomes in the 
context of body composition, particularly in relation to lean tissue and visceral fat stores.  
     The relationship between obesity and prognosis is complex, seemingly influenced by 
several possible metabolic and hormonal pathways. Proposed mechanisms include an increase 
in adipose tissue derived circulating estrogens resulting from the conversion of androgens in 
peripheral fat stores (Stephenson & Rose, 2003). Estrogen is known to play a role in the 
initiation and promotion of breast cancer by stimulating cell division, increasing the potential 
for DNA mutations and promoting the growth of estrogen dependent tumors (Rock & Demark-
Wahnefried, 2002). Body fatness also increases circulating levels of insulin, insulin-like 
growth factor and leptin; hormones that may exert mitogenic and angiogenic effects to promote 
breast cancer development (Carmichael, 2006; Stephenson & Rose, 2003) and increase the risk 
of disease recurrence (Goodwin, Ennis, Pritchard et al., 2002). In addition to these direct 
effects, insulin is known to down-regulate plasma concentrations of sex hormone binding 
globulin, resulting in an elevation of available bioactive estradiol and the potential for 




Increased body fat may be related to physical inactivity and dietary factors, before or after 
diagnosis. Thus, obesity may also serve as a marker for lifestyle behaviours that contribute to 
poor prognosis (Carmichael, 2006). Furthermore, poor outcomes in obese women may be 
related to more advanced disease at diagnosis, systematic under-treatment and/or poor 
treatment response (Carmichael, 2006).  
     While the evidence for a relationship between pre-diagnosis body weight and prognosis is 
compelling, particularly among women who are severely or morbidly obese, it is not yet clear 
whether weight gain after diagnosis impacts independently on breast cancer specific outcomes.  
1.3.1 Weight Gain and Disease Free Survival  
     The findings of twelve studies investigating the effects of weight gain after diagnosis on 
disease free survival are equivocal (Table 1.2). For the purposes of this review “disease free 
survival” (DFS) includes no breast cancer recurrence or breast cancer death over the follow-up 
period. 
     Five studies found a positive association between post-diagnosis weight gain and DFS 
(Chlebowski, Weiner, Reynolds et al., 1986; Kroenke, Chen, Rosner et al, 2005; Nichols et al., 
2009; Chen, Lu, Zheng et al., 2010; Thivat et al., 2010). Chlebowski et al. (1986) reported an 
inverse relationship between weight gain (>10kg) and DFS, however, small sample size (n=62) 
and the absence of data concerning other prognostic indicators make these results difficult to 
interpret.  
     Based on a sub-sample of women with breast cancer from the Nurses Health Study 
(n=5204), weight gain among women who had never smoked (n=2156) was associated with 
poor outcomes (Kroenke et al, 2005). Compared to women who maintained a stable weight in 




0.5 - < 2.0 BMI (kg/m2) units (median = 2.73 kg) and > 2.0 BMI units (median = 7.73 kg) were 
40% and 53% more likely to experience disease recurrence over a nine year follow-up period 
(p<0.05). Similar findings were observed for breast cancer death and all-cause mortality. 
Stratification by initial body weight revealed that the relationship between weight gain and 
breast cancer death was significant only among women with a BMI < 25 kg/m2 at diagnosis 
(RR = 1.63 and 1.90, p<0.01 for a median gain of 2.73 kg and 7.73 kg, respectively). Weight 
gain among women who were overweight or obese at diagnosis was not associated with 
increased risk.  
     Two studies reported a positive association between post diagnosis weight gain greater than   
5 kg (Chen et al., 2010) or greater than 5% of initial body weight (Thivat et al., 2010) and 
poorer prognosis. Over a median follow-up of 46 months, Chen et al., (2010) found that among 
5042 women in the Shanghai Breast Cancer Study, both modest weight gain (1-5 kg) and 
weight gain ≥ 5kg from one year pre-diagnosis to 18 months post diagnosis were associated 
with increased risk of disease recurrence (HR = 1.97, CI: 1.30, 2.97 and 1.90, CI: 1.23, 2.93, 
respectively) and all-cause mortality (HR = 1.89, CI: 1.27, 2.82 and 1.71, CI: 1.12, 2.60). 
Weight gain ≥ 5kg, restricted to the 18 month period after diagnosis, was significantly 
associated with all-cause mortality (HR = 1.54, CI: 1.03, 2.29). Thivat et al., (2010) reported a 
significantly increased risk of disease recurrence (RR = 2.28, CI: 1.29, 4.03) and all-cause 
mortality (RR = 2.11, CI: 1.21, 3.66) over 20.4 years, among breast cancer survivors (n=111) 
who gained or lost more than 5% of their initial body weight during chemotherapy treatment. 
This analysis makes it difficult to interpret the independent effects of weight gain after 
diagnosis, however, underscores the potential clinical significance of large weight variation 




     Lastly, Nichols et al. (2009) followed a large cohort of women with invasive non-metastatic 
breast cancer (n=3993) for an average of 6.3 years and found that weight gain >10kg was 
significantly associated with increased risk of all cause mortality (HR = 1.70, CI: 1.21, 2.41) 
and breast cancer mortality (HR = 1.78, CI: 1.01, 3.14). Among women who gained weight 
after diagnosis (>2kg), each 5 kg gain was associated with a 13% increase in breast cancer 
death (p=0.01) and a 12% increase in all-cause mortality (p<0.05). Cardiovascular disease 
mortality was similarly associated with weight gain (19% increase for each 5 kg weight gain, 
p<0.05) suggesting the possibility of a graded increase in the risk of breast cancer and non 
breast cancer related death and emphasizing the potential for weight maintenance to improve 
long-term survival (Nichols et al., 2009). It is noteworthy that 10 kg is substantially larger than 
the mean weight gain observed in recent studies, however represents the magnitude of weight 
change for some women (Gu et al., 2010, Nissen et al., 2011).  
     While these results are intriguing, seven additional studies, failed to identify a relationship 
between post-diagnosis weight gain and DFS (Heasman, Sutherland, Campbell et al., 1985; 
Goodwin et al., 1988; Camoriano et al., 1990; Levine, Raczynski & Carpenter, 1991; Costa et 
al., 2002; Caan et al., 2006; Makari-Judson et al., 2007). Camoriano et al., (1990) followed a 
large sample of node positive pre- and post menopausal women treated with or without 
chemotherapy (n=545), for more than 6 years. Controlling for age, tumor characteristics, nodal 
status and initial BMI, a median follow-up of 6.6 years revealed that premenopausal women 
who gained more than the median amount of weight (5.9 kg) were 60% more likely to die from 
any cause (HR = 1.62, CI: 1.01,2.62). Despite a similar trend, weight gain was not significantly 




     Combined data from early stage breast cancer survivors in the LACE and WHEL studies 
(n=3215) found that at five and seven year follow-ups respectively, weight gain (≥5%) from 
one year pre-diagnosis to study entry (median = ~ 2 yrs from diagnosis) was not associated 
with disease recurrence (Caan et al., 2006). A second study, based on a sub-sample of LACE 
participants (n=1692), found that over a follow-up period of almost seven years, weight gain 
was not associated with DFS or overall survival (Caan et al., 2008). While obesity before 
diagnosis was significantly associated with all-cause mortality (HR = 1.6, CI: 1.1,2.3), with a 
trend toward an increased risk of breast cancer death, weight gain after diagnosis did not seem 
to confer additional risk of recurrence, breast cancer death or death from any cause. As is 
suggested by the authors, it is possible that pre-morbid body weight, which may reflect longer 
exposure to the effects of overweight or obesity and may correlate with other lifestyle 
behaviours, may be more critical in predicting breast cancer outcomes (Caan et al., 2008). 
Other studies are less convincing due to relatively small sample sizes, retrospective design 
and/or short follow-up periods (Heasman et al., 1985; Goodwin et al., 1988; Levine et al., 
1991; Costa et al., 2002; Makari-Judson et al., 2007).  
     With conflicting results across a limited number of studies over a span of 25 years, it is 
clear that further research in this area is needed. Significant advances in breast cancer 
treatment over this time frame (e.g.. shorter chemotherapy protocols) and notable differences 
in methodology, including variation in the timing of weight measures (Kroenke et al, 2005; 
Caan et al., 2006; Nichols et al., 2009; Chen et al., 2010) and the definition of recurrence 
endpoints, may be confounding current results (Caan et al., 2008). For example, Kroenke et al. 
(2005) excluded local ipsilateral or contralateral breast cancer recurrences in their definition of 




very few studies (Caan et al., 2006, Nichols et al., 2009, Chen et al., 2010) have evaluated the 
possible cumulative effect of progressive weight gain after the first year, a well documented 
problem for many breast cancer survivors (Irwin et al., 2005; Makari Judson et al., 2007). 
Furthermore, all of the studies to date have investigated breast cancer and other health 
outcomes in relation to changes in body weight only, which may or may not adequately 
represent underlying changes in body composition. This is understandable, especially in the 
context of large population based studies, however, it is possible that some women who do not 
gain weight also change toward a more sarcopenic phenotype; with both fat gain and loss of 
lean tissue likely contributing to poorer outcomes.  
1.3.2 Other Health Consequences 
     Excessive weight gain, especially an increase in relative adiposity, may predispose breast 
cancer survivors to obesity-related disorders including cardiovascular disease, diabetes, 
gallbladder disease and orthopedic disturbances (Brown et al., 1993; Wingo et al., 1998). This 
is concerning since most women diagnosed in the early stages of disease will be cured of breast 
cancer, but are subsequently exposed to an increased risk of chronic disease in survivorship 
(Demark-Wahnefried et al., 1997b; Kumar et al., 1997). Data from the Nurses Health Study 
and the Framingham Heart Study suggests that weight gain itself, even among women whose 
BMI remains within the normal range, is associated with an increased risk of morbidity and 
premature death (Willet, Manson, Stampfer et al., 1995; Kawachi, 1999).  
   Since chemotherapies are largely water soluble, distributing and metabolizing in lean body 
compartments, loss of lean tissue may increase the risk of treatment complications including  
toxicity, treatment delays and poor treatment response (Aslani, Smith, Allen et al., 2000; Prado 




associated with decreased strength and functional impairment (Prado, Lieffers, McCargar et 
al., 2008) and, in conjunction with gains in adipose tissue, may lead to adverse metabolic 
changes including dyslipidemia, hyperinsulinemia and impaired glucose tolerance (Robinson 
& Graham, 2004).   
     Although the effect of weight gain on disease free survival is uncertain at this time, it is 
clear that obesity, weight gain and associated changes in body composition in the post 
diagnosis period have a negative effect on overall health. An extensive review of non-cancer 
deaths in adult cancer patients revealed an overall hazard ratio that was 1.37 times the expected 
age and sex-specific mortality rate for the general population (Brown et al., 1993).  A greater 
risk of non-cancer related death was attributed to the side effects of cancer treatment and the 
cumulative effects of co-morbid conditions. For breast cancer survivors in particular, the 
relative survival rate (all-cause mortality) is known to decrease with the number of years since 
diagnosis declining steadily to about 70% by 20 years (Canadian Cancer Society/National 
Cancer Institute of Canada, 2007).  
     In addition, weight gain after diagnosis is distressing for many women and may contribute 
to poor quality of life and loss of self-esteem at a time when vulnerable patients are already 
under a great deal of stress (Demark-Wahnefried et al., 1997a; Lankester et al., 2002,). A 
recent study of weight change among African American breast cancer survivors found that 
weight gain was associated with psychological distress, concern about overall health and poor 
body image, especially among women who were not overweight before diagnosis (Halbert et 
al., 2008). In 1986, Knobf reported that, compared to women who lost or maintained their 




distressed about their appearance. Moreover, for some women, weight change after diagnosis 
may serve as a constant reminder of their illness and treatment (Halbert et al., 2008).  
1.4 Potential Mechanisms Accounting for Energy Imbalance 
     Although current evidence suggests that post-diagnosis weight gain correlates most 
consistently with chemotherapy related factors (duration, type), some studies have reported 
significant, albeit smaller weight gains, among breast cancer patients who received no form of 
adjuvant treatment (Camoriano et al., 1990; Goodwin et al., 1988). In addition, some women 
who receive chemotherapy have been shown to lose or maintain a stable weight after 
diagnosis. These findings, coupled with data clearly showing progressive weight gain in many 
breast cancer survivors after initial treatment, suggest that behavioral changes affecting energy 
balance may play an important etiologic role (Rock et al., 1999).  
     Nutritional theory dictates that weight gain occurs when a state of positive energy balance 
follows from an increase in energy intake and/or a decrease in energy expenditure (resting 
metabolic rate, physical activity, thermogenesis) (Demark-Wahnefried et al., 1993; National 
Academy of Sciences, 2005). This section will review current evidence for the role of diet, 
resting energy expenditure and physical activity in the etiology of post-diagnosis weight gain. 
Since the contribution of diet induced thermogenosis (DIT) to total energy expenditure is 
relatively small (~10%) and there is no evidence at this time to suggest that a change in DIT 
contributes to weight gain after diagnosis, this minor component of energy expenditure will not 
be reviewed. It is important to recognize, at this point, that other factors including fatigue and 
psychosocial issues (e.g., depression, coping style) likely play a role. These factors however, 
are thought to be secondary, contributing to weight gain through their affect on energy intake 




1.4.1 Energy Intake – Evidence for the Role of Diet 
     Weight gain in breast cancer survivors has for many years been largely attributed to 
hyperphagia; an increase in food intake after diagnosis (Demark-Wahnefried et al., 1997b). 
Early support for this popular hypothesis was based on the assumption that food cravings and 
an increase in appetite, stress and disinhibition, depression and/or efforts to relieve treatment-
related nausea may lead to overeating in the post-diagnosis period. While there is evidence that 
some women experience these responses to treatment (Brewin 1980; DeGeorge, Gray, Fetting 
& Rolls, 1990; Heasman et al., 1985; Huntington, 1985; Knobf, 1986), early studies were 
limited by small sample size and the absence of dietary data or statistical analysis to 
corroborate patient reports (Demark-Wahnefried et al., 1997b).  
     More recently, food frequency questionnaires (FFQ), 24-hr recalls and food records have 
been used to estimate changes in energy intake after diagnosis. Despite the use of more precise 
dietary assessment tools, recent efforts to quantify energy intake and to evaluate the relative 
contribution of diet in promoting weight gain have produced mixed results.  
1.4.1.1 Changes in Energy Intake after Diagnosis  
     Four studies, in which dietary intake was assessed during treatment, found no significant 
change in energy intake (Del Rio et al., 2002; Harvie et al., 2004; Kumar et al., 2004; Kutynec 
et al., 1999). Using dietary intake before treatment as the baseline, Kutynec et al. (1999) found 
that mean energy intake at 12 weeks was not significantly changed from pre-treatment in pre 
and perimenopausal women (n=18) receiving four cycles of chemotherapy (1678±334 vs 
1897±285 kcals/day) or radiation therapy (1636±376 vs 1577±375). Likewise, mean energy 
intake among 30 postmenopausal women (Del Rio et al., 2002) was reported to be unchanged 




compared to intake before the initiation of treatment (1900±113 kcals). These findings are 
supported by those of Harvie et al. (2004) and Kumar et al. (2004) who found no significant 
change in energy intake after three months of chemotherapy compared to baseline. In the 
former study, participants (n=17) were followed for one year, at which time a small but non-
significant reduction in mean energy intake compared to baseline was observed. All of these 
studies used 3-4 day food records for dietary assessment.  
     One study assessed energy intake pre-diagnosis, during treatment and 12 months after 
diagnosis and found no significant change in mean energy intake over this time period 
(Demark-Wahnefried et al., 2001). Using data from a 116 item FFQ, mean energy intake 
among 36 women receiving adjuvant chemotherapy was estimated at 1543±564 kcals/day at 
baseline (6 month period before diagnosis) and 1578±768 kcals/day and 1631±700 kcals/day, 
six and twelve months after diagnosis, respectively. In the same study, mean energy intake 
derived from two unannounced 24-hr recalls (monthly for six months, bimonthly 6-12 months) 
revealed no significant change in energy intake among women treated with chemotherapy or 
localized treatment only, during or after treatment.  
     Conversely, two studies have reported a reduction in energy intake during and after 
treatment (Demark-Wahnefried et al., 1997a; Goodwin et al., 1999). Demark-Wahnefried et al. 
(1997a) measured dietary intake one to two weeks before chemotherapy and weekly 
throughout treatment using 3-day diet records. Mean energy intake was significantly lower at 
the end of treatment in this sample of premenopausal women (n=20), compared to baseline. 
Mid-treatment comparisons were not reported, however energy intake over the course of 
treatment was reported to be highly variable and responsive to treatment day. Using data from 




diagnosed pre and postmenopausal women (n=535), energy intake decreased significantly in 
the first year after diagnosis compared to intake during the previous year (-88 kcals, p<0.05).  
1.4.1.2 Association between Dietary Intake and Weight Gain 
     Efforts to establish a link between changes in energy intake and weight gain have also 
produced mixed results. Using a series of 24-hr diet recalls during the first and last cycles of 
chemotherapy, Foltz (1985) found that self-reported changes in diet were not significantly 
related to weight change during treatment. Women who did not gain weight (n=10) decreased 
their intake by an average of 193 kcals/day, while those who gained weight (n=24) reported a 
mean increase of 129 kcals; a difference that perhaps owing to small sample size did not reach 
statistical significance. Using 4-day food records before the first cycle of chemotherapy and at 
6 and 12 months, Nissen et al. (2011) found that, among 49 pre and postmenopausal women, 
change in energy intake from baseline was not associated with weight change at 12 months.   
     Rock et al. (1999), however found that in a large sample of women (n=1116) recruited to a 
diet intervention trial (Women’s Healthy Eating and Living), current energy intake, based on 
four 24-hr recalls over a two week period at the time of study entry (mean=26.2 months from 
diagnosis), was a positive and independent predictor of weight gain after diagnosis (p=0.01). 
Similarly, using a 29-item FFQ, Chen, Lu, Gu et al. (2011) reported a significant positive 
correlation between weight gain and total dietary intake (g/day) from diagnosis to 18 months 
post-diagnosis (n=4561, stage 0-IV). Adjusting for age and disease stage at diagnosis, women 
in the highest quartile for dietary intake gained an average of 2.09±0.12 kg compared to a 
mean of 1.45±0.14kg among women in the lowest quartile (p<0.001). These findings were 
based on a limited FFQ, from which energy intake was not estimated, thus limiting ability to 




was weakly correlated with weight change but only among women who did not experience a 
change in menopause status during treatment (premenopausal r=.26, p=0.02, postmenopausal 
r=.21, p=0.01). This suggests that other mechanisms, including changes in energy expenditure 
(reduction in metabolic rate and/or lower levels of physical activity), may be more important 
than changes in diet among women who become menopausal as a result of treatment and tend 
to gain larger amounts of weight (Goodwin et al., 1999).  
     Grindel, Cahill & Walker (1989) found that energy intake among women with stage II-III 
breast cancer (n=19) was significantly higher at baseline (onset of chemotherapy) and over six 
months of treatment, compared to a control group of age and geographically matched healthy 
women. No significant differences between patients and controls were apparent on measures of 
education, income or body weight. These findings however, were based on a small sample of 
women and a limited three day, 56 item dietary diary, suggesting that they should be 
interpreted with caution. Energy intake did not appear to increase over the course of treatment.  
     Lastly, Freedman et al. (2004) found that while 25% of breast cancer patients reported an 
increase in appetite during treatment, no association was observed between increased appetite 
and weight gain. It is noteworthy, however, that no overall weight gain was observed in this 
small sample of breast cancer patients (n=20) and dietary intake was not measured. 
1.4.1.3 Methodological Issues 
     It is clear that, at this time, there is little compelling support for the conventional belief that 
overeating is a primary cause of weight gain in this population. These results however, must be 
considered within the context of some important methodological limitations.  
     Most importantly, dietary assessments in this review were based on self-reported measures 




error, inaccurate estimation of portion sizes and response bias (Hill & Davies, 2001; Kristal, 
Andrilla, Koepsell et al., 1998). Social expectation bias may lead to underreporting, especially 
of foods perceived to be unhealthy or conversely to overreporting of foods considered to be 
healthy and desirable (Caan, Flatt, Rock et al., 2000; Martin, Su, Jones et al., 1996; Thomson, 
Rock, Giuliano et al., 2005). Underreporting is known to be more prevalent among women, 
especially those who are overweight or obese (Hill & Davies, 2001; Trabulsi & Schoeller, 
2001). In addition, the process of being closely monitored (food records, dietitian interviews) 
may have the effect of altering usual food intake during the recording period (Demark-
Wahnefried, 1997a; Stockley, 1985; Trabulsi & Schoeller, 2001).    
     Data from the WHEL study suggests that underreporting may be a confounder among breast 
cancer survivors. Using the methods of Goldberg et al. (1991), Caan and colleagues (2000) 
classified 25.6% of women diagnosed with stage I-III disease as “low-energy reporters” after 
diagnosis and 10.8% as “very low-energy reporters”.  A closer look at the data from the studies 
presented in this review supports the possibility of response bias in this population. Kutynec et 
al. (1999) for example, found that when self-reported energy intake was compared to energy 
expenditure, a negative energy balance was apparent despite having observed no significant 
change in body weight. Underreporting or an actual reduction in usual intake in response to 
record keeping, may explain this finding. Similarly, Harvie et al. (2004) suggested that the 
disparity between reported energy intake, energy expenditure and gains in body fat may have 
been due in part, to underreporting in this sample.  
     While it is recognized that self-reported measures are subject to potential bias, all are valid  
(r=0.4-.06) and reliable (r= 0.5-0.8) dietary intake assessment tools, the precision and accuracy 




techniques (Block & Hartman, 1989; Cann et al., 2000). Most of the recent studies are based 
on 3-4 day food records, which eliminate the potential for recall error and with careful 
instructions for measuring and recording intake, provide a more accurate and sensitive measure 
of dietary change (Block & Hartman, 1989; Hill & Davies, 2001). Food records are generally 
accepted as the more precise instrument and are often used to validate other self-report 
measures (Demark-Wahnefried et al., 1997a). Using doubly labeled water as the standard, 
Prentice, Mossavar-Rahmani, Huang et al., (2011) found that 4-day food records provided a 
stronger estimate of energy intake (ratio of self-report to doubly labeled water = 0.80) 
compared to FFQ (0.72) and three 24-hr recalls (0.77). Martin et al. (1996) found that reporting 
accuracy, based on 7-day food records, compared to doubly labeled water, was ~80% for 
energy intake. There is some evidence to suggest that reporting accuracy may be improved 
with 3-day rather than 7-day food records (Rebro, Patterson, Kristal & Cheney, 1998); a 
finding that is perhaps related to the degree of burden associated with multiple days of record 
keeping (Caan et al., 2000). Furthermore, most studies measured intake before and after 
treatment, focusing on dietary change rather than precision in specific nutrient values.  
     It is also important to acknowledge that while some studies have reported changes in energy 
intake that were not statistically significant, if a true difference exists, small increases in intake 
after diagnosis may well be clinically relevant. Del Rio et al. (2002) observed a trend toward 
an increase in energy intake over six months of treatment (mean of 1900 kcals at baseline vs 
1998 kcals & 2042 kcals at 3 and 6 months, respectively). An increase in energy intake of this 
magnitude, although not statistically significant, could translate into a 2.6 kg weight gain over 
six months; an estimate that is consistent with the observed weight gain in this sample group. 




significant increase in mean energy intake of 96 kcals and 88 kcal/day at three months post-
chemotherapy and one year, respectively; increases that might also produce clinically 
important weight gain over time. In addition, Foltz (1985) reported a 321 kcal/day difference in 
energy intake among women who gained weight compared to those who were weight stable, 
however small sample size, particularly in those who did not gain weight and wide variation in 
intake may have limited the ability of this study and others, to detect significant differences in 
energy intake between groups and over time.   
     Lastly, it must be recognized that differences in the timing of recruitment (pre-
chemotherapy vs. post-treatment), treatment protocols and length of follow-up may account for 
some of the inconsistency in this literature. Moreover, the studies included in this review span 
over more than two decades, during which time chemotherapy treatments have evolved, 
perhaps producing differences in nutrition-related side effects and dietary change.  
1.4.2 Energy Expenditure 
1.4.2.1 Resting Energy Expenditure  
     Basal metabolic rate (BMR) is the rate at which the body expends energy to support basic 
physiological function (heart, lungs, temperature regulation, kidney function etc.). Basal 
metabolism is the largest component of energy expenditure, representing for the average 
person about two-thirds of daily energy needs (National Academy of Sciences, 2005). BMR 
varies significantly from person to person as a function of age, growth and development, body 
size, body composition, illness, hormone levels and environmental stresses. Evidence that 
cancer treatment and therapy-induced hormonal changes could reduce basal energy 
requirements (Arbeit, Lees, Corsey & Brennan, 1984; Demark-Wahnefried et al., 1993) 




(Demark-Wahnefried et al., 1997b; Foltz, 1985). Research in this area however is limited and 
has produced inconsistent findings.     
     Indirect calorimetry has been used to estimate resting energy expenditure (REE) at various 
time points during and after treatment. Indirect calorimetry provides an estimate of resting 
energy expenditure derived from measured oxygen consumption and carbon dioxide 
production and the use of predictive equations. The accuracy and reliability of this measure is 
dependent on a number of factors including equipment calibration, comfortable room 
temperature, allowing for a stabilization period and simulating “resting conditions” as closely 
as possible (e.g., overnight fast, no vigorous exercise for 24-48 hrs, abstaining from smoking 
and caffeine for 12 hrs). Under these conditions, indirect calorimetry is reported to be accurate 
to within 2% of energy expenditure measured by doubly labeled water and is highly reliable 
(Horner, Lampe, Patterson et al., 2001; Jakicic, 2009). Although there were minor variations in 
the protocols, in all but one study (Foltz, 1985), these conditions were reported to have been 
achieved.            
     In seven studies in which REE was measured during treatment, two reported a decrease 
(Demark-Wahnefried et al., 1997a; Harvie et al., 2004), two reported an increase (Del Rio et 
al., 2002; Kutynec et al., 1999) and three found no significant change (Campbell et al., 2007; 
Demark-Wahnefried et al., 2001; Foltz, 1985). These studies are summarized in Table 1.3. 
   A decrease in REE was first noted among 18 premenopausal women undergoing three to six 
months of adjuvant chemotherapy for stage I-II disease (Demark-Wahnefried et al., 1997a). In 
this sample, a significant decrease in REE was seen at midtreatment (1277± 214 vs. 1354± 233 
kcals/d, p< 0.01), but had returned to baseline by the end of treatment. Harvie et al. (2004) 




and remained significantly lower than baseline, at the end of treatment  (-36 kcals/day, 
p<0.05). Post-chemotherapy follow-up of these patients revealed that REE remained low for an 
additional three months (-47 kcals/day) but returned to pre-treatment levels by one year. 
     Two studies found that REE increased significantly after four to six cycles of 
chemotherapy. Kutynec et al. (1999) measured REE in pre and perimenopausal women (age 
27-52 y, stage I-II) before and after four cycles of AC chemotherapy (n=8) or radiation (n=10) 
and found that REE expressed in kcals/kg of lean body mass (LBM) was significantly higher 
after treatment in both groups (39±5 vs 37±4 and 37±3 vs 35±4 respectively, p=0.01). LBM 
was estimated using DXA, which provides a precise measure of whole body and regional 
(head, trunk, limbs) bone mass and non-bone fat free soft tissue (Heymsfield, Lohman, Wang 
& Going, 2005). Small increases in REE in kcals/day and kcals/kg/day approached statistical 
significance (p=0.06). Del Rio et al. (2002) found that among 30 postmenopausal women 
(stage I-II), REE increased progressively over six cycles of CMF chemotherapy, reaching 
statistical significance at six months (p<0.05). This study further evaluated the acute effects of 
adjuvant chemotherapy on REE using repeat measures before and after each treatment. Among 
23 patients receiving chemotherapy, a significant decrease in REE was observed during the 
first and sixth cycle of treatment, however, this effect was also documented in a control group 
of patients receiving a placebo infusion.  
     A recent study in which REE was measured before the initiation of treatment, once per 
cycle and at the end of treatment found that REE was not significantly changed at the end of 
treatment or at any time point across four to six cycles of chemotherapy (Campbell et al., 





     Given that REE is strongly associated with lean body mass in particular (Wang, 
Heymsfield, Ying et al., 2010), changes in REE would be expected to correlate with changes in 
lean tissue, as well as changes in total body weight, however this has not been a consistent 
finding (Demark-Wahnefried et al., 1997a; Harvie et al. 2004). Harvie et al. (2004) for 
example, reported a significant reduction in REE after treatment, which was associated with a 
mean weight gain of 3.0 kg and no change in lean tissue. At one year, REE had increased to 
baseline values despite a significant loss of lean tissue, however, this finding is likely 
explained by progressive weight gain and a significant increase in body fat. Similarly, Demark-
Wahnefried et al. (2001) suggested that a loss of lean tissue during and after chemotherapy 
treatment may have been offset by an increase in fat mass producing a net zero effect on basal 
metabolism. A significant increase in REE (kcals/kg LBM) reported by Kutynec et al. (1999) 
correlated, as would be expected, with a significant loss of lean tissue, however, it is not clear 
why a trend toward an increase in overall REE (kg/day), despite a loss of lean tissue and no 
change in body weight was evident at the end of 12 weeks of treatment. A second study in 
which an increase in REE was reported, found that REE in kcals/day increased progressively 
with weight gain (FM & FFM) over six months of treatment (Del Rio et al., 2002).     
     Collectively, these findings argue against a direct effect of chemotherapy on REE, 
suggesting instead that changes in REE correlate more closely with changes in body 
composition (Del Rio et al., 2002). Inconsistencies across a limited number of studies may 
have resulted from differences in the timing of measurements, chemotherapy protocols      
(e.g., AC, CEF, CMF, CAF) and sample characteristics (Campbell et al., 2007).  Two of the 
current studies for example, measured REE before and after treatment (Foltz, 1985; Kutynec et 




Wahnefried et al., 2001) measured REE at baseline, mid-treatment and end of treatment, 
however mid-treatment timepoints (2 vs 3 months) varied as a function of the chemotherapy 
protocol that was used. Harvie et al. (2004) and Demark-Wahnefried et al., (2001) provided 12 
month follow-up measurements of REE and Campbell and colleagues (2007) measured REE at 
each cycle. The latter study, well designed to investigate possible temporal fluctuations in REE 
during treatment, found no significant change in REE across four to six cycles of AC or CEF.  
Further research, using repeat measures of resting energy expenditure across different 
treatment protocols, may clarify the potential role of treatment specific changes in basal 
metabolism in the etiology of post-diagnosis weight gain (Campbell et al., 2007).  
 1.4.2.2 Physical Activity 
     Physical activity is the most variable component of energy expenditure, on average 
accounting for one-third of total energy output (National Academy of Sciences, 2005).   
Among sedentary adults however, physical activity may account for as little as 15-20% of 
energy expenditure, with low levels of physical activity strongly linked to obesity and weight 
gain (American College of Sports Medicine, 2009). Given that as many as 96% of patients 
report fatigue during treatment (Demark-Wahnefried et al., 1997b; Kumar et al., 2004), a 
reduction in physical activity during this time is expected. Moreover, fatigue has been shown 
to persist for many breast cancer survivors in the years after diagnosis (Meeske, Smith, Alfano 
et al., 2007); a side effect that seems to parallel progressive weight gain.     
     Changes in physical activity patterns after diagnosis and the degree to which these changes 
associate with weight gain, is an area of active research. Early studies focused largely on 
changes in work, home and social activities with mixed results, however, recent investigations 




housekeeping, leisure time, structured physical activity) that can be transformed into an 
estimate of energy expenditure. It is important to acknowledge that all of the research to date 
has been based on self-report measures (diaries, questionnaires, surveys and recall interviews). 
Although many of these indirect measures have been validated (e.g. Standford Five-City 
Project Questionnaire - Sallis, Haskell, Wood et al., 1985; Modifiable Activity Questionnaire - 
Kriska, 1997) and offer the advantage of practicality, low cost and low response burden, all are 
subject to reduced precision and accuracy, recall error and response bias (Prince, Adamo, 
Hamel et al., 2008).     
     Despite these methodological challenges, several researchers have documented a significant 
decrease in physical activity during active treatment and in the year after diagnosis (Demark-
Wahnefried et al., 1997a; Demark-Wahnefried et al., 2001; Irwin, Crumley, McTiernan et al., 
2003; Irwin, McTiernan, Bernstein et al., 2004; Kumar et al., 2004). Using the Stanford Five-
City Project Questionnaire, in 1997 Demark-Wahnefried et al. found a significant decrease in 
the daily energy cost of physical activity (-53 kcals/day, p= 0.04) over 15 weeks of adjuvant 
chemotherapy (n=18, stage I-II, premenopausal). Likewise, Kumar et al. (2004) reported lower 
levels of physical activity (work outside the home/purposeful physical activity) based on the 
Stanford Five-City Project Questionnaire in 56% of pre and postmenopausal women (n=198, 
stage I-III) during six months of treatment. Furthermore, among 53 premenopausal women 
treated for stage 0-III disease, a decrease in physical activity (~30-85 kcals/day) was observed 
in the immediate period after diagnosis compared to usual levels before diagnosis (Demark-
Wahnefried et al., 2001). In the absence of a significant change in REE or energy intake, it was 
suggested by the authors, that reduced physical activity was the most likely contributor to 




was observed during and after treatment, however baseline levels were still not restored in the 
chemotherapy treated women (n=36) at 48 weeks.  
     Similarly, data based on the Modifiable Activity Questionnaire from the Health, Eating, 
Activity and Lifestyle (HEAL) study revealed a significant decrease in physical activity among 
early stage breast cancer survivors (n= 812), four to twelve months after diagnosis, compared 
to activity in the year before diagnosis (Irwin et al., 2003). Overall, patients decreased their 
activity by an average of 2.0 hours per week (11%, p<0.05), with greater decreases in sports 
activities noted among women treated with radiation and chemotherapy (-50%) compared to 
those who were treated with surgery (-24%) or radiation only (-23%, p<0.05). A third study in 
which physical activity during and after treatment was compared to pre-diagnosis levels (n=17) 
found that while a trend toward a decrease in physical activity during treatment and a small 
increase in physical activity at one year were apparent, small sample size may have limited the 
ability to detect a significant difference (Harvie et al., 2004). 
     Not all studies have reported a reduction in physical activity during treatment. Kutynec et 
al. (1999) for example, measured physical activity using a structured physical activity diary 
and found that activity expressed in kcals/day was not significantly different before and after 
chemotherapy or radiation treatment (12 weeks, n=18). Consistent with the findings of 
Demark-Wahnefried et al. (2001), a trend toward an increase in physical activity was in fact 
evident over the course of 12 weeks in the chemotherapy treated women, however perhaps due 
to small sample size and considerable within group variability, was not statistically significant. 
It is noteworthy that the women in this sample did not experience significant weight gain but 
did show an increase in percent body fat and a significant loss of lean tissue; changes in body 




al., 1999). As is suggested by the authors, the absence of data on physical activity before 
diagnosis makes these findings difficult to interpret. It is possible that the use of pre-
chemotherapy (after diagnosis) measures of physical activity as the baseline in this study and 
others (Demark-Wahnefried et al., 1997a; Kumar et al., 2004), may mask a sudden and 
significant reduction in physical activity that occurs at diagnosis (Demark-Wahnefried et al., 
2001) and persists in some women during and after treatment (Irwin et al., 2004).  
     Goodwin et al. (1999) observed a significant increase in physical activity among early stage 
breast cancer patients (n=535) at a one year follow-up, compared to baseline measures taken 
before or during the first month of chemotherapy. In this study, changes in physical activity 
over the year did not correlate with weight change, however the absence of intermittent 
measures of physical activity throughout the year, may have confounded these results. As the 
authors suggest, lower levels of activity during treatment (not measured) among those who 
gained weight gain, may have prompted an increase in activity by one year. Alternatively, an 
increase in physical activity at one year may reflect a return to normal physical activity 
patterns before diagnosis. These studies highlight the utility of pre-diagnosis estimates of 
physical activity, as well as repeat measures during and after treatment, in order to fully 
capture associations between activity and weight change.  
     There is some evidence to suggest that lower levels of physical activity in the post-
diagnosis period correlate with weight gain. Based on a sub-sample of participants from the 
WHEL study (n=1116), Rock et al. (1999) found that lower activity was significantly 
correlated with weight gain after diagnosis. The use of a non-standardized instrument to collect 
physical activity data and a cross-sectional design in which the analysis appears to be based on 




that these findings should be interpreted with caution. More recently, Nissen at al. (2011) 
found that a decrease in physical activity (number of blocks walked per day), based on the 
Paffenbarger Physical Activity Questionnaire, was significantly associated with weight gain 
over 12 months (p<0.05). Using the Modifiable Activity Questionnaire, Irwin and coworkers 
(2005) observed that weight gain and gains in percent body fat, from the first year after 
diagnosis to a follow-up within the third year after diagnosis, were significantly higher among 
women whose sports and recreational physical activity decreased over the same time frame. In 
addition, Goodwin, Esplen, Butler et al. (1998) found that within a multidisciplinary weight 
management program (psychosocial, nutrition, physical activity), aerobic exercise was the 
strongest predictor of success in achieving individual weight maintenance or weight loss goals 
in the first year after diagnosis. These associations are consistent with patient’s perceptions. In 
a small sample of African-American breast cancer survivors (n=34), women who reported 
weight gain (n=16 or 47%, mean weight gain =7.3 kg) attributed this weight gain to a decrease 
in physical activity after treatment (Halbert et al., 2008).  
     Two large cohort studies in which physical activity was measured two and three years after 
diagnosis, revealed that physical activity patterns among breast cancer survivors were 
comparable to women who are free of cancer, with only 32% meeting the minimum 
recommendation (150 min/week, moderate to vigorous activity) for the general adult 
population (Irwin et al., 2004; Caan et al., 2005). Clearly, as is the case with the majority of 
Canadian adults (Canadian Fitness and Lifestyle Research Institute, 2009), there is room for 
improvement in physical activity levels in this population and sufficient evidence to suggest 
that maintaining or increasing activity may assist with weight management. Furthermore, 




body composition (Irwin, Alvarez-Reeves, Cadmus et al., 2009; Winters-Stone, Dobek, Nail et 
al., 2011) and improved quality of life (Courneya, 2003; Sprod, Janelsins, Palesh et al., 2012) 
in breast cancer survivors.    
1.5 Summary of the Literature 
     Weight gain is a common and persistent problem for many breast cancer survivors. As 
many as 50-96% of women experience significant weight gain during treatment (Demark-
Wahnefried et al., 1997b) and many, including some women who remain weight stable during 
treatment, report progressive weight gain in the months and years after diagnosis.  Among 
those who gain weight, average increases typically range from 2.5-6.2 kg, however 
significantly higher gains are not uncommon. Several studies have reported unfavourable 
changes in body composition, with or without weight gain, in this population. Sarcopenic 
obesity, characterized by high body fat and a significant loss of lean tissue is prevalent. This 
unique pattern of weight gain and/or change in body composition is distressing for most 
women, poses significant risk for the development of co-morbid conditions and may impact on 
long term disease free survival.   
     Although there is an established link between adjuvant chemotherapy and weight gain, 
especially for women on longer duration treatments, the underlying mechanisms contributing 
to weight gain are not yet clearly established. It is possible that lengthy protocols, often 
involving the use of multi-agent therapies, simply reflect longer and harsher exposure to the 
conditions that affect behaviour change. Fatigue, nutrition-related side effects, psychological 
distress and the reality of multiple treatment days and medical consults may affect diet and 




     Despite recent efforts to capture possible changes in dietary intake during and after 
treatment, empirical support for an increase in energy intake after diagnosis and an association 
between increased energy intake and post-diagnosis weight gain is lacking. The hypothesized 
mechanisms by which eating behaviour and energy intake might be altered after diagnosis 
(fatigue, stress, changes in appetite, treatment-related nausea), coupled with the known 
limitations of the methodology, suggests however, that the potential role of diet in post-
diagnosis weight gain cannot be ruled out (Demark-Wahnefried et al., 2001).  
     Overall, there is little evidence at this time to suggest that a reduction in basal metabolic 
rate plays a significant role in post-diagnosis weight gain. In seven studies in which REE has 
been measured in breast cancer survivors, only two reported a significant decrease in REE 
during treatment: an effect that was relatively small and transient, returning to pre-treatment 
values within 6-12 months. Within the known limitations of the data collection methods, the 
bulk of the existing evidence suggests that physical inactivity is a significant contributor to 
energy imbalance and weight gain after diagnosis. Several studies have documented a 
significant reduction in physical activity during and after treatment and provide growing 
support for an association between lower levels of activity and weight gain.  
     It is important to recognize that treatment-related side effects likely play a role but are 
considered to be secondary, contributing to weight gain through their affect on energy intake or 
energy expenditure (Demark-Wahnefried et al., 1993). In addition, there is some evidence to 
suggest that alterations in ovarian function and sex hormone concentrations may produce an 
acceleration of the normal physiological changes associated with menopause (Tremollieries et 
al. 1996; Messier et al., 2009) promoting additional weight gain among women who 




based on this review, showing the possible and probable pathways by which diet, physical 
activity and resting energy expenditure interact with secondary factors to promote energy 
imbalance and weight gain in breast cancer survivors is provided in Figure 1.1.  
Figure 1.1: Conceptual Model Showing Possible (---) and Probable (___) Factors 




1.6 Clinical Applications and Future Directions 
     The best clinical advice for breast cancer survivors at this time seems to be a 
recommendation for regular physical activity. Post-diagnosis guidelines and interventions 
should encourage and assist women to be as physically active as is possible within the context 
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cardiovascular and resistance training, should be initiated early and delivered in conjunction 
with supportive programs throughout treatment. Evidence of progressive weight gain after the 
completion of initial treatment suggests that continued intervention and follow-up is also 
warranted. These recommendations are supported by the results of recent exercise 
interventions among breast cancer survivors, in which higher levels of physical activity, 
improvements in quality of life and positive changes in body composition (decreased fat mass, 
preservation of lean tissue and bone density) and physical function were reported (Irwin et al., 
2009; Winters-Stone et al., 2011; Sprod et al., 2012; Anderson, Kimmick, McCoy et al., 2012).   
      Future research should use direct measures of physical activity (heart rate monitors 
pedometers, accelerometers, SenseWear Pro Armbands™) to confirm initial findings in 
relation to post-diagnosis weight change. Sensewear™ armbands, in particular, show promise 
as an objective measure of physical activity over longer time periods, recently providing an 
estimate of mean energy expenditure that was not significantly different, compared to doubly 
labeled water over 10 days (2237±568 vs. 2315±625 kcal/day) (Mignault, St-Onge, Karelis et 
al., 2005).   
     Despite uncertainty concerning the role of diet in post-diagnosis weight gain, current data 
on dietary patterns after diagnosis argue in support of dietary intervention within this 
population. While some women have reported positive dietary changes after diagnosis (an 
increase in fruits, vegetables & fibre, decrease in fat), these changes which might support 
weight management are reported to have been modest, especially among older women, with 
current intakes of fruits and vegetables in particular, still well below recommendations 
(Thomson, Flatt, Rock et al., 2002; Wayne, Lopez, Butler et al., 2004). At this time, there are 




diagnosis. Limited data in this area are largely based on semi-quantitative FFQ (before and 
after diagnosis) and questionnaires or interviews, in which breast cancer survivors have 
reported changes in dietary intake after diagnosis. While these studies have provided important 
insights, changes in diet after diagnosis should be further evaluated, in the context of precise 
measures of current dietary intake.  
     In addition, changes in energy and macronutrient intake relative to treatment days and 
treatment-related side effects have not been reported. Efforts to capture within cycle 
variability, in response to acute side effects of treatment, as well as possible cumulative effects 
of treatment over time are needed, in order to more accurately evaluate possible relationships 
between dietary change, energy imbalance and weight gain after diagnosis. Since not all 
women experience weight gain during treatment, it will also be important to investigate 
possible differences in diet and eating behaviour among women who gain weight versus those 
who remain weight stable; a level of analysis that is not reported in the current literature.  
     While this review has focused on energy intake, since this is central to the energy balance 
equation, breast cancer and its treatment may alter the quality of the diet in ways that affect 
overall health (Doyle et al., 2006) independent of whether or not they result in a measurable 
influence on energy intake and body weight. Therefore, understanding the dietary challenges 
that women experience during and after breast cancer treatment, including psychosocial and 
treatment-related factors that may interfere with healthy eating, is an important first step in 




Table 1.1: Studies Reporting Weight Change among Breast Cancer Survivors                                         
                                                   Sample                                                                                      Frequency                  Mean Weight Gain      
Reference                 (size, key characteristics)             Follow-up    Weight Measures        of Wt Gain       All          Pre-Menop   Post-Menop      Comments                                  
Aslani, Smith, Allen  
et al., 1999  
 
n=25, age 26-70 y (mean = 47 y)  
Pre-Menop (60%), Post-Menop (40%), 
Stage I-III, CMF chemotherapy (6mos) 
6 mos measured ht & wt,  
day 1 of cycles 2 and 6  
 2.35 kg   Wt gain in pre-menop vs. 
post-menop – N/S 
Basaran, Turhal, 




n=176, age 30-100 y (median = 53 y) 
Pre-Menop (28%), Post-Menop (72%) 
Stage I-III, chemotherapy (97%) with 
(69%) or without (28%) hormone 
therapy. Hormone therapy only 3% 
1 y post 
treatment 
chart review of weight 
at diagnosis, < 1 month 
after chemotherapy and 








3.0 kg (1y) 
2.4 kg * 
(after 
treatment) 





2.7 kg (1y) 
 
Campbell, Lane, 
Martin et al., 2007  
 
n=10,  mean age = 46.9 y, 
Pre-Menop (70%), Post-Menop (30%), 
Stage I-IIIA, AC or CEF  
chemotherapy (3-6 mos) 
3-6 mos measured ht & wt  
before and after 
treatment 
70% 1.98 kg 2.6 kg 0.5 kg Trend toward higher wt gain 
in premenopausal women 
but N/S 
Caan, Edmond, 
Natarajan et al., 2006 
 
n=3215,  mean age = 55.3 y 
Pre-Menop (26%), Post-Menop (57%), 
Stage I-IIIA, chemotherapy and/or 
radiation, (15% surgery only) 
5-7 y self-reported wt 1 yr 
before diagnosis and at 




2.4 kg 5.6%  * 3.0%  
Cheney, Mahloch & 
Freeny, 1997 
 
n=34, age 39-73y (mean = 51-56 y) 
Pre-Menop (44%), Post-Menop (56%) 
Stage I-IIIA, current chemotherapy, or 
surgery and/or chemotherapy < 1 y  
6-12 mos measured or chart/self-
reported wt at diagnosis 
(<6mos) and after 
treatment (6-12mos) 
71%    Median gain among women 
who gained wt =  3.2 -3.3 kg 
Costa, Varella &  
del Giglio, 2002 
 
n=106, age 26-78 y (median = 49y) 
Pre-Menop (47%), Post-Menop (53%)  
Stage I-IV (23% palliative), CMF, 
FAC, FEC or AC chemotherapy 
mean = 
4.9 mos 
chart review of patients 
with ≥ 2 weight records 
(≥ 1 mos apart) during 
chemotherapy   
81% 0.91%      
per mos 
 
  Wt gain data excludes 
women receiving palliative 
treatment 
Del Rio, Zironi, 
Valeriani et al., 2002 
 
n=30, mean age = 56 y 
Post-Menop (100%), Stage I-II,  
6 cycles of CMF chemotherapy  
6 mos measured wt before and 
after treatment 
100% 2.8 kg    
Demark-Wahnefried, 
Hars, Conway 
et al., 1997 
n=20, age 27-52y (mean = 39.9 y) 
Pre-Menop (100%), Stage I-II, 
Adjuvant chemotherapy – 12-24 wks  
12 mos measured wt before and 
after treatment 
chart review at 12 mos 
 3.8 kg 
 
  No change in mean body wt 
during treatment 
Demark-Wahnefried, 
Peterson, Winer  
et al., 2001  
 
n= 53, age 27-54 y (mean = 41 y) 
Pre-Menop (100%), Stage I-III 
Surgery with or without radiation, or 
adjuvant chemotherapy 
12 mos measured wt before and 
after treatment (6mos) 
and 12 mos 
 1.0 - 2.1 kg      Mean wt gain at 6 mos      
0.5 - 2.2 kg 
 
Freedman Aziz, 
Albanes et al., 2004 
 
n=20, mean age = 48.2 y 
Pre-Menop (50%), Post-Menop (50%) 
Stage I-IIIA, Adjuvant chemotherapy 
10.5 mos measured ht & wt 
before treatment, 2 wks 
after treatment and 6 
mos post-treatment 
40-60% 0.27 kg  
 
2.43 kg  * 
(6 mos 
follow-up) 
- 0.24 kg  
(6 mos 
follow-up) 
Modest wt gain in 6 mos 
period after treatment     
(1.09 kg) offset by small N/S 
loss during treatment  
 




Table 1.1: continued                                       
                                                   Sample                                                                                      Frequency                  Mean Weight Gain      
Reference                 (size, key characteristics)             Follow-up    Weight Measures        of Wt Gain       All          Pre-Menop   Post-Menop      Comments                                  
Goodwin, Ennis, 
Pritchard et al., 1999 
 
n=535,  mean age = 50.3 y 
Pre-Menop (57%), Post-Menop (38%) 
Stage I-III, Adjuvant chemotherapy, 
tamoxifen or no adjuvant treatment 
12 mos measured ht & wt 
before or during the 1st 
mos of treatment and 12 
mos (n=445)  
84% 1.6 kg 1.93 kg  * 1.07 kg Onset of menopause was a 
significant independent 
predictor of wt gain (p<0.05) 
Gordon, Hurwitz, 
Shapiro & LeBoff, 
2011 
 
n=43, age 34-52 (median = 44) 
Premenopausal, Stage I-II 
12 mos measured ht & wt 
before treatment (within 
4 wks) and 12 mos 
79% median = 
2.7 kg 
  Weight gain in women who 
developed chemotherapy 
induced ovarian failure N/S 
different vs. those who 
retained ovarian function 
Gu, Chen, Zheng, 




n=5014,  mean age = 53.5 y            
Pre-Menop (49%), Post-Menop (51%) 
Stage 0-III, chemotherapy (91%), 
radiation (32%).  
36 mos self-reported wt at 
diagnosis + chart 
review for 95%.  
Measured ht & wt at 6, 
18 and 36 mos 
39% ≥ 2 kg 
(6mos)  
51% ≥ 2 kg 
(18 mos) 
46% ≥ 2 kg    
(36 mos)  
median = 
1.0 kg 





1.5 kg * 
(6mos)   
3.0 kg * 
(18 mos) 
2.0 kg * 
(36 mos) 
0.0 kg 





Weight gain ≥ 5 kg = 15%, 
24% and 21% at 6,18 and 36 
mos, respectively 
Halbert, Weathers, 
Esteve et al., 2008 
 
n=34,  mean age = 57.4 y 
Completed primary treatment for early 





self-reported ht & wt 
before diagnosis and at 
study enrollment (~ 5 y 
from diagnosis) 
47% 79%   Mean gain among women 
who gained wt = 7.3 kg 
Han, Lee, Kim  
et al., 2009  
 
n=260,  mean age = 47 y 
Pre-Menop (61%), Post-Menop (38%) 
Stage I-III, Adjuvant chemotherapy 
and/or hormonal therapy 
  
2 y chart review of ht & wt 
before and after           







0.30 kg    
(3 mos) 
 
6, 12, 24 
mos – N/S 
  Mean gain among women 
who gained wt at 12 mos     
=  1.93 kg  
Wt gain in pre-menop vs. 
post-menop – N/S 
Harvie, Campbell, 
Baildam & Howell, 
2004  
n=17, mean age = 46 y 
Pre-Menop (76%), Post-Menop (24%) 
Early stage, Adjuvant chemotherapy 
12 mos measured ht & wt 
before, mid (3rd cycle) 
and after treatment (1 
month and 9,12 months 
from diagnosis) 
 5.0 kg   Mean wt gain after treatment 
(~6 mos) = 3.3 kg 
Heideman, Russell, 
Gundy et al., 2009 
 
n=271, mean age = 54 y 
Pre-Menop (47%), Post-Menop (53%) 
Stage I-III, 71% chemotherapy and/or 




chart review of ht & wt 
at diagnosis, 1 y after 





(≥ 5 kg) 
2.4 kg 3.9 kg  * 1.1 kg  
Ingram and Brown 
2004  
n=76, age 26-54 y (mean = 44 y) 
Pre-Menop (100%) 
Stage I-II, Adjuvant chemotherapy 
6 mos measured ht & wt 
before, every other 
cycle, after treatment 
34% 
(≥ 2.5 kg) 
1.4 kg   Mean gain among women 
who gained wt = 5.0 kg 
 




Table 1.1: continued                                        
                                                   Sample                                                                                      Frequency                  Mean Weight Gain      
Reference                 (size, key characteristics)             Follow-up    Weight Measures        of Wt Gain       All          Pre-Menop   Post-Menop      Comments                                  
Irwin, McTiernan, 
Baumgartner et al., 
2005  
n=514, mean age = 56 y 
Pre-Menop (31%), Post-Menop (69%) 
Stage 0-IIIA, surgery only (30%), 
surgery and radiation (42%),  
chemotherapy (27%) 
3 y measured ht & wt 
within first year of 
diagnosis (~ 6 mos) and 
2 years after baseline  
(within third year of 
diagnosis) 
 
68% 1.7 kg   Mean gain among women 
who gained wt = 3.9 kg 
18% gained ≥ 5 kg 
Kumar, Allen, Cantor 
et al., 1997  
 
 
n=200, mean age = 56-62 y 
Pre-Menop (11-26%), Post-Menop 
(74-89%), Stage I-II 




chart review of ht & wt 
at diagnosis, after 
treatment (mean = 34 
mos for tamoxifen) and 
final follow-up 




Riccardi et al., 2004 
 
n=198, mean age = 49 y 
Pre-Menop (47%), Post-Menop (53%) 
Stage I-IIIB, Adjuvant chemotherapy 
with or without radiation 
~ 12 mos measured ht & wt 
before and after 
treatment - self-reported 
6 mos post-treatment 
 3.1 kg      
(6 mos 
follow-up) 
  Mean wt gain during 
treatment  N/S 
22% gained ≥ 2.3kg  
Wt gain in pre-menop vs. 
post-menop – N/S 
Kutynec, McCargar, 
Barr & Hislop, 1999 
 
n=18, mean age = 42-44 y 
Pre or perimenopausal (100%) 
Stage I-II, AC chemotherapy (44%) or 
radiation only (56%) 
12 wks measured ht & wt 
before and after 
treatment 
 0.0 -1.0 kg    Follow-up (66-103wks) for 
13 of 18 women revealed wt 
gain in 57-66% of women 
(mean = 4.1-4.7kg) 
Lankester, Phillips & 
Lawton, 2002  
n=100, age 29-73 y (mean = 50 y) 
Pre-Menop (69%), Post-Menop (31%) 
Stage I-III, 6 cycles of  FEC or CMF 
chemotherapy 
~ 6 mos chart review of ht & wt 
before and after 
treatment 
64%          
(> 2 kg)  
27 % 
(> 5 kg) 
3.68 kg   Wt gain in pre-menop vs. 
post-menop – N/S 
Makari-Judson, 




n=185, age 20-91 y (mean = 51 y) 
Pre-Menop (50%), Post-Menop (50%) 
Stage I-IIIB, Adjuvant chemotherapy 
and/or hormonal therapy, 4% no 
systemic treatment 
3 y chart review of ht & wt 







1.5 kg (1y) 
 
2.7 kg (2y) 
 
2.8 (3y) 
  Mean gain among women 
who gained wt (1 y) = 3.7 kg  
Among women who were 
weight stable in year 1, 32% 
gained weight in year 2 
McInnes & Knobf, 
2001  
 
n=44, age 29-75 y (mean = 50 y) 
Pre-Menop (57%), Post-Menop (43%)  
Stage I-II, Adjuvant chemotherapy 
with or without radiation 
 
3 y chart review of ht & wt 






71% (3y)  
4.1 kg (1y) 
 
4.0 kg (2y) 
 
4.9 kg (3y) 
4.2 kg (1y) 
 
4.2 kg (2y) 
 
4.6 kg (3y) 
4.0 kg (1y) 
 
3.8 kg (2y) 
 
5.3 kg (3y) 
Mean gain among women 
who gained significant wt     
( ≥ 2.3 kg)  = 4.7 kg (1 y) 
Frequency of weight gain    
> 2.3 kg = 63%, 68% and 
40% at 1, 2 and 3 y 
 





Table 1.1: continued                                        
                                                   Sample                                                                                      Frequency                  Mean Weight Gain      
Reference                 (size, key characteristics)             Follow-up    Weight Measures        of Wt Gain       All          Pre-Menop   Post-Menop      Comments   






n=49, age 40-54 y (mean = 47 y) 
Pre-Menop (71%), Peri/Post Menop 
(29%). Stage I-III, Adjuvant or 
neoadjuvant chemotherapy randomized 
to physical activity or bisphosphonate 
intervention 
12 mos measured ht & wt at 
baseline (within one 
month of starting 




   Baseline BMI was inversely 
associated with weight gain  
at 12 mos (mean wt change: 
normal weight + 2.0 kg, 
overweight  - 1.4 kg 
obese  - 1.9 kg,  p=0.01)  
Age – N/S 
 
Rock, Flatt, Newman 
et al., 1999  
 
n=1116, age 26 – 70 y (mean = 51 y) 
Pre-Menop at study entry (mean = 26 
mos from diagnosis) (21%),  
Post-menop at study entry (79%) 
stage I-IIIA, Adjuvant chemotherapy 




self reported ht & wt    
1 y before diagnosis and 
study entry  
+ measured ht & wt at 
study entry  
60% 2.7 kg 2.4 kg 4.5 kg  ¶        
(< 50 y) 
 
2.0 kg 
(> 50 y) 
Postmenopausal women       
< 50 y were likely 
premenopausal at diagnosis 
Tredan, Bajard, 




n=272, age 25-73 y (median = 52 y) 
Pre-menop (45%), Post-Menop (55%) 




measured ht & wt at 
baseline (before 
treatment), 9 and 15 






















Mean gain among women 
who gained = 3.2 kg at 9 
mos and 3.9 kg at 15 mos 
Thivat, Therondel, 




n=111, age 32-55 y (median = 54) 
Pre-Menop (45%), Post-Menop (55%) 
Stage I-III, Anthracycline- based 
chemotherapy 
Median 
= 20.4 y 
measured ht and wt 
beginning of treatment 




    
Yaw, Kandiah, 
Shariff et al., 2010 
 
 
n=368, mean age = 54 y 
Pre-Menop (20%), PostMenop (80%) 
Stage I-III, completed chemotherapy 
mean = 
4.9 y 
self reported wt at 
diagnosis. Measured ht 
& wt at study entry  
(mean = 4.9 y post 
treatment) 
49.5% 3.47 kg 5.0 kg * 3.1 kg  
 
Pre-Menop = premenopausal at diagnosis, Post-Menop = postmenopausal at diagnosis  * p<0.05 compared to postmenopausal ¶  p<0.05 compared to premenopausal & 










Table 1.2: Studies Investigating Weight Gain after Breast Cancer Diagnosis and Disease Free Survival (DFS)  
(References for studies in which a positive association between weight gain and DFS are bolded) 
 
                                      Sample                      Follow-up              Weight                                                                     Relationship between                                                                     
Reference        (size, key characteristics)                                   Measures                        Weight Gain                   Weight Gain & OS/DFS             Comments  
Camoriano et al., 
1990  
 
n=646, age 20-75 y 
Node positive disease 
treated with or without 
adjuvant chemotherapy 
 
median = 6.6 y Body weight at 
randomization 
(within 8 wks of 
surgery) and after 
treatment (60 wks) 
Median weight gain: 
Premenopausal = 5.9kg 
Postmenopausal treated = 3.6kg 
Postmenopausal non-treated    
= 1.8 kg 
Premenopausal women who 
gained > median weight had 
higher risk of death (RR=1.6, 
p<0.05). Trend toward 
increased risk of recurrence but 
N/S (RR=1.5, p=0.17)  
Controlled for multiple 
known prognostic 
indicators 
Postmenopausal women – 
weight gain N/S   
Caan et al., 2006 
 
Caan et al., 2008 
 
n=3250, age 18-70  y 




median =  
5 y (LACE)  
7 y (WHEL) 
Body weight 1 y 
before diagnosis 
and at enrollment  
(mean = 23 mos 
from diagnosis) 
Mean weight gain = 2.4 kg 
Weight gain was progressive 
after diagnosis in both groups, 
stabilizing at ~ 3 yrs 
 
No association between weight 
gain and risk of breast cancer 
recurrence 
No association between weight 
gain and DFS or all-cause 
mortality (LACE only ~ 7 y) 
Controlled for multiple 
known prognostic 
indicators 






n=5042, age 20-75 y 
(mean = 53.5) 
Non metastatic disease 
treated with chemotherapy 
(93%) and/or radiation 
(32%) 
median = 46 
mos 
Body weight 1 y 
before diagnosis, 
at diagnosis, 6 and 
18 mos after 
diagnosis 
Mean weight gain = 1.0 kg at 6 
mos and 1.7 kg at 18 mos 
Weight gain 1-5 kg (37%) 
Weight gain >5kg (24%) 
Weight gain 1-5 kg and >5kg 
from one year pre-diagnosis to 
18 mos associated with an 
increased risk of recurrence 
(HR=1.97 and 1.90, p<0.05) 
and all-cause mortality 
(HR=1.89 and 1.71, p<0.05) 
Weight loss >1.0 kg also 
associated with increased 
risk of disease recurrence 
and all-cause mortality.  
Controlled for multiple 
known prognostic 
indicators 




n= 62,   
≥ 4 positive nodes 
Adjuvant chemotherapy  
 




before and after 
treatment 
(12 mos) 
91% of CMF treated women 
gained weight  
Mean = 3.7 kg 
74% of 5FU treated women 
gained weight  
Mean = 2.0 kg 
Weight gain > 10 kg assoc with 
poor prognosis - all 5 women 
who gained > 10 kg had not 
survived at follow-up vs. 48% 
survival in women who gained 
< 10 kg 
All patients at high risk 
for recurrence, based on 
inclusion criteria 
 
Costa et al., 2002 
 
n=106, age 26-78 y, 





up not given  
~ 54 mos  
Body weight  
before and after 
one or more cycles 
of chemotherapy  
(mean=4.9 mos) 
81% of women receiving 
adjuvant or neoadjuvant 
treatment gained weight 
Mean =  0.91 ± 1.19 % / mos  
Trend toward decreased DFS 
for women who gained weight 
but N/S (p = 0.08) 
 
Goodwin et al., 
1988  
n=637,   
mean age across groups = 
42.2-56.5 y 
Localized disease treated 
with or without adjuvant 
chemotherapy 
median follow-
up not given 
Recruitment  
1960-1984 
Body weight at 
diagnosis and 1 
year after 
diagnosis 
Mean weight gain = 
1.21 – 5.55 kg across                
5 treatment groups 
 
No association between weight 
gain (quartiles) and DFS or 
overall survival 
Controlled for multiple 
known prognostic 
indicators 
Weight missing in up to 




Table 1.2: continued 
                                      Sample                      Follow-up              Weight                                                                      Relationship between                                                                     
Reference        (size, key characteristics)                                   Measures                        Weight Gain                  Weight Gain & OS/DFS               Comments  




n=237, age 25-70 y 
(mean = 47.5 y) 
Stage 11  
Adjuvant chemotherapy  
≥ 2 y 
 
Body weight 
before and after 
treatment (12 mos) 
96% of patients gained weight 
during treatment  
Mean = 4.3 kg 
 
No association between weight 
gain (quartiles) and DFS or 
overall survival 
Controlled for lymph node 
status, menopause status 
and type of treatment 
 




n=5204, age 30-55 y 
Invasive non-metastatic 
disease  
Sub-sample from the 
Nurses Health Study US 
median = 9 y 
(range 2-26 y) 
Pre-diagnosis BMI  
and post-diagnosis 
BMI (most recent 
measure ≥ 12 mos) 
32% of patients gained         
0.5-<2.0 kg/m2  
Median = 2.73 kg 
14% of patients gained 
≥ 2.0 kg/m2 
Median = 7.73 kg 
Among never smokers weight 
gain associated with increased 
risk of recurrence   
Wt gain 0.5-<2.0 kg/m2 
RR = 1.40,  p<0.05 
Wt gain ≥ 2.0 kg/m2   
RR = 1.53,  p<0.05  
 
Controlled for multiple 
known prognostic 
indicators 
Similar findings for breast 
cancer death and all-cause 
mortality 




n=32, age 26-68 y 
(mean = 46 y) 
27/32 lymph node 
involvement 
Adjuvant chemotherapy 
~ 2 y Body weight 
before and after 
treatment  
(3 mos) and 2 y 
follow-up 
69% of patients gained weight 
during treatment 
Mean = 1.8 kg 
84% of patients gained wt at 2y  
Mean = 4.18 kg 
Women who had gained weight 
at 2 y had a 36% higher risk of 
recurrence but this effect was 
N/S (p>0.05) 
Stratification by 
menopause status did not 
effect relationship 
between weight gain and 
DFS  
Makari-Judson et 
al., 2007  
 
n=185, age 20-91 y 
(mean = 50.8 y) 
Stage 1-111 
Adjuvant chemotherapy 
and/or hormonal therapy 
3 y Body weight at 
diagnosis and 1,2,3 
years after 
diagnosis 
71 % of patients gained weight 
in the first year- Mean = 1.5 kg  
Mean wt gain at 2 y = 2.7 kg 
Mean wt gain at 3y = 2.8 kg  
Weight gain (>2.5 kg) at 1 y 
was not associated with DFS 
(any breast cancer event 
including new primary),  
relapse-free survival 
(recurrence) or overall survival    
 






n=3993, age 25-87 




6.3 y Body weight 1-5 y 
before diagnosis 
and at study 
enrollment (mean 
= 5.8 y from 
diagnosis 
56% of patients gained > 2.0 kg 
 
14% of patients gained > 10kg 
 
Weight gain >10 kg - 70% & 
78% increase in all-cause and 
breast cancer mortality. 
Among women who gained 
weight, each 5 kg gain was  
associated with increased risk 
of all-cause mortality           
(RR = 1.12, p<0.05) and breast 
cancer death (RR =1.13, <0.05) 











n=111, age 32-55 y 
(median = 54) 
Pre-Menop (45%), Post-
Menop (55%) 
Stage I-III, Anthracycline- 
based chemotherapy 
median = 20.4 y measured ht and 
wt beginning of 




14% of patient gained > 5% of 
initial body weight 
Weight variation - gain or loss 
>5% of initial body weight was 
associated with an increased 
risk of disease recurrence (RR 






Table 1.3: Studies Investigating Changes in Resting Energy Expenditure (REE) During and After Treatment for Breast Cancer   
 (References for studies in which a change in REE was observed are bolded) 
 
Reference                     Sample                                    REE Measure                    Timing of REE                  Key Findings/ 
                                     (size, key characteristics)                                                    Measures                           Comments  
 





mean age = 46.9 
pre and postmenopausal, 
stage 1-111A 
 
Indirect calorimetry using 
formula provided by 
manufacturer 
(K4 b2 metabolic cart) in 
the patient’s home  
Fasted for 12 hrs 
Before chemotherapy, 
once per cycle (within 7 
days of last dose, every 3-
4 weeks) and after 
chemotherapy (4-6 
months) 
No significant change in REE from baseline to after treatment 
(1190±80.27 vs. 1206±56.71 kcal/day, p=0.74) or across 4 
cycles of chemotherapy 
 




mean age 56 y, 
postmenopausal, 
stage 1 or 11 
 
Indirect calorimetry using 
the abbreviated Weir 
formula 
Fasted for 12 hrs 
First day of the 1st, 3rd  and 
6th cycles of  
chemotherapy 
(6 months) 
Significant increase in REE at 6 months (p<0.05) correlating 
with weight gain (mean = 2.8 kg) 
 
Demark-Wahnefried 
et al., 1997 
n=18, age 27-52 y, 
premenopausal,  
stage 1 or 11 
 
Indirect calorimetry using 
the Weir formula 
Fasted and no physical 
activity for 12 hrs 
Before chemotherapy, 
midtreatment and after 
chemotherapy (3-6 
months) 
Significant decrease in REE at midtreatment (1277kcals/d ±214 
vs. 1354± 233 kcals, p< 0.01), but had returned to baseline by 







mean age 41 y 
premenopausal, 
stage 0-111A   
 
Indirect calorimetry using 
the Weir formula 
Fasted and no physical 
activity for 12 hrs 
Before chemotherapy, 2 
months, 6 months and  
1 year 
No significant change in REE over time in women treated with 











Resting state not achieved 
Before and after 6 cycles 
of chemotherapy  
(6 months) 
Change in REE N/S different between women who gained 
weight and those who were weight stable. Significance of 
change over time – not reported 
 





mean age = 46.1 y 
pre and postmenopausal, 
invasive disease  
 
Indirect calorimetry using 
the Weir formula 
Fasted for 12 hrs, no 
caffeine or smoking for 12 
hrs, no vigorous exercise 
for 24 hrs 
Before chemotherapy, 
midtreatment, after 
chemotherapy, 3 months 
post-chemotherapy and 
1 year 
REE appeared to be lower midtreatment (-93 kcals/day) 
(statistical analysis not undertaken at this time point). 
Significant decrease in REE at the end of chemotherapy (-36 
kcals/day, p<0.05). REE lower (-47 kcals/day) at 3 months post 
chemotherapy but had returned to baseline at 1 year (p=0.94) 
REE in kcals/kg FFM appeared to be lower midtreatment but 
was not significantly changed at the end of chemotherapy or 1 
year follow-up  
 





mean age 42-46 y 
pre and perimenopausal,  
stage 1 or 11 
 
Indirect calorimetry using 
the Weir formula 
Fasted for 12 hrs and no 
physical activity for 48 hrs 
Before and after 4 cycles 
of chemotherapy 
REE in kcal/kg LBM/day increased significantly from before 
treatment to after treatment (p=0.01) in chemotherapy and 
radiation treated women – correlating with significant loss of 
lean tissue. Small increases in REE in kcals/day and 




CHAPTER 2:  METHODS 
 
2.1 Sample Recruitment and Selection Criteria 
 
     Participants were recruited from the Waterloo, Guelph, Hamilton and London, Ontario 
Regions to participate in a single qualitative interview, complete validated questionnaires 
(physical and psychological distress), identify changes in diet since diagnosis and provide      
3-day food records. The catchment area was initially limited to the Waterloo and Guelph 
regions, in an effort to increase the homogeneity of the sample (e.g., increase likelihood that 
participants were treated with similar chemotherapy protocols, at the same regional cancer 
centre). Recruitment was expanded to include the Hamilton and London regions after eight 
months, in response to slower than anticipated accrual rates.  
     Recruitment took place over a 14 month period and was conducted using several strategies. 
First, through collaboration with the Canadian Breast Cancer Foundation, a recruitment letter 
(Appendix C) was placed in the “run kits” for the Guelph location of the CIBC Run for the 
Cure on October 3, 2010. On the same day, the recruitment letter was available in the survivor 
tent in the Waterloo location, with the researcher present before and after the run to respond to 
questions. Also in October 2010, the recruitment letter was posted in the Well-Fit Centre at the 
University of Waterloo and with prior consent, four eligible women who had participated in 
our pilot study were re-contacted and invited to participate.  
     In December 2010 the recruitment letter was posted on the Canadian Breast Cancer 
Network (CBCN) online Bulletin Board, with a follow-up research summary posted in the 
CBCN “Outreach” online newsletter in June 2011. Local support groups and programs 
(identified through the CBCN website) were contacted in December 2010, leading to an 




2011 and an offer to circulate the recruitment letter at the Annual General Meeting of the 
Guelph Dragonboat Team later in the month. In addition, advertisements were placed in 
several local, community newspapers early in January 2011 and again in June, July and August 
2011. (Appendix D).  
    In February 2011, the recruitment letter was posted in the HopeSpring Cancer Support 
Centre in Waterloo and forwarded to all group leaders in the main centre and satellite location 
in Cambridge. The recruitment letter was also posted in the Nu Me Boutique in Kitchener, a 
boutique catering to post surgical breast form, compression garments and lingerie needs for 
women having undergone mastectomy, with additional copies made available to interested 
customers. Later in the month, a display booth was set up at the Total Woman Show in 
Kitchener, with the recruitment letter and researcher present over a two day period.    
     With assistance from the Applied Health Sciences Communications Manager, a news 
release providing an overview of the research and contact information was posted in the 
University of Waterloo Daily Bulletin on March 7, 2011 (Appendix E). Also in March 2011, 
contact was made with the Clinical Trials Manager at the Grand River Regional Cancer Centre 
in Kitchener, leading to an invitation to present to the Scientific Review Committee in May 
2011 and subsequent approval (August 2011) to post the recruitment letter in key areas of 
patient care (chemotherapy clinic, supportive care) within the centre.  
     In June 2011, the recruitment letter was circulated via Dietitians of Canada to the Waterloo 
Region Registered Dietitians network, prompting further interest from HopeSpring and a 
research summary posting on the homepage of their website. Finally, attempts to contact 
additional programs for breast cancer survivors (YMCA Encore, Juravinski Cancer Centre: 




made in May, June and September 2011 and the recruitment letter was posted on Kijiiji online, 
an advertising/sales network, in the Waterloo and London areas. Recruitment and accrual 
results summarized in table 2.1. 
   Table 2.1: Recruitment Procedures and Accrual Results  
 
Organization  Procedure 
 
 
Canadian Breast Cancer 
Foundation 
CIBC Run for the Cure, Oct/10.Recruitment letter in “run kits”  
Guelph, Ontario. Recruitment letter and researcher present in 
survivor tent - Kitchener/Waterloo, Ontario   
2 
University of Waterloo Recruitment letter posted in Well-Fit, Oct/10 
(group exercise program for cancer patients) 
5 
University of Waterloo Contacted eligible participants from our pilot study (n=4).      
Interest in pilot study but not eligible (n=1), Oct/10 
5 
Canadian Breast Cancer 
Network 
Recruitment letter posted - online “Bulletin Board”, Dec/10 
Research summary posted in “Outreach” online newsletter, June/11 
0 
Women’s Breast Cancer 
Support  
Email to Kitchener/Waterloo Support Group, Dec/10 0 
Guelph & Wellington Breast 
Cancer Support Group 
Research overview - presentation to breast cancer survivors, Jan/11 
support group meeting 
1 
Guelph DragonBoat Team  Recruitment letter circulated - Annual General Meeting, Jan/11 0 
Your Classifieds Cambridge Times, Kitchener Record, Guelph Mercury, Jan/11 0 
HopeSpring Cancer Support 
Centre 
Recruitment letter posted in centre and forwarded to all group 
leaders, Feb/11. Research overview posted online, June/11 
2 
Nu Me Boutique Mastectomy Specialist 
Recruitment flyer posted in store, Feb/11 
0 
Total Woman Show Display booth, recruitment letter and researcher present, Feb/11 0 
University of Waterloo UW Daily Bulletin - Research overview, March/10 2 
Grand River Regional Cancer 
Centre 
Contacts/Meetings Clinical Trials Manager, March-April/11 
Presentation to Scientific Review Committee, May/11 
Recruitment letter posted in patient areas including chemotherapy 
clinic and supportive care, Aug/11 
1 
Juravinski Cancer Center Email to supportive care services - Wellness Program, May/11 0 
YWCA Encore Email to Encore (exercise program for cancer survivors), June/11 0 
Dietitians of Canada Recruitment letter circulated to Waterloo Region –               
Registered Dietitians network, June/11 
0 
Your Classifieds Cambridge Times, Kitchener Record, Guelph Mercury, June/11 2 
Your Classifieds Hamilton Spectator, Ancaster News, Dundas Star News, Hamilton 
Mountain News, StoneyCreek News, July/11 
2 
Kijiiji Recruitment letter posted online Waterloo, London, July-Sept/11 0 
Canadian Cancer Society Email to “Living Well Beyond Cancer Program”, Sept/11 0 
Your Classifieds Cambridge Times, Guelph Tribune, Waterloo Chronicle, Hamilton 
Spectator, London Community News, Aug/11 
3 





     Those who were interested in the study, based on these initiatives, were asked to call a local 
telephone number or to contact the researcher by email for further information. Once initial 
contact was made, potential participants were screened for eligibility (telephone or email) and 
provided with a detailed information letter (Appendix F). A second telephone call or email 
contact was made within one week, to determine if they were still interested in participating in 
the study, to review study details and respond to any questions. At this point, 100% of eligible 
participants chose to proceed and interviews were scheduled within one-two weeks. All 
women provided written consent before participating (Appendix G).    
Eligibility Criteria 
 
1. Female breast cancer survivors > 18 years of age 
2. Within 12 months of completing chemotherapy 
3. Clinical stage I-IIIA 
4. Able to communicate freely in English (oral and written) 
5. Sufficient cognitive ability to provide informed consent and participate in the study.   
 
     Eligibility was initially based on clinical stage I-II but was expanded to include stage I-IIIA 
after 3 months, in the interest of being more inclusive and to expand recruitment potential. This 
modification prompted a decision to include women who had received both adjuvant and 
neoadjuvant chemotherapy. Two women who were just beyond the 12 month eligibility criteria 
(13 months) but were highly motivated to participate were included early in the research. Two 
women who were five year survivors and one who was pregnant during treatment were 
excluded.  
     Theoretical sampling; a process in which decisions are made as the research unfolds where 
to look for data to best develop an emerging theory (Daly, 2007), was used in the final month 
of recruitment to screen for additional women who had gained weight after diagnosis. At this 
time, it was felt that theoretical saturation had been reached among women who had not gained 




or after treatment. Based on this sampling technique, one potential participant was excluded 
and one was added; this shift in recruitment emphasis thus having minimal impact on the final 
sample.      
2.2 Data Collection Procedures & Instruments 
2.2.1 Study 1  
     The purpose of study 1 was to describe the unique challenges associated with chemotherapy 
in relation to diet and weight management and to explore possible relationships among 
psychosocial and treatment-related factors, dietary intake and weight gain during treatment.  
2.2.1.1 Demographic/Medical Questionnaire 
     All participants completed a demographic/medical questionnaire with the researcher before 
the interview, to collect background data on age, marital status, education and employment 
status, medical and treatment information and weight history (Appendix H). Where there were 
uncertainties (e.g., names of chemotherapy agents or other medications, clinical stage) 
participants referred to official medical documents in their possession or consulted with their 
medical oncologist. Current weight was measured on the same portable scale (Tanita, BF680, 
Arlington Heights, Illinois), calibrated against a standard platform balance scale, with 
participants wearing one light layer of clothing and no shoes. Participants were also asked to 
self-report their weight at diagnosis, end of treatment and current weight and to recall their 
weight history in the year before diagnosis (stable vs. gain or loss > 2.3 kg/5lbs).  
 2.2.1.2 Qualitative Interview  
     A semi-structured qualitative interview explored individual experiences of chemotherapy in 
relation to food intake, eating patterns and factors which may have influenced changes in diet 




researcher and audio recorded, with the written and verbal consent of participants, for 
subsequent analysis. Interviews were scheduled in the participant’s home (n=18) or at the 
University of Waterloo (n=9) based on participant preference. In one case, at the request of the 
participant, the interview was conducted at a local library in close proximity to her home. The 
average interview length was 90 minutes. 
Qualitative Approach 
     Interview questions were largely open-ended with a priori “probes” (based on the current 
literature) in place, to encourage elaboration and richer description. Probes addressed each of 
the following; changes in appetite, food cravings, changes in eating patterns, treatment-related 
side effects, fatigue, emotional distress/mood, family/social support and burden of treatment. 
In many cases, probes were introduced to support elaboration on spontaneously generated 
concerns. Where these factors did not arise spontaneously, they were specifically probed for. 
For example, probes were expressed in either of the following ways, “You mentioned that taste 
changes were a problem for you during treatment, can you tell me a little more about that and 
talk about how it may have impacted on your food intake?” or “Some women have spoken 
about changes in smell during treatment, was this something that you experienced?”.  
     In addition closed-ended questions asked the participants to identify changes in the quantity 
of food intake and physical activity during treatment, compared to their normal diet and 
activity level (before diagnosis). For example: “During treatment, compared to your normal 
diet before diagnosis, do you feel you ate the same amount as you would usually eat, more than 
you would usually eat, or less than you would usually eat?”. These questions were followed by 
probes for changes in food intake and physical activity relative to treatment days, the duration 




and physical activity patterns within cycles or across treatment. Lastly, participants were asked 
to discuss their previous knowledge and level of concern about weight control during 
treatment, including their experience of weight change, their reaction to weight gain or loss and 
whether they were engaged in any weight management efforts during treatment.  
     This approach is consistent with the key tenets of grounded theory methodology; 
“systematic yet flexible guidelines for collecting and analyzing qualitative data to construct 
theories ‘grounded’ in the data”, that start with an emergent, open-ended design (Charmaz, 
2006; Daly, 2007). As outlined in the introduction of this thesis, the qualitative approach was 
designed to circumvent some of the research gaps and methodological challenges associated 
with collecting dietary data during treatment and to go beyond food intake to understand the 
reasons behind dietary choices that women make. Grounded theory methodology provided a 
framework in which to explore the rich detail of the “lived experience” (Charmaz, 2006) that 
would not be captured by food records alone. Using this approach, recalled food intake and 
dietary patterns were placed within the context of the psychosocial and treatment-related 
challenges that women face as they undergo chemotherapy treatment for breast cancer. 
     Grounded theory methods lend well to this exploratory area of research, since there is a 
good fit between the outcomes of grounded theory research and clinical practice (Daly, 2007). 
Aspects of the emergent theory can highlight potential barriers to healthy eating and weight 
management during treatment and suggest possible intervention strategies that are “rooted in 
the lived experience of the participants”. As such, a grounded theory approach may expedite 
the link between research and practice (Daly, 2007) by guiding the development of dietetic 




     It is important to recognize that the kinds of explanations presented in a grounded theory are 
generative rather than definitive, meaning they are offered as a framework that can be further 
tested and are subject to change, as the conditions and experiences of participant’s lives change 
(Daly, 2007). This is a critical concept in the research area under study, since cancer treatments 
are evolving rapidly and the experiences of patients receiving chemotherapy are likely to 
change over time.  
     In keeping with the principles of grounded theory, interviews proceeded according to the 
interview script, which provided structure, consistency and focus (Daly, 2007), but were 
permitted to vary in response to participant issues or concerns. In other words, interviews were 
semi-structured but flexible, with an openness and appreciation for any concerns that arose. 
When necessary, the researcher asked for clarification, invited additional comments, 
paraphrased and summarized responses, in order to ensure that the interview accurately 
reflected each woman’s experience. Informal pre-testing of interview questions was conducted 
with a breast cancer survivor who was ineligible for the current study, to ensure that questions 
were understandable and appropriate (e.g., allowing for open discussion focused on participant 
concerns). 
Statement of Disclosure 
     The current study was designed around a constructivist theoretical position to gather and 
analyze the data. This contemporary approach differs from traditional objectivist grounded 
theory by the belief that theory is not “discovered” based on an objective external reality, but 
instead is co-constructed between the researcher and research participants (Charmaz, 2006). 




are many perspectives on the same reality and meaning is attached through social interaction 
(Charmaz, 2006, Daly, 2007).   
     Based on this assumption, rather than “assuming the pretense of a blank slate”, the 
researcher approaches the investigation with an understanding that qualitative research is 
influenced by the researcher’s guiding interests, previous knowledge and experience (Daly, 
2007). Sensitizing concepts provide initial ideas or questions that serve as “points of departure” 
but should be held lightly, as participants offer clues about the importance of key issues 
(Charmaz, 2006, Daly, 2007). In this study, sensitizing concepts originated from my 
understanding of the current literature and our pilot work, which informed potential and 
presumably relevant lines of inquiry. For example, a priori probes for changes in food intake 
relative to treatment day were based on preliminary findings from our pilot study suggesting 
that energy intake was highly responsive to time from treatment.  
     It is important to acknowledge that, while I adopted a constructivist approach in conducting 
the interviews, some of the methods that were employed reflect an objectivist position. For 
example, the semi-structured format and probes that were used across all interviews, allowed 
for frequency counts to support qualitative findings and to assist in establishing the salience of 
emerging themes (Daly, 2007). This is not uncommon in grounded theory research, since 
variations in grounded theory share many of the same methodological practices (Daly, 2007). 
     It is also important to disclose that my interest in pursuing this area of research was shaped 
by my personal experiences with close friends and family members who have undergone 
chemotherapy treatment for breast cancer. Lastly, several women articulated their comfort in 
sharing their personal information with a health professional, suggesting that my experience 




2.2.2 Study 2.  
     The purpose of study 2 was to investigate relationships among physical and psychological 
distress, current dietary intake, changes in diet and weight gain since the completion of 
chemotherapy treatment. The data for study 2, with the exception of current dietary intake, 
were collected in conjunction with the qualitative interview for study 1.   
2.2.2.1 The Rotterdam Symptom Checklist (RSCL) 
     Symptoms of physical and psychological distress were assessed using the Rotterdam 
Symptom Checklist (Appendix J). This self-report instrument was designed to measure quality 
of life (QOL) in cancer patients and has been used and validated (r=.52-.84 for anxiety, 
physical function and depression) in patients with disease at different sites, including breast 
cancer (deHaes, van Knippenberg & Neijt, 1990; Hopwood, Howell & Maguire, 1991; 
Ibbotson, Maguire, Selby, et al., 1994; deHaes, Olschewski, Fayers et al., 1996; Hall, A’Hern 
& Fallowfield, 1999). In breast cancer patients (n=478), internal consistency based on 
Cronbach’s alpha (r=0.8-0.9) suggests that the Rotterdam Symptom Checklist (RSCL) is 
highly reliable in this population (deHaes et al., 1996).  
     The RSCL is a multidimensional tool, providing sub-scales for physical distress (23 items), 
psychological distress (7 items) and global QOL (1 item), which is easily administered and 
takes approximately 8 minutes to complete. This instrument has been used with early and late 
stage patients undergoing different treatments (surgery, chemotherapy, radiation), proving to 
be easily understandable in a variety of settings (de Haes et al., 1996). A standardized method 
of scoring and extensive normative data, allowed for comparisons of the level of impairment 




     Using this instrument, participants were asked to indicate the extent to which they have 
been bothered by a series of common symptoms (e.g., lack of appetite, tiredness, worrying, 
depressed mood) in the past week. Symptoms of physical and psychological distress were 
interspersed, with responses ranging from 1 (not at all) to 4 (very much). A single global QOL 
item asked the participants to respond to the question “all things considered, how would you 
describe your quality of life during the past week?” This item was scored on a 7 point scale 
ranging from 1 (excellent) to 7 (extremely poor). The sum of physical (range = 23-92) and 
psychological (range = 7-28) symptom scores were calculated to provide a summary estimate 
(composite score) of overall physical and psychological distress, respectively.  
     All raw scores (physical distress, psychological distress, global QOL) were transformed 
([raw score – minimum raw score / maximum – minimum score] X 100) to provide a 
standardized score on a 100 point scale for each domain (see sample raw score transformation, 
pg. 2 of Rotterdam Symptom Checklist). This transformation adjusts for differences in the 
number of items for each sub-scale and allows for comparisons of the level of impairment 
across domains (deHaes et al., 1996). Lower scores imply better functioning or well-being. 
2.2.2.2 Distress Thermometer (DT) 
     The distress thermometer (DT) is a simple, self-report measure in which participants were 
asked to circle the number (0-10) on a visual scale that best describes the amount of distress 
they have been experiencing in the past week (pg. 2 of Rotterdam Symptom Checklist, 
Appendix I). The DT was developed for the evaluation of distress in cancer patients (National 
Comprehensive Cancer Network , 2012) and has been used and validated in breast cancer 
patients (Jacobsen, Donovan, Trask et al., 2005; Hegel, Moore, Collins et al., 2006; 




Saidi et al., 2012). Recent studies have indicated good overall accuracy of this single item to 
identify clinically significant distress in breast cancer patients, relative to the 14-item Hospital 
Anxiety and Depression Scale (0.80-0.95), the 18-item version of the Brief Symptom 
Inventory (0.78) and the Patient Health Questionnaire 9-item Depression Module (0.87) 
(Jacobsen et al., 2005; Hegel et al., 2008; Yong et al., 2012). The DT has been reported in the 
cancer survivorship literature and was included to allow for comparisons of findings.     
  2.2.2.3 Fatigue Symptom Inventory (FSI) 
     The Fatigue Symptom Inventory (Appendix K) was used to conduct a more comprehensive 
assessment of current fatigue. The Fatigue Symptom Inventory (FSI) is designed to measure 
the intensity and duration of fatigue and the extent to which fatigue impacts on quality of life 
(Hann, Jacobsen, Azzarello et al., 1998). This symptom was of particular interest at the time of 
interview, since it is the most commonly reported symptom among breast cancer survivors and 
has been reported to persist for several months (Meeske et al., 2007). This 13 item 
questionnaire has been used with breast cancer patients (Hann et al., 1998; Kumar et al., 2004) 
and has proven to be moderately to highly valid (r=0.57-0.86) among breast cancer survivors, 
both during and after treatment (Hann et al., 1998). Internal consistency based on Cronbach’s 
alpha (r=0.93-0.95) suggest that the FSI is a highly reliable scale (Hann et al., 1998). 
     The FSI consists of 4 items related to intensity, in which participants were asked to rate 
their level of fatigue at its most, least and “on average” in the last week, as well as current 
fatigue, on an 11 point rating scale ranging from 0 (not at all) to 10 (extreme fatigue). 
Participants were also asked to rate how much, in the last week, fatigue had interfered with 
daily living (e.g., general activity, work activity, concentration, relationships) in a 7-item 




final items related to duration evaluated how many days in the past week participants were 
fatigued for any part of the day (range = 0-7) and how much of the day “on average” they felt 
fatigued in the past week (range = 0 - none of the day to 10 – the entire day). Single scores 
were reported for most, least, mean and current fatigue (intensity), number of days and amount 
of time (duration), with a composite score (mean of 7 items) calculated for “interference”. 
     Based on extensive use and strong psychometric properties of the RSCL, DT and FSI in 
breast cancer survivors and evidence that they are easily administered and understood in 
multiple settings, it was determined that further pilot testing of these instruments for the 
current study was not required.   
2.2.2.4 Changes in Food Intake and Physical Activity since       
            the Completion of Treatment 
 
     Changes in diet since the completion of treatment were assessed using a closed-ended 
question asking participants to identify changes in the quantity of food intake since the 
completion of treatment, compared to their normal diet (before diagnosis) and an initial “filter” 
question asking “since your diagnosis have you  made any changes to the kinds of foods you 
eat?” Women who indicated that they had made changes to their diet were asked to elaborate 
about specific changes in food groups/dietary components (Qualitative Interview pg 3, 
Appendix I). Nine items, used in previous research with breast cancer survivors and grounded 
in current dietary recommendations for healthy eating (Maunsell, Drolet, Brisson et al., 2002, 
Health Canada, 2007), were evaluated including fruits and vegetables, legumes, meat, fish, 
dairy products, breads/cereals, desserts, alcohol and supplements. Participants were asked to 
indicate whether they had “introduced”, “increased”, “decreased” or “eliminated” these items 
from their diet since the completion of treatment. In addition, 4 items were further explored to 




and supplements. Based on the work of Maunsell et al. (2002), changes were categorized as 
positive if intake of fruits and vegetables, legumes and fish were reported as increased (or 
introduced) and if intake of meat, desserts and alcohol were reported as decreased (or 
eliminated). Changes in dairy products and breads/cereals were considered positive if women 
report consuming products with a lower fat content or higher fibre content, respectively. Added 
to this study was one additional positive change, based a “change in type” for meat intake 
(lower fat content). Changes in dietary supplement use were of interest, however, in the 
absence of clear evidence (Greenlee, Hershman & Jacobson, 2009) were not classified as 
positive or negative (Maunsell et al., 2002). 
     Although a comprehensive assessment of current physical activity was not included in this 
study, a single closed-ended question asked participants to identify changes in the quantity of 
physical activity since the completion of treatment, compared to their normal activity level 
before diagnosis. This question was followed by probes for changes in work, leisure and 
structure exercise, changes in activity since the completion of treatment compared to activity 
levels during treatment and current level of exercise (type, frequency and duration) over the 
past week. These data were used to provide context for dietary data and energy balance and to 
estimate current physical activity level (sedentary, lightly active, etc) for the purposes of 
calculating estimated energy requirements.  
2.2.2.5 Perceptions of Weight Change, Dietary Supports and Patient Care  
     Lastly, participants were asked to discuss any concerns they may have regarding weight 
management since the completion of treatment, including their experience of weight change, 
their reaction to weight gain or loss and whether they have been engaged in any weight 




chemotherapy treatment, to discuss their knowledge and use of dietary support services and if 
they felt there were additional supports and services that might have been helpful in promoting 
healthy eating and weight management after diagnosis (Appendix I). Probes for the type of 
services, specific guidelines and whether, from the participant’s perspective, there is an 
optimal time in the cancer trajectory to intervene, were designed to inform future research and 
the development of guidelines (with appropriate supports) for healthy eating and weight 
management after diagnosis.    
2.2.2.6   3-Day Food Record  
     Current dietary intake was assessed using a 3-day food record (Appendix L). The 3-day 
food record was provided at the time of interview, for completion in the following week.    
Dietary records were chosen as the method of assessment since, compared to other self-report 
measures (FFQ, 24 hr recalls), they do not rely on recall and may provide a more precise 
measure of dietary intake (Block & Hartman, 1989) (see methodological limitations, pg 36). 
Two weekdays and one weekend day were included in each 3-day record, to control for 
possible day-of-the-week effects (Trabulsi & Schoeller, 2001). 
     Participants were asked to record everything they eat or drink over a 3-day period. Detailed 
written instructions for recording daily food intake and a “sample day” were provided. Each 
day was broken down into separate pages for morning meal, mid-morning snack, mid-day 
meal, mid-afternoon snack, evening meal and evening snack, with columns on each page to 
provide a description (brand, flavour, method of cooking), unit of measure (teaspoon, cups 
ounce, piece) and the number of units for each food item. The time and location of each meal 
and snack was recorded, as well as intake of vitamin/mineral and herbal supplements over the 




normal diet (over the last couple of weeks), they felt they had eaten the same amount, more or 
less than they usually eat. In other words, did this day of recording accurately reflect habitual 
intake?  
     The diet record was reviewed with each participant at the time of interview, to clarify 
instructions and answer any questions. Participants were encouraged to provide as much detail 
as possible and to use household measures (teaspoons/measuring cups/scales) and food labels 
to estimate serving sizes. The goal of capturing usual eating habits (e.g., importance of eating 
as they would normally eat on that day), in as accurate and honest a record as possible, was 
emphasized. During the recording period, participants were contacted by the researcher, by 
telephone or email to see if they had any questions or concerns. Arrangements were made, at 
this time, to pick up the completed diet record at the participant’s home or to coordinate pick 
up at another location that was convenient for the participant (local library, workplace, 
HopeSpring, Well-Fit).  Each completed record was reviewed with the participant, for 
clarification and completeness. 
2.3 Data Analysis and Statistics 
2.3.1 Study 1 
     Descriptive statistics were used to characterize the sample in terms of age, marital status, 
education and employment status, medical and treatment background and weight history.  
Self-reported weight at diagnosis and end of treatment, and measured weight at the time of 
interview were used to categorize participants by weight change (weight gain, weight loss, 
weight stable) during (diagnosis to end of treatment) and after treatment (end of treatment to 
the time of interview). Weight gain or loss was defined in this study as a change in body 




2004) or more recently, a change from baseline weight greater than 5% (Thivat et al., 2010; 
Nissen et al., 2011) to define weight change, while others have elected to use the 2.0 kg 
criterion used in the present study (Lankester et al., 2002; Nichols et al., 2009; Gu et al., 2010). 
This definition was chosen since normal short-term fluctuations in body weight (changes in 
water balance, glycogen stores, dietary intake, illness) may be as high as 2.0 kg in some adults 
(Groff & Gropper, 2000). Recognizing that this level of flux may be transient, several longer 
term studies suggest that weight gain in breast cancer survivors is progressive and durable, 
with a very small percentage of women returning to their pre-diagnosis weight within three 
years of treatment (Irwin et al., 2005, Makari-Judson et al., 2007, Gu et al, 2010). Furthermore 
weight gain itself, regardless of baseline BMI, is associated adverse health consequences 
(Kawachi, 1999; Willet et al., 1995) and may be more distressing among women who were not 
overweight before diagnosis (Halbert et al., 2008). Therefore it was decided that a weight gain 
greater than 2.0 kg in the first year after diagnosis, which is likely to endure, may have 
important clinical relevance. Body mass index (BMI) at diagnosis, end of treatment and time of 
interview were calculated as weight (kg) divided by height (m2). Weight status at each of these 
time points were categorized, according to the World Health Organization classification system 
(WHO, 2011b), as underweight (BMI<18.5 kg/m2), normal weight (BMI 18.5-24.9 kg/m2), 
overweight (BMI 25-29.9 kg/m2) or obese (BMI ≥30 kg/m2).   
     The use of self-reported weight is a potential limitation, however several studies have 
reported excellent correlation (r=0.92-0.99, p<0.01) between self-reported weight and 
measured weight in this population (Rock et al, 1999; Herman, Ganz, Petersen et al. 2005; 




self-reported weight versus measured weight at the time of interview was 0.99 (p<0.01), 
suggesting that self-reported weight is reliable in this sample.   
     Audio recordings were transcribed verbatim by a professional transcriber and imported into   
N-Vivo 9 (QSR International, Cambridge MA) data management software, for organization 
and coding. Qualitative analysis was based on a grounded theory approach (Charmaz, 2006), in 
which key themes and sub-themes around food intake and eating patterns (objective 1) and 
common psychosocial and treatment-related factors associated with changes in food intake 
(objective 2) were coded. The constant comparative method (Charmaz, 2006) was used to 
compare emerging themes across participants and among women who gained weight versus 
women who did not gain weight during treatment (objective 3). These data were used to 
develop a theoretical model (objective 4) to identify possible relationships between 
psychosocial and treatment-related factors, food intake and eating patterns and weight gain 
during treatment.   
     In order to complete this process, coding progressed through three distinct phases.  
Initial coding was based on a line by line review of the transcripts to describe the data and 
identify preliminary codes for subsequent analysis. A list of recurring themes (preliminary 
codes) was established and through a process of focused coding, those most salient were 
retained and combined into related categories, while less frequently occurring themes were 
excluded from the present analysis. Sub-themes within each category were then identified, and 
compared across women who gained weight, lost weight or were weight stable during 
treatment. Theoretical coding was employed in the final stage of analysis, to identify possible 
relationships between categories, to explain how psychosocial and treatment-related factors 




was employed throughout data collection and analysis in order to preserve context and support 
the development of key themes and categories (Charmaz, 2006). 
     Samples of transcripts were reviewed by a second researcher trained in qualitative analysis, 
to establish inter-rater reliability for emerging themes and sub-themes. Inter-rater reliability 
checks were designed to minimize researcher bias and “generate confidence in the 
interpretation of the data” by determining the extent to which similar conclusions were drawn 
(Daly, 2007). During this phase, samples of initial line by line coding of broad themes (n=21), 
as well as detailed summary notes and frequency counts were reviewed.  
     Finally, Spearman’s nonparametric correlation coefficient was used to assess relationships 
between self-reported changes in the quantity of food intake or physical activity and weight 
gain during treatment. Statistical analysis was conducted using the Statistical Package for the 
Social Sciences (SPSS version 20 IBM, Armonk, New York). Significance was set at p< 0.05.   
2.3.2 Study 2 
Objective 1: Descriptive statistics (mean, SD, range) were used to present self-reported 
symptoms of physical and psychological distress (past week), global quality of life and distress 
thermometer scores. These findings are presented in the context of previously reported data in 
early stage breast cancer survivors and random samples of cancer-free adults from the general 
population (deHaes et al., 1996;  Hegel et al., 2006; Yong et al., 2011).      
Objective 2:  Descriptive statistics (mean, SD, range) were used to present the intensity          
(4 items) and duration (2 items) of fatigue and the level of interference (1 item) of fatigue on 
daily activities. A composite score for “interference” was calculated based on the mean values 
across 7-items. These findings are presented in the context of previously reported data in early 




Objective 3: Descriptive statistics were used to identify the nature (positive/negative) and 
extent (percentage of women reporting changes, mean number of changes) of self-reported 
changes in diet (quantity, specific foods groups/dietary components) since the completion of 
treatment.  
Objective 4: Current intake (mean, SD, range) of energy (kcal), carbohydrates (g, % energy), 
protein (g, % energy), fat (g, % energy), fibre (g), calcium (mg) and vitamin D (ug/IU) are 
presented and compared to current dietary recommendations (percentage of women above, 
within, below the DRI Acceptable Macronutrient Distribution Ranges, percentage of women 
below the EAR cut-point). Servings of vegetables & fruit (total, dark green and orange) and 
milk & alternatives were hand calculated based on the 3-day food record. Intake of these food 
groups (mean, SD, range) are presented and compared to Eating Well with Canada’s Food 
Guide (percentage of women above and below age and gender specific recommendations). 
Mean intakes (energy, % energy from macronutrients, fibre, food groups, calcium and vitamin 
D) are also described relative to national data from the Canadian Community Health Survey, 
Cycle 2.2, Nutrition (2004) (Health Canada, 2009).  
Objective 5:  Pearson’s correlations were used to investigate relationships between weight gain 
(kg) since the completion of treatment (dependant variable) and composite scores for 
symptoms of physical and psychological distress, intensity of fatigue, duration of fatigue, level 
of interference associated with fatigue, current dietary intake (energy, carbohydrate, protein 
and fat intake) and self-reported changes in diet (number of positive changes) after diagnosis. 
In order to identify women more likely to gain weight since the completion of treatment, crude 
odds ratios comparing women who gain weight to those who do not gain weight (stable/loss), 




level of interference associated with fatigue, current dietary intake (energy, carbohydrate, 
protein and fat intake) and self-reported changes in diet (number of positive changes) were 
calculated. (Cohen, Cohen, West et al., 2003; Maunsell et al., 2002). Statistical analysis was 
conducted using the Statistical Package for the Social Sciences (SPSS version 20 IBM, 
Armonk, New York). Statistical significance was set at p< 0.05.   
 2.3.3 Sample Size Considerations 
     The projected sample size (n=30) was based on the expected number of participants 
required to reach saturation of qualitative data (Halbert et al., 2008) and to provide novel 
description of physical and psychological distress after treatment, changes in diet and current 
dietary intake. Based on a medium to large effect size and a desired power level of 0.8, a 
sample size of 28-85 is required to detect significant correlations at α = 0.05 (Cohen, 1992). It 
was acknowledged in the design stage that a sample size of 30 may limit statistical power to 
detect significant correlations between survey and diet variables, however we anticipated that 
this research would serve to generate hypotheses and power calculations for future studies.  
2.4 Ethics Approvals  
     This research project was reviewed and received ethics clearance through the Office of 
Research Ethics at the University of Waterloo on September 20, 2010 (Appendix M). Ethics 
modifications were approved on January 14, 2011 to expand the inclusion criteria to clinical 
stage IIIA, add the distress thermometer to the study instruments and to include advertising in 
local newspapers in the recruitment process. Additions to the participant recruitment 
procedures (minor modifications to recruitment letter, permission to include collaboration with 
the Grand River Regional Cancer Centre and expanding the recruitment region to include the 




2.5 Remuneration/Participant Feedback 
Participants received an honorarium of $30 and a breast cancer bracelet at the time of 
interview, in appreciation for their time. In addition, all participants were provided with a 
participant feedback letter (Appendix N) and personalized nutritional assessment (Appendix 







































CHAPTER 3: FOREWARD 
 
     Chapters 3 presents the qualitative findings from study 1 and is focused on food intake and 
eating patterns, factors associated with changes in food intake, and weight change during 
treatment. The data for study 1 are based on the recalled experiences of 28 early stage breast 








































CHAPTER 3:   The Voice of Experience: A Qualitative Analysis of Food Intake, 
Psychosocial and Treatment-related Factors and Weight Change in Women Treated with 
Chemotherapy for Early Stage Breast Cancer. 
 
The work presented in this chapter will be submitted to the Journal of the Academy of 
Nutrition and Dietetics as: 
 
Vance V, Campbell S, McCargar L, Mourtzakis M and Hanning R. The voice of experience: a 
qualitative analysis of psychosocial and treatment-related factors, food intake and weight 




Objectives: Weight gain is a common and persistent problem for many breast cancer 
survivors, however relationships between acute and chronic effects of treatment, dietary 
change and weight gain after diagnosis are poorly understood. The purpose of this study was to 
gain an appreciation of the experience of food intake and weight change during treatment, as 
recalled by women who have received chemotherapy for breast cancer. 
 
Methods: Comprehensive qualitative interviews were conducted with 28 breast cancer 
survivors, within 12 months of completing treatment, to explore individual experiences of 
chemotherapy in relation to food intake and eating patterns and factors which may have 
influenced changes in diet during treatment. Demographic, medical, treatment and weight 
history were collected via questionnaire.  
 
Results:  Food intake during treatment appears to be highly responsive to treatment day, with 
most women reporting smaller, irregular meals and snacks as tolerated and lower food intake 
for the first few days after receiving chemotherapy. In most women, acute side effects of 
treatment began to recede toward the end of the first week, leading to gradual increase in food 
intake and more structured eating in the second and third weeks of the cycle. Women who lost 
weight during treatment (n=6) tended to report more severe and persistent side effects of 
treatment, leading to a more prolonged reduction of food intake after each cycle. Increased 
appetite, food cravings and intake of energy dense comfort foods seemed to be more common 
among women who gained weight during treatment (n=11). In these women, changes in taste, 
nausea and emotional distress were central in promoting these dietary responses. Most women 
reported a reduction in physical activity during treatment.  
 
Conclusions: While the etiology of weight gain in this population is complex, findings from 
this study suggest that food intake and dietary patterns during treatment may play an important 
role for some women. A theoretical model based on these findings may serve to guide future 











     In 2011, it was estimated that 23,400 Canadian women and 230,480 American women 
would be diagnosed with breast cancer (Canadian Cancer Statistics, 2011; National Cancer 
Institute, 2011). Increased screening and advances in treatment have lead to significant 
improvements in survival rates over the last 25 years, however a growing number of women, 
currently estimated to include more than 2.7 million Canadian and American women, are 
living with a diagnosis of breast cancer (Canadian Breast Cancer Foundation, 2011; National 
Cancer Institute, 2011).  
     While most women, particularly those diagnosed in the early stages of disease, will be 
cured of breast cancer, many will gain weight, increase body fat and lose lean tissue after 
diagnosis (Vance et al., 2011). These unfavourable changes in body composition are 
distressing for many women (Halbert et al., 2008; Knobf, 1986) and may increase the risk of 
co-morbid conditions (Brown et al., 1993; Wingo et al., 1998; Robinson & Graham, 2004), 
treatment complications and poor clinical outcomes (Carmichael, 2006; Prado et al., 2007). 
Identifying and addressing modifiable risk factors that will promote overall health, disease 
remission and long-term survivorship is an important health care concern.  
     There are several hypothesized mechanisms by which breast cancer and its treatment might 
influence diet and eating behaviours in ways that promote positive energy balance, but little 
empirical evidence at this time. Although nutrition-related side effects are well documented, 
relationships between acute and chronic effects of treatment, dietary change and weight gain 
after diagnosis are poorly understood. Previous research however, is limited by imprecise 
dietary assessment methods, small sample size and limited dietary data over the treatment 




of treatment, food intake and eating patterns would be expected to be highly variable across 
treatment and within treatment cycles. Dietary intake relative to treatment days and treatment-
related side effects however, has not been reported. This research was designed to explore 
these gaps in the literature; to gain an appreciation of the experience of food intake and body 
weight during treatment, from the perspective of women who have received chemotherapy for 
breast cancer. These findings will help to identify women who may be most at risk of weight 
gain and may assist in the development of nutrition guidelines and appropriate targeted weight 
management interventions after diagnosis.  
     Specific objectives were (1) to describe food intake and eating patterns in relation to the 
experience of chemotherapy, (2) to identify common psychosocial and treatment-related 
factors associated with changes in food intake and eating patterns during treatment, (3) to 
describe similarities and differences in food intake and eating patterns, among women who 
gained weight during treatment, compared to women who did not gain weight and (4) to 
develop a theoretical model based on the experiences of breast cancer survivors, to explain 
how psychosocial factors and treatment-related side effects might influence diet and eating 
patterns in ways that promote weight gain during treatment.  
3.3 Participants and Methods 
 
 3.3.1 Study Sample 
 
     Female breast cancer survivors were recruited from the Waterloo, Guelph, Hamilton and 
London, Ontario regions to participate in a semi-structured qualitative interview. To be eligible 
for this study, women had to be >18 y, clinical stage I-IIIA, within 12 months of completing 
chemotherapy treatment, able to communicate freely in English (oral and written) and capable 




 3.3.2 Procedures 
     Participants were made aware of the study by a recruitment letter that was posted through 
professional organizations/events (Canadian Breast Cancer Foundation Run for the Cure, 
Canadian Breast Cancer Network online Bulletin Board/Newsletter, Waterloo Region 
Registered Dietitians network), local businesses and community support groups. 
Advertisements were also placed in several local newspapers and a recruitment letter was 
posted in the University of Waterloo’s Well-Fit Centre (group exercise program for cancer 
patients) and the Grand River Regional Cancer Centre, Kitchener, Ontario. Interested 
participants were asked to call a local telephone number or to contact the researcher via email, 
at which time they were screened for eligibility and provided with a detailed information letter. 
A second telephone call or email contact was made within one week, to review study details 
and respond to questions. Interviews were scheduled within one-two weeks in the participant’s 
home or at the University of Waterloo, based on participant preference. This research project 
received ethics clearance through the Office of Research Ethics at the University of Waterloo. 
All women provided written consent before participating.  
     Before the interview proceeded, participants completed a demographic and medical 
questionnaire with the researcher, to collect background data on age, marital status, education 
and employment status, medical and treatment information and weight history. Participants 
were asked to self-report their weight at diagnosis and end of treatment and to recall their 
weight history in the year before diagnosis (stable versus gain or loss > ~2.3 kg/5 lbs). In the 
event of uncertainty regarding medical or treatment information, participants referred to 




     The qualitative interview explored individual experiences of chemotherapy in relation to 
food intake, eating patterns and factors which may have influenced changes in diet during 
treatment. Interview questions were largely open-ended with a priori “probes” (based on the 
current literature) in place, to encourage elaboration and richer description. Probes addressed 
each of the following: changes in appetite, food cravings, changes in eating patterns, treatment-
related side effects, fatigue, emotional distress/mood, family/social support and burden of 
treatment, and were used consistently across interviews.   
     Closed-ended questions asked the participants to identify changes in the quantity of food 
intake and physical activity during treatment, compared to their normal diet and activity level 
(before diagnosis). These questions were followed by probes for changes in food intake and 
physical activity relative to treatment days, the duration of acute treatment effects and patterns 
of diet and physical activity within cycles or across treatment. Interviews were conducted by 
the same researcher and audio recorded for subsequent analysis. The average interview length 
was 90 minutes. Participants received a $30 honorarium and a breast cancer bracelet at the time 
of interview and a summary of the research findings at the completion of the study.  
3.3.3 Data Analysis 
     Descriptive statistics were used to characterize the sample in terms of age, marital status, 
education and employment status, medical and treatment background and weight history. 
Weight at diagnosis and end of treatment was used to categorize participants by weight change 
(weight gain, weight loss, weight stable) during treatment. Given that normal short-term 
fluctuations in body weight may be as high as 2.0 kg in some adults (Groff & Gropper, 2000), 
weight gain or loss was defined in this study as a change in body weight greater than 2.0 kg. 




divided by height (m2). Weight status was categorized according to the World Health 
Organization classification system (WHO, 2011), as underweight (BMI<18.5 kg/m2), normal 
weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25-29.9 kg/m2) or obese (BMI ≥30 kg/m2).  
     Qualitative analysis was based on a grounded theory approach, in which key themes and 
sub-themes around food intake and eating patterns and common psychosocial and treatment-
related factors associated with changes in food intake were coded. The constant comparative 
method (Charmaz, 2006) was used to compare emerging themes across participants and among 
women who gained weight versus women who did not gain weight during treatment. Samples 
of transcripts (n=21) were reviewed by a second researcher trained in qualitative analysis, with 
good consensus for themes and sub-themes between both researchers (Daly, 2007). The sample 
size was based on data saturation, however a target of 30 women was anticipated based on 
similar research (Halbert et al., 2008). Spearman’s nonparametric correlation coefficient was 
used to assess relationships between self-reported changes in the quantity of food intake and 
physical activity, and weight gain during treatment. Data management and analysis were 
conducted using N-Vivo 9, (QSR International, Cambridge, MA) and SPSS version 20 (IBM, 
Armonk, New York). Statistical significance was set at p< 0.05.   
3.4 Results 
 
  3.4.1 Sample Characteristics 
 
     A total of 28 women were recruited over a 14 month period between Oct, 2010 and Nov, 
2011. The mean age was 49.8±8.5 y (range = 33-69). Eighteen of the participants (64%) were 
married and most (n=22, 79%) had a college or university education. At the time of interview, 
10 women (36%) were working outside the home, 7 (25%) were on an extended leave of 
absence and 11 (39%) were unemployed or retired. Most of the women (n=25, 89%) were 




Twenty-five women (89%) had undergone lumpectomy or mastectomy. Most of the sample 
group (n=21, 82%) had received or were scheduled to receive radiation therapy. Participants 
received an average of 5.9±1.9 chemotherapy treatments, over a period of 15±4 weeks. The 
mean length of time from completing chemotherapy treatment was 6.4±4.4 months. Twenty-
two women (79%) were receiving hormone therapy at the time of interview. Sample 
characteristics are summarized in Table 3.1.      
Table 3.1: Demographic, Clinical and Treatment Characteristics of the Participants 
 
Characteristic (n=28) Mean (SD) Range n (%) 
Demographic    
Age (yrs) 49.8±8.5  33-69  
Ethnicity                       White 
                                      Black, Asian, West Asian 
 
 
    25 (89%) 
     3 (11%) 
Marital Status               Married 
                                      Single 
                                      Divorced 
     18 (64%) 
     4 (14%) 
     6 (22%) 
Education Completed   High School 
                                      College 
                                      University 
       6 (21%) 
     7 (25%) 
   15 (54%) 
Employment Status       Employed 
                                      Leave of Absence 
                                      Unemployed/Retired 
     10 (36%) 
     7 (25%) 
   11 (39%) 
Clinical History    
Clinical Stage                I 
                                      II 
                                      IIIA 
       3 (11%) 
   15 (53%) 
   10 (36%) 
Menopause Status        Premenopausal 
 (at diagnosis)               Postmenopausal 
     19 (68%) 
     9 (32%) 
Treatment History    
Surgery Type                Lumpectomy 
                                      Mastectomy 
                                      Planned (Mastectomy) 
     15 (54%) 
   13 (35%) 
     3 (11%) 
Chemotherapy              Number of Cycles 
                                     Duration of Treatment (weeks) 
                                     Treatment Type  AC + T * 
                                                                 CT 
                                                                 FEC + T 
                                                                 Other 
                                     Time from Treatment (months)     
  5.9 (1.9) 
   15 (4.0) 
 13 (47%) 
   7 (25%) 
   6 (21%) 
     2 (7%) 









Radiation Therapy        Yes 
                                      No 
                                      Planned 
     16 (57%) 
     5 (18%) 
     7 (25%) 
Hormone Therapy        Tamoxifen 
                                     Aromatase Inhibitor     
                                     None  
17 (61%) 
  5 (18%) 
  6 (21%) 
  






     The mean BMI at diagnosis was 25.9±5.7 kg/m2, with 14 women (50%) in the normal 
weight category and 13 (46.4%) classified as overweight or obese. The mean weight change 
during treatment for all participants was +0.8± 4.6 kg (range = -12.3 - +9.1). Among women 
who gained >2.0 kg (n=11), the mean weight gain was 5.1±2.8 kg. Six participants lost an 
average of 5.2±3.7 kg during treatment. At the end of treatment, the mean BMI was 26.2±5.5 
kg/m2, with 11 women (39.3%) in the normal weight category and 16 (57.1%) classified as 
overweight or obese. Over the treatment period, three women moved from normal weight 
status to the overweight category, while one woman who was overweight at diagnosis was 
classified as obese at the end of treatment. The majority of women (n=19, 68%) reported that 
their weight had been stable in the year preceding their breast cancer diagnosis. Weight history 
is summarized in Table 3.2.   
Table 3.2: Weight History 
 
Weight History (n=28) Mean (SD) Range n (%) 
Weight Status (at diagnosis)    
Body Weight (kg) 72.1 (15.2) 50.9-104.5  
BMI (kg/m2) 25.9 (5.7) 18.1-38.6  
Body Weight Classification  Underweight (BMI < 18.5) 
                                               Normal Weight (BMI 18.5-24.9) 
                                               Overweight (BMI 25-29.9) 
                                               Obese (BMI ≥30) 
 
 
     1 (3.6%) 
14 (50.0%) 
  7 (25.0%) 
  6 (21.4%) 
Weight Change During Treatment     
All participants (kg) 
Women Who Gained Weight (kg)  
Women Who Lost Weight (kg)  
+ 0.8 (4.6) 
+ 5.1 (2.8) 
- 5.2 (3.7) 
-12.3 - +9.1 
+ 2.3 - +9.1 
-2.3 - -12.3 
 
11 (39.3%) 
  6 (21.4%) 
Weight Status (end of treatment)    
Body Weight (kg) 72.9 (14.6) 48.2-101.8  
BMI (kg/m2) 26.2 (5.5) 17.1-36.7  
Body Weight Classification  Underweight (BMI < 18.5) 
                                               Normal Weight (BMI 18.5-24.9) 
                                               Overweight (BMI 25-29.9) 
                                               Obese (BMI ≥30) 
      1 (3.6%) 
11 (39.3%) 
  9 (32.1%) 
  7 (25.0%) 
Weight Change - Year Preceding Diagnosis    
Weight Stable  
Weight Gain 
Weight Loss 
     19 (68%) 
     5 (18%) 




 3.4.2 Food Intake and Eating Patterns during Treatment  
 
     Changes in food intake and eating patterns were universal during chemotherapy treatment, 
with several recurring themes emerging from the data. Most salient among them were changes 
in food intake relative to treatment day, changes in appetite and “food appeal”, including food 
cravings, comfort foods and food aversions. Each of these key themes arose frequently and 
spontaneously in response to an open-ended question inviting women to “discuss their 
experience of chemotherapy from the perspective of food intake and eating patterns”, with 
sub-themes and patterns identified through the use of probes and follow-up questions.   
Changes in Food Intake Relative to Treatment Day 
     Most women reported considerable disruption to their normal eating patterns, relative to the 
day of their chemotherapy treatments. Changes in eating patterns were predominant in the first 
week after treatment, during which time a general trend toward lower food intake was reported. 
Mealtimes tended to be less regular during the first week, with most women reporting smaller 
more frequent meals and snacks, as tolerated. Post-treatment recovery led to a gradual increase 
in food intake and enjoyment in eating in the second and third weeks of the cycle. More 
structure to meals and a return to regular eating patterns were apparent in week three, among 
women who received chemotherapy on a three week treatment cycle (n=19, 68%) . 
* Janelle: So right after the chemo [first day] it was, yeah I wanted to sleep. I didn’t want 
to eat, I just wanted to sleep. By the weekend [3-4 days] it was getting better.  
 
Connie: By the weekend before my next treatment I was starting to feel a little more 
energy, a little stronger, wanted to eat a little bit more.....  
 
Bridget: Back to normal was I’d say, that last 7 days..... because my mouth felt better and 
so on, I made an effort to say you know, I’m eating this for breakfast, this for lunch..... 
 
 * Note: all names presented in this paper have been changed and bear no resemblance to the 





     While most women found that eating was disrupted from the day of treatment, two women 
reported three or four “good’ days, during which they could eat relatively normally, in terms of 
both type and amount of food, before treatment effects presented fully. One of these women 
however, reported fewer good post-chemotherapy days as treatment progressed, while several 
other women found that the “acute” effects of treatment lasted longer with each cycle; both 
patterns suggesting cumulative effects across treatment.  
Lana: Initially, I’d say four or five days and then I found as you go, you get more chemo, 
it knocks you back even more so. It would take longer to do the recovery. 
 
     For some women (n=7, 25%), side effects of treatment persisted into the second and third 
weeks, allowing for a very short window of time in which they felt they could eat normally 
before the next cycle. Three other women reported gradual improvements in eating in the 
second or third week but felt that they had not fully recovered before it was time for the next 
treatment.  
Heather: …..then I’d have about three days I’d feel really good. Not really good, but just 
felt like you were kind of getting better and then it would be time for another one. 
Gail: You know I never actually got back to normal with the taste, with regards to the 
food. But it would have been a lot better compared to the first week. 
Changes in Appetite 
 
     Many women reported varying degrees of reduced appetite during treatment (n=17, 61%). 
Since the terms appetite and hunger are often used interchangeably, for the purposes of this 
paper, appetite refers to the “desire to eat”, based on the sight, smell, taste and thought of food 
(Sizer, Whitney & Piche, 2012). Consistent with eating patterns relative to treatment day, low 
appetite was most commonly reported in the first few days after treatment, generally improving 
by the second and third weeks within two-three week cycles. Many foods were reported to be 




foods that would be well tolerated. Most women reported lower food intake in response to low 
appetite, including irregular meals and smaller portion sizes. 
Quin: I just didn’t have enough energy to grasp any appetite really, nothing was 
appealing. 
 
Faye: For the first three days after treatment, I only ate the bare minimum, wasn’t  
hungry, I had no interest in doing anything and then my appetite increased a little… 
 
     Some women reported an increase in appetite during the treatment cycle (n=8, 29%). 
Among these women, appetite was low for the first couple of days after treatment but spiked 
quickly thereafter. Two women found that their appetite was elevated for 2-3 days only, while 
others felt their appetite was higher through the remainder of each cycle.  
Bridget: That was during the AC [Adriamycin, Cyclophosphomide] that I would get those 
hunger spikes right at the end of that first week and I would eat, that whole weekend. 
 
Seven out of eight of these women felt that increased appetite had led to increased food intake; 
either eating more frequently or an increase in portion sizes at regular meals. 
 Odette:…..I  would eat three servings of lasagna. All of my family noticed…”mom  
        you’re  finishing that?” Yeah, I ate like a horse and I was hungry. 
 
 Nina:…..yeah, I took in a bigger amount of food, that’s for sure. 
Food Appeal - Food Cravings, Comfort Foods and Food Aversions 
     Many women in this sample reported food cravings during treatment (n=21, 75%). Most 
common were cravings for starchy carbohydrates (potatoes, pasta, bread/crackers), salt or sour 
(potato chips, citrus fruits) and sweet foods (ice cream, chocolate milk). Food cravings were 
often very specific, in some cases for foods or food combinations not typically consumed. A 
few women reported a craving for high protein foods (fish, eggs) or high fat foods including 
deli meats, bacon, hamburgers and cheese. Most women accommodated their food cravings 
during treatment. 




Bridget:. ...and it would have to be a specific food, so I would make pasta or with fish in it 
or something bizarre because I wanted to eat that much protein or fat or something. 
 
Heather: ….every once in a while I’d get a craving and it would be something that I  
wouldn’t even really eat. I wanted macaroni and cheese out of the box. Now it’s not  
something I grew up with, but I said “oh today I really want macaroni and cheese”. 
 
     With or without specific cravings, some foods and food groups were reported to be 
especially comforting and well-tolerated during treatment. The most frequently reported 
“comfort foods” during chemotherapy included starchy carbohydrates, bananas, applesauce, 
puddings, yogurt, ice-cream, soups and chocolate milk. With considerable overlap in the 
characteristics of these foods, the common underlying traits were a preference for bland, easily 
digested foods and soft texture or cool temperature, in response to treatment-related 
gastrointestinal disturbance.  
Karen: I pretty much went to a BRATT diet [banana, rice, applesauce, tea and toast]. So it 
worked. I had crackers - you know little crackers and munchies like that. 
 
Bridget: Well I made a lot of soup in the first half. I would make squash and then I would  
mix it with kale and broccoli and beans and I’d make myself a real kind of heavy 
vegetable soup. I’d mash it up and I’d put spice in it like ginger, cinnamon ….it would 
make me feel better. 
 
Roberta: I ate an awful lot of applesauce….. it was good, yes the coolness, the texture.      
I put in some extra cinnamon and that was good, applesauce was really, really good. 
 
      Less commonly reported comfort foods included eggs, ginger ale, sweet foods (cookies, 
syrup) and citrus fruits. While most comfort foods were described in terms of providing 
physical comfort, some women (n=7, 25%) reported that occasional “treats”, typically sweet 
foods or starchy carbohydrates, also provided some emotional comfort during treatment.  
     Food aversions were equally common during treatment (n=21, 75%). Among the most 
commonly reported aversions were meats (red meat in particular), raw vegetables and sweet 
foods. Citrus fruits and juices were poorly tolerated by a few women (n=3, 11%) and were 




related to what they had eaten on or around the day of treatment; a negative association that 
persisted for two of the women beyond treatment.  
Bridget: So I used to be a big fan of Tim Horton’s™ coffee, and I can’t drink it anymore.  
Since then, because there’s something just reminds me of doing chemo and just that taste 
in my mouth and I’ll never touch it again. 
    
     While there were some common themes around food cravings and food aversions in this 
sample group, a preference or distaste for certain foods seemed to be highly individual and 
variable across treatment. Some women for example, reported a craving for sweet foods or 
citrus fruits, while others identified the same foods as extremely unappealing and poorly 
tolerated during treatment. 
Key themes emerging from the data on food intake and eating patterns during treatment are 
summarized in Figure 3.1. 
Figure 3.1: Key Themes for Food Intake and Eating Patterns during Treatment 
 
 
(1) Changes in Food Intake  
      Relative to Treatment Day 
  
• irregular meals and snacks and lower 
food intake in week 1 
• gradual increase in food intake and 
meal structure in weeks 2-3 
 
(2) Changes in Appetite 
 
 
• decreased appetite 
 
• increased appetite 
 
(3) Food Appeal 
 • food cravings 
• comfort foods  
• food aversions 
 
 3.4.3 Treatment-Related and Psychosocial Factors Affecting Food Intake  
     Most women appeared to have excellent recall of their chemotherapy experience at the time 
of interview, and identified several common psychosocial and treatment-related factors 
associated with changes in food intake during treatment. Key themes including fatigue, 




ended question asking “can you talk about how you were you feeling during treatment and 
what factors you think may have influenced your food intake and eating patterns during this 
time”. Follow up questions and probes for other common gastro-intestinal disturbances, 
emotional distress, family/social support and burden of treatment served to identify 
psychosocial factors, sub-themes and patterns within categories.     
3.4.3.1 Treatment-Related Side Effects 
     Most treatment-related side effects presented within one to two days of treatment, with the 
full impact of chemotherapy and associated medications experienced by most women by day 
three or four. Most women found that side effects began to recede by the end of the first week, 
reporting gradual improvements across most symptoms in the second and third weeks after 
treatment.  Women on an accelerated dosing schedule (chemotherapy every two weeks, n= 9, 
32%), tended to report fewer days in which they felt well before the next cycle.  
Karen: Well the timing of the chemo, like I got to experience that within about four  
days. The full impact of the chemo would be there and that affected taste and  
            energy and you know, just the desire to eat or cook. 
Fatigue 
 
     Fatigue was a pervasive and progressive side effect of chemotherapy, reported in 100% of 
women in this sample. Fatigue was described as more acute in the first week after treatment, 
improving gradually for most women in the second and third weeks of the cycle. In addition, 
most women reported a cumulative effect across treatment, with reduced energy and longer 
recovery periods as treatment progressed. For one participant, fatigue was an overwhelming 
side effect that did not relent until the completion of treatment.    
 Faye: …..the actual three to five days [after] in all the treatments were extreme  
            fatigue. I didn’t go anywhere. And then after that I would gradually start feeling  
            stronger and stronger. But with each treatment I had more fatigue. By the fourth one I  





 Valerie: It was very severe in the first week and then by the third week you’d feel ok. 
 
            Elise: I could feel myself starting to feel a bit more run down towards the end, so I  
            was glad I was only doing four [cycles] and then it was going to be done, because I  
            was just feeling more tired.  
 
Quin: The day after I might be fine. Maybe even into the second day. And then after  
that it started going downhill. I got more tired, more tired, more weak, more weak. By  
the time we hit the fourth chemo, I got pretty weak.     
 
     The impact of fatigue was far reaching, with most women reporting very little activity in the 
first week after treatment. Low energy interfered with activities of daily living during this 
phase, including cooking, housecleaning, socializing and structured exercise. The typical 
response to treatment induced fatigue was to rest and recover at home until the acute phase 
passed; afternoon naps and/or resting for much of the day were common. Most women 
appeared to adapt to low energy by doing what they could in small increments and accepting 
that other things could wait until their energy level improved. 
 Lana: I was definitely sleeping, napping through the day. Or just flaked out on the  
            couch. I watched more TV than I’ve ever watched in my life. 
 
 Maureen: Quite tired, certainly there were a couple of days I just spent on the sofa,  
            rather than doing anything at all.  
 
     Fatigue was associated with lower food intake in some women (n=9, 32%), particularly in 
the first few days after treatment. This group of women described that they were “too tired to 
eat”, “couldn’t be bothered” or didn’t have the energy to prepare food, especially if they were 
living alone.  
 Gail: Sometimes, as I said, it’s really the whole thought of food, to make yourself    
            start cooking and that can be pretty difficult.  
 
Changes in Taste 
 
     Taste changes were reported in all but one woman in this sample and appeared to have a 




chemical taste in their mouth, presenting within one to three days of receiving chemotherapy 
and persisting well into the second week after treatment. During this time, there was a general 
sense that their taste buds were “off”; that many foods and beverages tasted bad (n=18, 64%) 
or had no taste at all (n=9, 32%), a loss of taste sensation known as hypogeusia.  
     Taste changes were frequently described in relation to specific foods (e.g., milk, meat, 
fruits, vegetables, coffee) and produced a wide range of dietary responses including food 
cravings, food aversions and lower appetite. Cravings for salt, sour and sweet foods, for 
example were often explained in this context.  
Odette:…. I felt a need for salt and just something sort of vinegary…..something  
that I could taste I think was the reason, because other things were just so bland. 
 
Maureen: The first few days, really the only thing that tasted half way decent was  
sweets, sweet foods, so I was eating more of that. It was pretty much the flavour, 
everything else did not taste good at  all. I didn’t even want it. Not interested. 
 
     Others found that taste changes promoted food aversions; the metallic or chemical taste in 
their mouth exacerbated by certain foods.  
Heather: Toast tasted like metal, so I just, I wouldn’t even eat it. Peanut butter and jam 
on it, eww no. So I’d make myself eat an egg. Something like that...eggs were ok for me. 
Roberta: I never drank milk, I hardly remember eating any salads or fruits, I didn’t eat 
a whole lot, bananas were horrible, peanut butter was horrible, all those things. 
Everything tasted horrible.  
For some women, lack of taste led to low interest in food and poor appetite.   
Lana: There’s just no taste and so it just became kind of a chore to think about eating. 
 
Roberta:…..the worse thing for me with chemo was the taste in my mouth and nobody 
told you about that. I didn’t want to eat anything, nothing. Like nothing tasted good. 
The things that I loved, I don’t know what I survived on really for the first two weeks.  
     A common strategy for coping with taste changes was to add salt or lemon to foods and 
beverages in an effort to enhance flavour or to mask unpleasant tastes. Most women found that 




to resume their regular pattern of eating. For some women (n=5, 18%), severe and persistent 
changes in taste during treatment produced lower than normal food intake and decreased 
enjoyment in eating throughout treatment.  
Gastrointestinal Disturbance 
     Common chemotherapy protocols for non-metastatic breast cancer include 3-4 cycles of 
combined chemotherapy including Adriamycin and Cyclophosphamide (AC) or 5-Florouracil, 
Epirubicin and Cyclophosphamide (FEC), followed by 3-4 cycles of Paclitaxel or Docetaxel 
(T) alone. Among women receiving one or the other of these treatment combinations (n=19, 
68%), many expressed having had more difficulty with gastrointestinal disturbance during the 
AC or FEC cycles. Gastrointestinal symptoms seemed to be less severe while receiving 
Paclitaxel or Docetaxel and most women reported an increase in appetite and food intake 
during this phase of treatment. Paclitaxel or Docetaxel were more commonly associated with 
muscle and joint pain.  
Connie: The Taxol was different because I didn’t really not want to eat. I didn’t have any 
nausea. It’s just after three to four days, maybe two days, by the Saturday I had the aches 
and pains. 
 
Amy: The Taxol was much better than the AC in terms of diet and that nauseous feeling. 
The Taxol I had more leg and joint pain and numbness. 
 
Nausea and Vomiting 
     Some degree of nausea was reported by most women (n=23, 82%) during treatment. Based 
on their recall of the severity and duration of symptoms, nausea was generally mild to 
moderate, frequently described as an unpleasant, flu-like feeling for 3-4 days after treatment.  
 Yvonne: Almost like you’re getting the flu kind of thing, just down more than all out  
         nausea.  
 
 Roberta: I felt nauseated. I didn’t throw up….but if just felt like my stomach was queasy  





     Nausea occurred without vomiting in most cases, however a small group of women             
(n=8, 29%) reported single episodes of vomiting or more prolonged periods of vomiting in one 
or two cycles of their treatment. During this period, dietary responses varied across women. 
Some women reported a decrease in appetite and lower than normal food intake, while others 
found that eating more frequently, starchy carbohydrates in particular, helped to relieve nausea 
for the first few days after treatment.  
 Donna: You want something that’s going to satisfy you and you just keep your  
 stomach full because you’re always hungry and you always want something in your  
 mouth…. I was nauseous and I just wanted to always have something to eat.  
 
 Zoe: Well I also felt like if I didn’t eat, I’d feel more nauseous. So I did try to eat,  
 you know small meals and snacks. 
 
     Overall it appears that for most women, routine use of anti-nausea medications (reported in 
100% of participants) provided reasonably good control of this common side effect of 
chemotherapy treatment. Persistent nausea or extended periods of vomiting however, were 
reported by five women (18%), leading to longer periods of reduced food intake. For most 
women, symptoms tended to be more acute in the first cycle, improving based on increased 
awareness of treatment effects and better anti-nausea medication management in subsequent 
cycles.  
               Maureen:…..and then I went back to oncology [second cycle] and she changed up  
               all my anti-nausea drugs. So the next time was much easier. Still felt kind of icky, but 
               not too bad. By the third time I was eating dinner when I got home from chemo. 
 
Other strategies to help manage nausea included drinking club soda, snacking on soda crackers 
and being outdoors/exercise.  









Constipation and Diarrhea 
      
     Constipation and diarrhea were common concerns during treatment, reported in 21 (75%) 
and 11 (39%) women, respectively. Constipation typically occurred within the first day or two 
after chemotherapy, lasting for two to five days and followed in some cases by diarrhea. Most 
women reported some degree of bloating and abdominal discomfort during this time and ate 
smaller portions until the problem had resolved. Diarrhea seems to have been a relatively 
minor gastro-intestinal side effect of treatment that did not interfere with food intake for most 
women. Diarrhea was generally described as mild and of short duration, however four women 
experienced intermittent episodes throughout treatment. Medications to prevent constipation 
are commonly recommended during treatment such that, with routine use from the onset of 
chemotherapy, some women were able to minimize or avoid this well established side effect. 
For others, the addition of stool softeners (e.g., Colace, Dulcolax) and fibre laxatives after the 
first cycle helped to relieve symptoms. In addition, many women managed this potential side 
effect using dietary strategies including increased fruit and vegetable intake, high fibre cereals 
and plenty of fluids. 
Heartburn  
     Heartburn was an issue for 16 women (57%) during treatment, five of whom had a history 
of acid reflux before diagnosis. The majority of women described their experience of heartburn 
as mild, occasional and/or of short duration, however some reported more severe or persistent 
symptoms across treatment. For these women, the discomfort associated with heartburn lead to 
sleep disturbance and lower food intake.  
Irene: All the time. I ate Tums like there was no tomorrow. I’d wake up in the middle 
of the night with it. Oh, it doesn’t matter what you eat and there was no rhyme or 
reason to it. You’d get heartburn and ok I’ll stay away from that food. Try another 




     Some women reported the routine use of prescription medications or over-the-counter 
antacids to manage symptoms. Others found that heartburn resolved within a few days, without 
the need for medical intervention.          
Mouth Sores 
     Mouth sores are a common side effect of chemotherapy, however they were reported in this 
sample in only 9 women (32%). In addition, a few women (n=4, 14%) reported tender gums or 
sore throat that did not develop into open mouth sores. Symptoms were typically mild, with 
minimal sores occurring in a single cycle for most women. The majority of women managed 
this side effect through careful oral hygiene and regular use of mouthwash or salt water rinses. 
One woman experienced more severe symptoms in the first four cycles. Her symptoms were 
relieved somewhat by initiating routine use of mouthwash in the second half of treatment; 
stressing the importance of prophylactic management early in treatment.  
Tory: Once I sort of figured it out, like just used it [mouthwash] as much as possible, it 
really helped. I think mine got really bad because I didn’t start using it right away. And 
then I learned that right after chemo, there are certain days that they would just flare up.  
     Overall mouth sores did not seem to have a significant influence on food intake during 
treatment. Some women however, mentioned that soft or cool “comfort foods” were especially 
well tolerated when mouth sores were present.         
  3.4.3.2 Psychosocial Influences on Food Intake  
Family Influences and Social Support 
    
     Twenty of the women in this sample group (71%) were married or living with a partner or 
parent during the treatment period. Most reported that their husband, partner or parent had 
done much or all of the food shopping and cooking while they were in treatment and that they 
were able to eat with their family on most days. In some cases, special foods that were better 




treatment. Living with a spouse, partner or parent appeared to have a significant impact on 
food intake for these women, with many suggesting that having someone else do the cooking 
contributed to both the quantity and quality of meals and snacks throughout treatment. A few 
women (n=5, 18%) found that they were able to do most of the cooking, with some help from 
family and friends. Two of these women reported that they preferred to do the cooking and 
were focused on preparing healthy meals for themselves and their families.   
     Seventeen women (61%) had children living at home while they were receiving treatment. 
Having children at home did not seem to influence food intake for most women, however some 
expressed that maintaining family meals was part of an effort to create a sense of “normalcy”, 
especially for younger children.  
     Extended family and friends prepared and delivered food for most of the women during 
treatment, however very few women felt that this impacted significantly on their overall food 
intake. Some women reported that meals and snacks from family and friends were well 
tolerated and alleviated worry about food preparation after treatments.  
Paula: People were bringing in food and things like that, which was really nice. Then I 
thought to myself I don’t have to worry about eating today. 
Others found that enjoyment of outside foods was challenged by taste changes that were not 
well understood by those bearing food. Although meals and snacks provided by family and 
friends were sometimes poorly tolerated by the women themselves, many expressed 
appreciation for the practical assistance this provided, since these foods were frequently 
enjoyed by their husbands and children. Moreover, many women commented that regardless of 
their food tolerances, the show of support and social visits around food provision were 
comforting. Many women also emphasized that practical assistance (parents caring for young 




other expressions of support (phone calls, cards, flowers) provided much comfort during 
treatment. In most cases there was a strong sense of having been “well cared for”, which seems 
to have played a significant role in emotional well-being. 
Gail: I was extremely lucky and I think I had a very, very good support system and 
everybody wanted to do something whenever they could, you know. That was great. 
Heather: Yeah a lot of good people and cards came every day. I got 150 cards. And 
some people, one friend, she was working all the time but she wrote me every week. 
Tory: My parents live [close by], so yeah they’ve been good through all this, and my 
dad… he used to come with me for my oncology checkups and he always wanted to….. 




     Many of the women in this sample expressed that “all things considered” they felt 
“reasonably good” emotionally and that the emotional impact of cancer and its treatment was 
not a determinant of food intake during treatment. Others (n=13, 46%) however, expressed 
some degree of anxiety, largely centered on anticipated or unknown side effects of treatment.  
Karen: Like the first time, you didn’t know what to expect. I mean people tell you all 
this stuff, but your experience is your own…..bit of anxiety with that you know. 
 
     Most of these women felt that stress may have contributed to nausea and fatigue, leading to 
lower food intake (n=6, 21%) or an increase in intake of energy dense, comfort foods (n=5, 
18%) for at least a portion of the treatment period.   
 Connie: Well I think the first time for sure there’s a little bit of stress and fear and that  
            would have contributed to some of that [nausea]. 
 
 Janelle: I think I probably eat less when I’m stressed. Yeah, I know some people love to  
            eat when they’re stressed, other people don’t. 
 
 Yvonne: If I have a lot of emotions, I tend to overeat. So if anything it would have  
            caused me to eat the high calorie stuff….frozen yogurt with sauce or something like  
            that. 
 





     For most women however, anxiety was mild and transient, dissipating somewhat as 
treatment progressed. A small group of women (n=4, 14%) appeared to have a more 
pronounced emotional response to their breast cancer diagnosis that persisted throughout 
treatment. These women expressed anxiety about survival, low mood or concern for being 
dependent on others. Two of these women reported that during treatment they had eaten more 
than they would usually eat compared to their normal diet before diagnosis. The other two 
women reported that they had eaten less than they would usually eat, suggesting that food 
responses to stress are highly variable.      
Treatment Burden  
     It was expected that the burden of multiple appointments, medical tests and treatments may 
contribute to fatigue and changes in food intake during treatment. Although most women 
acknowledged that treatment for breast cancer was a “full time job”, only two reported 
interference with food intake associated with the burden of treatment. For one woman, lower 
food intake on treatment day was associated with anxiety and longer waiting periods, while the 
other felt that she had relied more on convenience foods after treatments.  
 Sadie: The first time I went [for chemotherapy], I sat there for a very long time and that  
            got me you know, very anxious and all there was  was those cookies there.  
 
 Wendy: …..if you’re mentally tired, you don’t have the energy then to make the food.  
            You know, you look at the fridge or the freezer and you think “ugh”. There was a time  
            when all I was doing was buying Lean Cuisines™ and eating those basically.   
 
     Most women found that their appointments and treatments were predictable and were thus 
able to plan accordingly. Depending on the time of day, many women took snacks with them 
on treatment days, especially when lengthy intravenous chemotherapy was anticipated.  
 Elise: My appointments were pretty well scheduled…..When you first decide you’re  
            going to do chemotherapy, there’s a great flurry of appointments and then I find it kind  





     Three women who lived a further distance from the cancer centre, were accommodated with 
appointments and treatments scheduled on the same day and likewise reported no difficulties 
or interference with food intake. Although there was no direct link between treatment burden 
and changes in food intake for most women, many felt that keeping pace with the need for 
multiple appointments, contributed to fatigue during treatment.  
Key themes emerging from the data on treatment-related side effects and psychosocial factors 
associated with food intake and eating patterns during treatment are summarized in Figure 3.2. 
Figure 3.2: Key Themes for Treatment-Related Side Effects and Psychosocial Factors 
Associated with Food Intake and Eating Patterns during Treatment       
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     While common underlying themes were apparent across the sample group, individual 
dietary responses to psychosocial and treatment-related side effects varied considerably. Taste 




responses to nausea ranged from decreased appetite and lower food intake to reports of 
increased appetite and eating more frequently throughout the day, in an effort to relieve 
symptoms. Likewise, the emotional impact of cancer and its treatment was associated with 
increased intake of energy dense comfort foods in some women but not others. With these key 
themes in mind, the constant comparative method was used to identify similarities and 
difference in food intake and eating patterns among women who gained weight versus women 
who did not gain weight during treatment.  
 3.4.4 Food Intake and Eating Patterns in Women who Gained Weight Compared  
               to Women who Did Not Gain Weight During Treatment.  
 
     The qualitative design of this study precludes statistical comparisons, however, some 
patterns emerged from the analysis suggesting possible group differences among women who 
gained, maintained or lost weight during treatment. Among women who gained weight, acute 
disruption in eating patterns (lower food intake after treatment) appeared to be shorter in 
duration, with most experiencing a return to normal eating patterns within one week of 
treatment. Those who were weight stable during treatment reported disruptions in eating 
generally ranging from 7-14 days. Women in either category generally reported more regular 
meals or smaller, more frequent meals/snacks across treatment compared to women who lost 
weight. Conversely, most of the women who lost weight during treatment reported a more 
prolonged reduction in food intake or irregular eating patterns throughout treatment. These 
women were more likely to report pronounced day to day variability in food tolerance and 
more difficulty in selecting foods that were appealing and enjoyable compared to women who 
gained weight or were weight stable during treatment.  
     Increased appetite appeared to be more commonly experienced by women who gained 




treatment reported an increase in appetite, compared to 12% among those who lost weight or 
were weight stable during treatment. Although many of the women who gained weight 
reported an increase in appetite, others felt that their appetite was lower during treatment. 
Some of these women however, were conscious of eating regular meals, despite poor appetite, 
over concern for maintaining adequate nutrition and avoiding treatment delays.  
Paula: I had to force myself to eat because I know that if I didn’t, if the blood result 
were not good, they weren’t going to give me my treatment. So I tried to eat nutritious 
meals. 
 
Heather: I wasn’t really interested in food during all of chemotherapy. I made myself 
get up and eat breakfast. I told myself I was going to make sure I got up every day and I 
ate every day. 
 
     For some women who gained weight, low appetite and low food intake alternated with food 
cravings and increased intake of energy dense comfort foods. 
Faye: There again it’s up and down. I wouldn’t want any food. I could go days without 
eating food and then I would want comfort food, and then I’d eat too much. 
 
Heightened awareness of eating enough food and periods of comfort eating in this sub-group of 
women may account in part, for positive energy balance during treatment. Others may have 
compensated or over-compensated for lower energy intake in the first few days, as acute side 
effects receded and regular eating patterns resumed in the second week after treatment. 
Furthermore for two of these women, appetite improved after the first cycle of treatment, with 
the introduction of a new medication and better control of treatment-related nausea. 
     Food cravings also seemed to be more commonly described by women who gained weight 
(82%), compared to those who were weight stable (72%) or lost weight during treatment 
(66%). Overall, the types of food cravings across weight change categories were quite similar, 
however women who lost weight or were weight stable described their cravings as occasional 




more enduring across treatment. The nature of food aversions or comfort foods did not appear 
to vary between women who gained weight and those were did not gain weight during 
treatment.  
     There were some apparent differences in the experience of chemotherapy, across weight 
change categories, that may explain some of the variability in food intake and dietary patterns 
that were reported. First, although fatigue was a universal side effect of treatment, six women 
(21%) felt that extreme fatigue had led to a more prolonged reduction in food intake. Four of 
these women lost weight during treatment. Persistent, overwhelming fatigue was reported in 
one woman who lost more than 12 kg over 18 weeks. Two women felt that they had eaten 
more in response to fatigue, in an effort to increase energy. Both of these women gained more 
than 2.0 kg during treatment. Similarly, taste changes were reported across all weight change 
categories, however, a search for foods that would taste good or a “need to eat” in order to 
mask bad taste was a response described only by women who gained weight or were weight 
stable during treatment.   
Sadie: They put all this stuff in your body and then it just comes out. Like I could taste the 
poison in my mouth. And then at the same time like you know, you want to eat because 
you want to get rid of that taste.  
     Persistent nausea or extended periods of vomiting were reported in only a small number of 
women, most of whom lost weight during treatment. One woman who was weight stable, 
despite persistent nausea, received two cycles of chemotherapy and refused further treatment 
and one who gained weight reported several episodes of vomiting in one cycle only. The latter 
participant and others (n=4) found that eating more frequently and having starchy carbohydrate 
rich foods in the stomach helped to relieve treatment-related nausea. All of these women 




     Constipation seemed to be reported more frequently among women who lost weight during 
treatment (100%) compared to those who gained weight (64%) or were weight stable (73%), 
producing abdominal discomfort and reports of decreased food intake in many of these women, 
for longer periods of time between cycles. Heartburn concerns were equally dispersed across 
weight change categories, although seemed to be more severe among women who lost weight 
during treatment, producing sleep disturbance and decreased food intake. The timing of 
heartburn symptoms was highly variably across women and within cycles, such that no 
consistent patterns were evident.  
     Severe muscle and joint pain was reported only in women who gained weight or were 
weight stable suggesting that this side effect of treatment and the associated reduction in 
physical activity may play a role in promoting energy imbalance during treatment.  
     Living arrangements may also be associated with weight change during treatment. Forty-
five percent of women who were married or living with a partner or parent during treatment 
gained weight and 20% lost weight, compared to 25% and 33% respectively, among women 
who lived alone. This finding likely reflects the level of cooking support available to women 
after treatment, since those who had a significant other in the home, expressed that their 
husband, partner or parent had assumed most of the responsibility for food preparation. Some 
women who lived alone found that fatigue interfered with their ability or motivation to prepare 
meals.   
     While dietary responses to stress seem to be highly variable, weight gain was reported in 
four out of five of the women who felt that anxiety and stress had lead to periods of overeating 
during treatment; suggesting that the emotional impact of breast cancer and its treatment may 




     In response to the standardized question “during treatment, compared to your normal diet 
before diagnosis, do you feel you ate the same amount as you would usually eat, more than you 
would usually eat or less than you would usually eat?”, 18 women (64%) reported that they 
had eaten less and 9 (32%) reported that they had eaten more. Seventy-three percent (n=8) of 
women who gained weight during treatment reported an increase in food intake. Most of these 
women felt that they had increased their portion sizes and/or increased their consumption of 
energy dense foods including fast foods, high fat and high sugar snacks.  
 Fran:…I was craving certain things probably more than I used to….hamburgers, fries 
            and anything really. I don’t eat that kind of stuff ever…..maybe bread, sugar, stuff with 
            sugar in it.  
 
All of the women who were weight stable and 83% of women who lost weight, reported a 
decrease in food intake during treatment. Self-reported increase in food intake was 
significantly correlated with weight gain during treatment (r=0.55, p<.01). 
 3.4.5 Diet, Physical Activity and Weight Gain during Treatment.  
 
     These findings provide support for an association between diet and weight gain, however in 
order to characterize energy imbalance during treatment, changes in food intake must be 
considered within the context of changes in physical activity during the same time frame. In 
response to the standardized question, “during treatment, compared to your normal physical 
activity level before diagnosis, do you feel were as active as usual, less active or more 
active?”, 22 women (79%) reported that they were less active during treatment, 3 (10.5%) felt 
that they were as active as usual and 3 (10.5%) felt they were more active. 
     Lower levels of activity were attributed to treatment-related side effects (fatigue, nausea, 
muscle/joint pain), as well as a reduction in work-related activity. Physical activity was 




reduction in both structured exercise and activities of daily living. Most women reported a 
gradual increase in activity in the second or third weeks, with many able to resume their 
normal day to day activities (shopping, housecleaning, socializing) and some structured but 
lower intensity exercise by week three.  
Gail: The first week I literally wouldn’t or couldn’t do a whole lot. And then by the  
second and third week I would feel like doing some exercise, you know, trying to move  
and do things. 
 
Faye: Initially… probably the first 10 days, I didn’t feel like doing much activity at all. 
I didn’t have the strength. …as the weeks got up, into the second week after treatment,  
I would start feeling a little better and feel like getting up and doing more. 
 
     For some women (n= 6, 21%) the effects of fatigue in particular were persistent and 
cumulative across cycles, leading to reports of very low levels of activity throughout treatment.  
Quin: I was watching a lot of television, not much desire to do anything…..no, go for   
            a walk, are you kidding? No way, no energy for that kind of thing. 
      
     Among those who felt they were as active as usual or more active during treatment (n=6, 
21%), there was an underlying theme of having “pushed themselves” to keep going. These 
women were able to maintain their regular walking or running routines throughout treatment or 
to resume their structured exercise within a few days of receiving chemotherapy.  
Roberta: Everyday, I’d get up in the morning and I would get up and get out there 
[walking]. So I kept going and I just thought “just do it”.  
 
Bridget: By that third week it was always my goal on that Friday of the third week, 
before that weekend, I’d say “those are my 15 km days…. just go and don’t think about  
it, just go”.  
 
Sadie: I really pushed myself to still walk the dogs. 
 
Social support played a role in maintaining physical activity for some women who found that 
family and friends were helpful in motivating them to exercise, as tolerated, during treatment.   
     Most of the women who gained weight during treatment reported a decrease in physical 




also felt they had been less active during treatment. Among those reporting an increase or no 
change in activity during treatment (n=6), two gained weight, one lost weight and three were 
weight stable. Self-reported change in physical activity did not correlate with weight change 
during treatment (r=0.08, p=.69). Collectively, these findings suggest that while lower levels of 
physical activity likely play a role, physical inactivity is clearly not the only factor contributing 
to energy imbalance. Based on the current data, it appears that dietary factors also play a role 
in promoting weight gain during treatment.   
     A theoretical model to explain how psychosocial factors and treatment-related side effects 
may influence diet and eating patterns in ways that promote energy imbalance and weight gain 
during treatment is presented in Figure 3.3. In light of emerging evidence to suggest that 
weight loss is also associated with adverse health effects (Chen et al., 2010; Thivat et al., 2010) 





Figure 3.3: Relationships between Psychosocial & Treatment-related Factors, Food Intake and Weight Gain in Breast Cancer 







Figure 3.4: Relationships between Psychosocial & Treatment-related Factors, Food Intake and Weight Change in Breast 
Cancer Survivors during Treatment. 
 






     This study provides a unique description of recalled food intake and eating patterns, 
psychosocial and treatment-related factors and weight change during chemotherapy treatment, 
among early stage breast cancer survivors. Twenty-eight women were interviewed, within 12 
months of competing treatment, in order to gain an appreciation of food intake and weight 
change during treatment and to investigate possible differences in diet and eating patterns 
among women who gained weight compared to those who were weight stable or lost weight 
during treatment.  
     Overall, food intake during treatment appears to be highly responsive to treatment day, with 
most women reporting smaller, irregular meals and snacks as tolerated and lower food intake 
for the first few days after receiving chemotherapy. Fatigue, taste changes, nausea and 
constipation were key factors contributing to changes in food intake during this time. In most 
women, acute side effects of treatment began to recede toward the end of the first week, 
leading to gradual increase in food intake and more structured eating in the second and third 
weeks of the cycle. While there were underlying themes across the sample group, treatment-
related side effects and psychosocial factors produced a wide range of dietary responses 
including changes in appetite, food cravings, food aversions and comfort eating that varied 
across women. The constant comparative method was used to look for patterns in women who 
gained weight versus women who were weight stable or who lost weight during treatment. 
Some notable differences in food intake and eating patterns were evident.  
     It appears that women who gain weight, may experience a shorter acute treatment response 
(fatigue, gastrointestinal disturbance), in which food intake is generally lower after each cycle. 




leading to a more prolonged reduction of food intake after treatment. Increased appetite, food 
cravings and intake of energy dense comfort foods seemed to be more prevalent and persistent 
among women who gained weight during treatment. Based on women’s perceptions, changes 
in taste, nausea and emotional distress were central in promoting these dietary responses. 
Given that fatigue is a pervasive side effect of treatment affecting activities of daily living, 
weight gain and weight loss may also be influenced by living arrangements and the level of 
cooking support that is available in the home. In this sample, weight loss appeared to be more 
common among women who lived alone.  
     Most studies to date support physical inactivity, in response to treatment-related fatigue, as 
the dominant factor contributing to energy imbalance and weight gain after diagnosis (Demark-
Wahnefried et al., 1997a; Demark-Wahnefried et al., 2001; Kumar et al., 2004). The majority 
of women in our study also reported a decrease in physical activity during treatment, compared 
to their usual activity before diagnosis. Lower activity however, was reported in both women 
who gained weight and those who lost weight and some women who gained weight reported an 
increase in physical activity, suggesting that other components of energy balance contribute to 
weight change during treatment. It has been suggested that changes in basal metabolism may 
play a role in post-diagnosis weight gain (Foltz, 1985; Demark-Wahnefried et al., 1997a), 
however research in this area is limited and has produced inconsistent findings. In addition, 
there is some evidence to suggest that alterations in ovarian function may promote additional 
weight gain among women who experience treatment-induced menopause (Goodwin et al., 
1999). In the current sample, the prevalence of treatment-induced menopause could not be 
determined, since the length of time from treatment was less than 12 months. However, it is 




that 19 women (68%) were premenopausal at diagnosis and only one reported a return of 
menses at the time of interview. While the etiology of weight gain in this population is 
complex, based on several possible inter-related pathways, our findings suggest that food 
intake and dietary patterns may play an important role for some women.  
     Despite recent efforts to capture possible changes in food intake during and after treatment, 
empirical support for an increase in energy intake after diagnosis and an association between 
increased energy intake and post-diagnosis weight gain is lacking. Using 4-day weighed food 
records, Harvie et al. (2004) found that, in 17 pre and postmenopausal women, mean energy 
intake did not change significantly over six cycles of chemotherapy; a finding that is supported 
by three other investigations (Kutynec et al., 1999; Del Rio et al., 2002; Kumar et al., 2004). 
Based on 24-hr recalls (Foltz et al., 1985) and 4-day food records (Nissen et al., 2011) changes 
in energy intake from the first cycle to the last cycle of chemotherapy were not significantly 
related to weight change during treatment. Most of these studies, however, are limited by small 
sample size and the absence of dietary data over the treatment trajectory. Many studies, for 
example, have used pre and post chemotherapy measures only, which will not detect 
fluctuations in intake over the course of treatment or within treatment cycles (Kutynec et al., 
1999; Kumar et al., 2004; Nissen et al., 2011). This limitation likely reflects the elevated level 
of burden that multiple days of record keeping would place on patients during active treatment. 
Demark-Wahnefried et al., (1997a) measured food intake one-two weeks before the initiation 
of chemotherapy and weekly throughout treatment using 3-day diet records and found that 
energy intake over the course of treatment was highly variable and responsive to treatment day. 
Mean energy intake was significantly lower at the end of treatment in this sample, compared to 




response to intense monitoring. Alternatively, it is possible that intense record keeping may 
have lead to underreporting. There is some evidence to suggest that reporting accuracy may be 
improved with  3-day rather than 7-day food records (Rebro et al., 1998); a finding that is 
perhaps related to the degree of burden associated with multiple days of record keeping    
(Caan et al., 2000). 
     In an effort to circumvent some of these research gaps and methodological challenges, we 
chose to investigate food intake and eating patterns during treatment using a qualitative design. 
Grounded theory methodology provided a framework in which to explore the rich detail of the 
“lived experience” (Charmaz, 2006) that was designed to go beyond food intake to understand 
the reasons behind dietary choices that women make. Using this approach, recalled food intake 
and dietary patterns were placed within the context of the psychosocial and treatment-related 
challenges that women face as they undergo chemotherapy treatment for breast cancer. 
     The decision to interview women after treatment was based on our pilot work with patients 
in active treatment, which suggested post-treatment interviews would be less invasive and may 
allow for a larger, more representative sample. Furthermore, follow-up consultations revealed 
that most women had vivid recall of their chemotherapy experience and could provide 
important insights that had not been explored. To the author’s knowledge, this study is the first 
to relate changes in food intake and dietary patterns to treatment days and treatment-related 
side effects and to describe changes in food intake and dietary patterns in women who gained 
weight compared to those who did not gain weight during treatment. 
     Our findings support earlier studies, in which it was hypothesized that food cravings, 
increased appetite, nausea and emotional distress may lead to overeating in the post-diagnosis 




1990). Our findings are also consistent with those of Demark-Wahnefried and colleagues 
(1997a), suggesting that food intake is highly variable across treatment and within treatment 
cycles. Moreover, variation in individual responses that were described, underscore the 
difficulty in choosing the optimal days and weeks for dietary assessment during active 
treatment. Together, these findings suggests that efforts to capture fluctuations in intake via 
food records or 24-hr recalls would clearly be challenging, especially in light of the extreme 
fatigue that seems to be associated with the days of most disturbed intake.  
     Most notable among our findings were some apparent differences in the experience of 
chemotherapy and associated dietary responses among women who gained weight compared to 
those who did not gain weight during treatment. In this sample, nausea, taste changes and 
emotional distress were associated with food cravings, increased appetite and increased intake 
of energy dense comfort foods in women who gained weight during treatment; qualitative 
findings which are supported by a significant correlation between perceived changes in the 
quantity of food intake and weight gain during treatment. While this single self-reported 
measure is a crude assessment of dietary change, these findings add to the limited data in this 
area and are further supported by the subjective impressions of women in this sample group, 
who felt that both increased food intake and lower levels of physical activity had contributed to 
weight gain during treatment.  
     Since not all women gain weight during treatment, possible differences in treatment-related 
effects, food intake and eating patterns among those who gain weight versus those who do not 
gain weight is an important question that is not addressed in the current literature. One early 
study in this area (Foltz, 1985), presented change in energy intake between the first and last 




stable during this timeframe. In this study, women who did not gain weight decreased their 
intake by an average of 193 kcals/day, while those who gained weight reported a mean 
increase of 129 kcals; a difference that perhaps owing to small sample size did not reach 
statistical significance. It is noteworthy that other studies have also reported small increases in 
mean energy intake (88 - 142 kcals) over the course of treatment, that were not statistically 
significant (Demark-Wahnefried et al., 2001; DelRio et al., 2002; Harvie et al., 2004). If a true 
difference exists, increases in energy intake of this magnitude may lead to clinically important 
weight gain over time.  
      Grounded theory methods lend well to this exploratory area of research, since there is a 
good fit between the outcomes of grounded theory research and clinical practice (Daly, 2007). 
Data on food intake and associated psychosocial and treatment factors, that are “rooted in the 
lived experience of the participants”, highlight the challenges that women face while receiving 
chemotherapy and may inform the development of tailored dietary intervention strategies, 
within this context. For example, dietitians should be alerted to the potential role of nausea in 
promoting weight change (both gain and loss) during treatment and draw on the experiences of 
breast cancer survivors to develop dietary management strategies that support energy balance. 
It is important to recognize that the kinds of explanations presented in a grounded theory are 
generative rather than definitive, meaning they are offered as a framework that can be further 
tested and are subject to change, as the conditions and experiences of participant’s lives change 
(Daly, 2007). This is a critical concept in the research area under study, since cancer treatments 
are evolving rapidly and the experiences of patients receiving chemotherapy are likely to 




     The current study is not without limitations. The use of self-reported weight is a potential 
limitation, however several studies have reported excellent correlation (r=0.92-0.99, p<0.01) 
between self-reported weight and measured weight in this population (Rock et al, 1999; 
Herman et al. 2005; Caan et al, 2006; Gu et al., 2010). In the current study, the intra-class 
correlation coefficient for self-reported weight versus measured weight at the time of interview 
was 0.99 (p<0.01), suggesting that self-reported weight is reliable in this sample. The 
magnitude of weight gain reported in our sample is lower than some studies (Lankester et al., 
2002; Del Rio et al., 2002) but comparable to others, in which the mean weight change across 
all participants during treatment was not significant (Demark-Wahnefried et al, 1997a; 
Kutynec et al., 1999; Freedman Aziz et al., 2004). Almost 40% of women in our study 
however, gained a mean of 5.1 kg; a finding that is consistent with other investigations 
(Lankester et al., 2002; Ingram & Brown, 2004; Gu et al., 2010).  
     A cut-off of 2.0 kg was used to define weight change in our sample, a criterion that has 
been used in previous studies with breast cancer survivors (Lankester et al., 2002; Nichols et 
al.2009; Gu et al., 2010). Others have used a cut-off of 2.5 kg (Ingram & Brown, 2004) or 
more recently, a change from baseline weight greater than 5% (Thivat et al., 2010; Nissen et 
al., 2011) to define weight change. Recognizing that weight flux as high as 2.0 kg may be 
transient in some adults (Groff & Gropper, 2000), several long-term studies suggest that 
weight gain in breast cancer survivors is progressive and durable, with a very small percentage 
of women returning to their pre-diagnosis weight within three years of treatment (Irwin et al., 
2005, Makari-Judson et al., 2007, Gu et al, 2010). Moreover weight gain itself, regardless of 
baseline BMI, is associated with adverse health consequences (Kawachi, 1999; Willet et al., 




(Halbert et al., 2008). Therefore it was decided that a weight gain greater than 2.0 kg during 
treatment, which was expected in some women over 4-6 cycles of chemotherapy (Lankester et 
al., 2002, Ingram & Brown, 2004) and is likely to endure, may have important clinical 
relevance. 
     Data on body composition were not available for our sample, therefore we cannot ascertain 
if weight changes reflect changes in body composition as well. Furthermore, previous studies 
suggest that unfavourable changes in body composition may occur with or without weight gain 
(Demark-Wahnefried et al. 2001; Kutynec et al., 1999). Absence of weight change in some 
participants, may have masked increases in body fat and loss of lean tissue; both of which are 
associated with adverse health consequences. Lastly our study was based on a convenience 
sample of self-selected women, who may not be representative of the population of breast 
cancer survivors. However this was an exploratory study, designed to be hypothesis generating 
and to provide novel description of food intake and dietary patterns during treatment.   
     In summary, the experience of chemotherapy, from the perspective of breast cancer 
survivors, supports several pathways by which psychosocial factors and treatment-related side 
effects might influence diet and eating patterns in ways that promote weight gain. In depth, 
qualitative interviews with women who have completed chemotherapy provided the 
opportunity to explore factors associated with changes in food intake during treatment; a 
critical first step in understanding the dietary challenges experienced by women after 
diagnosis. Our theoretical model is presented as a preliminary framework that may serve to 






CHAPTER 4: FOREWARD 
 
     Chapter 4 presents the findings from study 2 (objectives 3 and 4). The data for this chapter 
are based on self-reported changes in diet after diagnosis and current dietary intake estimated 
from 3-day food records, at the time of interview. Study 2 was a follow-up to study 1, within 
the same study population.  
 

































CHAPTER 4:   Dietary Changes and Food Intake after a Breast Cancer Diagnosis.  
The work presented in this chapter will be presented to the Canadian Journal of Dietetic 
Research and Practice as: 
 
Vance V, Campbell S, McCargar L, Mourtzakis M and Hanning R. Dietary Changes and Food 




Objectives: For the growing population of women who have undergone treatment for breast 
cancer, healthy eating and weight management are important to support optimal health in 
survivorship. Understanding dietary habits of women after diagnosis is an important first step 
in developing nutrition guidelines and effective intervention strategies. The objective of this 
study was to describe self-reported changes in diet among breast cancer survivors in the first 
year after treatment, and to evaluate these changes in the context of current dietary intake. 
 
Methods: Changes in diet were assessed in 28 early stage breast cancer survivors, using a self-
reported survey in which women identified if they had introduced, increased, decreased or 
eliminated several foods since their diagnosis. Current dietary intake was estimated from 3-day 
food records and described relative to age and gender specific recommendations and data from 
the 2004 Canadian Community Health Survey, for women in corresponding age ranges. 
 
Results: Participants in this study were a mean of 6.4±4.4 months from completing 
chemotherapy treatment. The mean energy intake for the sample was 1883±359 kcals, with 
protein, carbohydrate and fat providing 17.9%, 52.2% and 28.5% of energy, respectively. 
Mean intakes for macronutrients fell within the AMDR and saturated fat intake (8.9±2.8%) 
was, on average, below the current American Dietetic Association and Dietitians of Canada, 
recommendation. Compared to women from the general population, women in this sample 
appeared, on average, to have lower fat intake, higher fibre intake and higher mean vegetable 
and fruit servings. The majority of women reported positive changes in diet after diagnosis. 
Dietary changes were largely consistent with current recommendations for cancer prevention, 
however some women were still above the guidelines for total (11%) and saturated fat (39%), 
and many were below Canada’s Food Guide’s minimum recommendation for vegetables/fruit 
(61%), and milk/alternatives (≤50y-65%, >50y-91%). Based on the EAR cut-point method, the 
group prevalence of inadequate calcium and vitamin D intakes from foods was high (47-96%) 
in this sample and even when supplements were included, intakes below the EAR for calcium 
and vitamin D were found in 18% and 36% of women, respectively. Many women reported 
that they had initiated dietary changes while they were in active treatment, while others had 
waited until the post-treatment period.  
 
Conclusions: Our findings add to a limited number of studies in which dietary changes among 
breast cancer survivors have been reported. Evidence that some women are willing and able to 
initiate positive changes in diet early in the treatment trajectory suggests that early intervention 
may be effective in promoting dietary habits that will assist with weight management and 
overall health. Data on current dietary habits highlights several possible targets for intervention 






     The population of breast cancer survivors in Canada and the U.S. is growing substantially, 
with more than 250,000 new cases expected each year and significant improvements in 
survival rates since the mid 1980’s (Canadian Cancer Statistics, 2011; National Cancer 
Institute, 2011). Many of these women gain weight, both during and after treatment (Vance et 
al., 2011). Furthermore, with or without weight gain, gains in body fat and loss of lean tissue 
are prevalent in this population (Rock & Demark-Wahnefried, 2002; Visovsky, 2006). These 
unfavourable changes in body composition are distressing for many women (Knobf, 1986; 
Halbert et al., 2008) and may lead to metabolic disturbance (Robinson & Graham, 2004), 
increased risk of obesity-related disorders (Brown et al., 1993; Wingo et al., 1998) and poorer 
prognosis (Nichols, 2009; Chen et al., 2010; Thivat et al., 2010). As prevalence increases, the 
need for dietary counseling and nutrition intervention after diagnosis is expected to grow. 
     The optimal diet for breast cancer survivors is uncertain at this time, however current 
evidence suggests that a diet aimed at primary prevention may also improve long-term disease 
free (World Cancer Research Fund/American Institute for Cancer Research, 2007) and overall 
survival (Kroenke, Fung, Hu et al., 2005, Kwan, Weltzien, Kushi et al., 2009). Thus a diet that 
supports a healthy body weight, is low in fat and rich in a variety of fruits and vegetables is 
currently recommended for women who have undergone treatment for breast cancer (Hauner, 
Janni, Rack et al., 2011). With these guidelines in mind, understanding dietary habits of 
women after diagnosis is an important first step in developing intervention strategies. At this 
time there are very limited data concerning dietary changes made by women after a breast 
cancer diagnosis, when these changes are initiated and how nutrient intakes in this population 




changes in diet among breast cancer survivors in the first year after completing chemotherapy 
treatment, and to evaluate these changes in the context of current dietary intake. These findings 
may help to identify factors associated with energy imbalance after primary treatment and will 
provide a preliminary basis on which to develop nutrition guidelines that may guide dietetic 
counseling and nutrition intervention.  
4.3 Participants and Methods 
 4.3.1 Study Sample 
 
     Data for this analysis were collected as part of a more extensive study in which breast 
cancer survivors participated in qualitative interviews to explore individual experiences of food 
intake and weight change during chemotherapy. Participants were recruited from the Waterloo, 
Guelph, Hamilton and London, Ontario regions. Eligibility requirements included female 
breast cancer survivors >18 y, clinical stage I-IIIA, within 12 months of completing 
chemotherapy treatment, able to communicate freely in English (oral and written) and capable 
of providing informed consent.  
 4.3.2 Procedures 
     Participants were made aware of the study via a recruitment letter posted at local events 
(e.g., Canadian Breast Cancer Run for the Cure), businesses and community support programs, 
as well as online through the Canadian Breast Cancer Network (Bulletin Board/Newsletter) 
and Dietitians of Canada (Waterloo Region Registered Dietitian’s network). The recruitment 
letter was also posted in the University of Waterloo’s Well-Fit Centre (group exercise program 
for cancer patients) and the Grand River Regional Cancer Centre, Kitchener, Ontario and 
advertisements were placed in several local, community newspapers. Women who were 




researcher via email. At this time, they were screened for eligibility and provided with a 
detailed information letter. Potential participants were contacted by the researcher by telephone 
or email  within one week of initial contact, to review study details and respond to questions. 
Interviews were scheduled within one-two weeks in the participant’s home or at the University 
of Waterloo, based on participant preference. Background data were collected via a 
demographic and medical questionnaire. This research project received ethics clearance 
through the Office of Research Ethics at the University of Waterloo. All women provided 
written consent before participating.  
Dietary Changes after Diagnosis 
     Changes in diet after diagnosis were assessed using a closed-ended question asking 
participants to identify changes in the quantity of food intake since the completion of 
treatment, compared to their normal diet (before diagnosis) and an initial “filter” question 
asking “since your diagnosis have you made any changes to the kinds of foods you eat?” 
Women who indicated that they had made changes to their diet were asked to elaborate about 
specific changes in food groups/dietary components. Nine diet categories, adapted from 
previous research with breast cancer survivors and grounded in current dietary 
recommendations for healthy eating (Maunsell et al., 2002; Health Canada, 2007), were 
evaluated including vegetables and fruit, legumes, meat, fish, dairy products, breads/cereals, 
desserts, alcohol and supplements. Participants were asked to indicate whether they had 
“introduced”, “increased”, “decreased” or “eliminated” these items from their diet since their 
diagnosis. In addition, four items were further explored to determine if there had been a 
“change in type” including meat, dairy products, breads/cereals and supplements. Based on the 




and fruit, legumes and fish were reported as increased (or introduced) and if intake of meat, 
desserts and alcohol were reported as decreased (or eliminated). Changes in dairy products and 
breads/cereals were considered positive if women reported consuming products with a lower 
fat content or higher fibre content, respectively. Added to this study was one additional 
positive change, based a “change in type” for meat intake (lower fat content). Changes in 
dietary supplement use were of interest, however, in the absence of clear evidence (Greenlee, 
Hershman & Jacobson, 2009) were not classified as positive or negative (Maunsell et al., 
2002). 
3-Day Food Records 
     Current dietary intake was assessed using a 3-day food record. Dietary records were chosen 
as the method of assessment since they do not rely on recall and, compared to other self-report 
measures (FFQ, 24 hr recalls), they may provide a more precise measure of dietary intake 
(Block & Hartman, 1989). Two weekdays and one weekend day were included, to control for 
possible day-of-the-week effects (Trabulsi & Schoeller, 2001). Detailed verbal and written 
instructions for recording daily food intake and a “sample day” were provided. Participants 
were encouraged to provide as much detail as possible and to use household measures 
(teaspoons, measuring cups, scales) and food labels to estimate serving sizes. During the 
recording period, participants were contacted by telephone or email to see if they had any 
questions or concerns. Completed records were reviewed with participants, for clarification 
and completeness.  
4.3.3 Data Analysis 
     Nutrient analysis was conducted using The Food Processor SQL version 10.5.2 (Esha 




Canada, 2010). Servings of vegetables and fruit (total, dark green/orange vegetables) and milk 
and alternatives were hand calculated, based on servings sizes from Eating Well with Canada’s 
Food Guide (2007).  
     Descriptive statistics were used to characterize the sample group and to identify the nature 
and extent of self-reported changes in diet since diagnosis. Current dietary intakes are 
presented as means, standard deviations and ranges, and described relative to age and gender 
specific recommendations (Dietary Reference Intakes, National Academy of Sciences, 2005; 
Eating Well with Canada’s Food Guide, Health Canada, 2007) and data from the Canadian 
Community Health Survey (Cycle 2.2, 2004). The Canadian Community Health Survey 
(CCHS) data are based on multiple pass 24-hr recalls and represent the weighted averages for 
reported intakes among women in the 31-50 y (n=2686) and 51-70 y (n=3200) age groups. 
Milk and alternatives, fibre and calcium intakes are presented separately for women ≤ 50 y 
(n=17) and > 50 y (n=11), to reflect differences in the current dietary recommendations for 
these age groups. Distributions of nutrient intakes across the sample are provided, including 
the percentage of women whose intake fell below, within and above current guidelines.  
 4.4 Results 
  4.4.1 Sample Characteristics 
 
     A total of 28 women were recruited over a 14 month period between Oct, 2010 and Nov, 
2011. Mean age was 49.8±8.5 y. Sixty-four percent of participants were married and 79% had 
a college or university education. Most of the women were diagnosed at clinical stage II or 
IIIA and 68% were premenopausal at diagnosis. Participants received an average of 5.9±1.9 
chemotherapy treatments, over a period of 15±4 weeks. The mean time from the completion of 




Table 4.1: Demographic, Clinical and Treatment Characteristics of the Participants 
Characteristic (n=28) Mean (SD) Range n (%) 
Demographic    
Age (y)   49.8±8.5       33-69  
Ethnicity                       White 
                                      Black, Asian, West Asian 
 
 
  25 (89%) 
   3 (11%) 
Marital Status                Married 
                                      Single 
                                      Divorced 
   18 (64%) 
   4 (14%) 
   6 (22%) 
Education Completed   High School 
                                      College 
                                      University 
     6 (21%) 
   7 (25%) 
 15 (54%) 
Employment Status       Employed 
                                      Leave of Absence 
                                      Unemployed/Retired 
   10 (36%) 
   7 (25%) 
 11 (39%) 
Clinical History    
Clinical Stage                I 
                                      II 
                                      IIIA 
     3 (11%) 
 15 (53%) 
 10 (36%) 
Menopause Status        Premenopausal 
 (at diagnosis)               Postmenopausal 
   19 (68%) 
   9 (32%) 
Treatment History    
Surgery Type                Lumpectomy 
                                      Mastectomy 
   15 (54%) 
 13 (46%) 
Chemotherapy              Number of Cycles 
                                     Duration of Treatment (weeks) 
                                  * Time from Treatment (months)     
   5.9 (1.9) 
    15 (4.0) 
   6.4 (4.4) 
     2-8 
     4-24 
     0.5-13 
 
Radiation Therapy        Yes 
                                      No 
                                      Planned 
   16 (57%) 
   5 (18%) 
   7 (25%) 
Hormone Therapy        Tamoxifen 
                                     Aromatase Inhibitor     
                                     None  
  17 (61%) 
    5 (18%) 
    6 (21%) 
  
      * completed 
 
 
4.4.2 Dietary Changes after Diagnosis 
 
     Twenty-four women (86%) reported that they had made changes to their diet since 
diagnosis, the majority of which were categorized as positive. The most common change was 
an increase in vegetables and fruit (75%), followed by a decrease in overall meat consumption 
or a change to lower fat options (decreased red meat, increased chicken, 57.1%), increased 
intake of fish (46.4%) and reduced alcohol intake (39.3%). Reports of negative dietary changes 




Among women reporting any dietary change, the mean number of positive changes was 
3.88±1.4 (range = 0-6).   
     Many women reported that they had initiated these changes while they were in active 
treatment (n=10, 36%), while others (n=14, 50%) had waited until the post-treatment period. 
Among the latter group, most women reported that trying to make changes in their diet earlier 
in the treatment trajectory was challenged by the stress of their cancer diagnosis and the side 
effects of treatment.  
     Supplement changes were reported by 61% of women. Most common was the addition of   
calcium and/or vitamin D (32%) and removal of multi-vitamins or single antioxidant nutrients 
(18%). Dietary changes after diagnosis are summarized in Table 4.2. 
Table 4.2: Self-reported Changes in Diet after a Diagnosis of Breast Cancer. 
 Change Type of Change 








Reported any Dietary Change 24 (85.7)  4 (14.3)   
Vegetables & Fruit  21 (75.0)  7 (25.0) 21 (75.0)  0 (0) 
Legumes   7 (25.0) 21 (75.0)  7 (25.0)  0 (0) 
Meat 17 (60.7) 11 (39.3) 16 (57.1)           1 (3.6) 
Fish 13 (46.4) 15 (53.6) 13 (46.4)   0 (0) 
Dairy   8 (28.6) 20 (71.4)     7 (25) 1 (3.6) 
Breads/Cereals     10 ( 35.7) 18 (64.3)  9 (32.1) 1 (3.6) 
Desserts 13 (46.4) 15 (53.6)  9 (32.1)          4 (14.3) 
Alcohol 11 (39.3) 17 (60.7)        11 (39.3)    0 (0) 
Supplements 17 (60.7) 11 (39.3) - - 
     
     In response to the standardized question “since the completion of treatment, compared to 
your normal diet before diagnosis, do you feel you have been eating: the same amount as you 
would usually eat, more than you would usually eat or less than you would usually eat?”, 53% 
of women (n=15) reported that they had been eating less, while 36% (n=10) and 11% (n=3) felt 
they had eaten the same amount or more than they would usually eat, respectively. For many 




treatment) reflected a receding of symptoms and a return to normal eating patterns, in terms of 
the overall quantity. Two of the women who reported that they were eating more felt that they 
had been eating lighter and healthier immediately after treatment but as time passed they were 
eating more and had become less diligent about making healthy choices. Eating less was 
related to one of two underlying themes. About half of the women who felt they were eating 
less (n=7), reported that their appetite had not yet returned to normal and they were still 
experiencing early satiety with small portions of food. Others (n=8) were actively engaged in 
weight management and were consciously reducing food intake in an effort to lose weight after 
treatment. Self-reported change in quantity of food intake was not associated with weight 
change since the completion of treatment. 
4.4.3 Current Dietary Intake 
 
     Current dietary intake based on the mean daily values from 3-day food records are 
summarized in Table 4.3, relative to national data from the CCHS (Cycle 2.2, 2004) and age 
and gender specific recommended intakes.  
     The mean energy intake for the sample was 1883±359 kcals, with protein, carbohydrates 
and fat providing 17.9%, 52.2% and 28.5% of energy, respectively. Mean intakes for 
macronutrients fell within the Acceptable Macronutrient Distribution Ranges (AMDR) and 
saturated fat intake (8.9±2.8%) was, on average, below the current recommendation (<10%) 
(American Dietetic Association / Dietitians of Canada, 2007). Mean fibre intake was above the 
adequate intake (AI) for women ≤ 50 y (25.6±12.3 vs. 25 g) and > 50 y (28.4±8.9 vs. 21 g).  
     Vegetable and fruit servings (6.0±3.1) were below the minimum recommendation (7/day), 
based on Canada’s Food Guide to Healthy Eating (2007). The mean intake of milk and 




recommendations for both age groups. Mean calcium intakes from foods among women ≤ 50 y 
(813±299 mg) and >50y (1032±294 mg) were also below current recommendations (1000 mg 
and 1200 mg, respectively). Mean vitamin D intake from foods was 4.7±3.0 ug (185±121 IU) 
across all participants; well below the recommendation for women in this age group (15ug).  
     Calcium and vitamin D supplement use was common in this sample of breast cancer 
survivors (n=15, 54%). When supplement use was considered in the calculation of total intake 
of these nutrients, mean calcium intakes from food and supplements among women ≤ 50 y 
(1224±476.7 mg) and >50y (1613±586 mg) were above the current recommendation for both 
age groups. Similarly, mean vitamin D intake from food and supplements combined (18.7 ug) 
exceeded the recommended intake for adult women.   
     Statistical comparisons are not possible, however compared to women of similar age from 
the general population (CCHS, 2004), it appears that the mean energy intake in this sample 
may be a little higher (1883 vs. 1767 kcals), while the percent energy derived from total fat 
(28.5 vs. 31.7%) and saturated fat (8.9 vs. 10.2%) may be slightly lower. Vegetable and fruit 
intake in this sample (6.0 servings/day) was, on average, a little higher than vegetable and fruit 
intake reported in the CCHS (5.1 servings/day). Mean fibre intake appears to be higher in the 
current study (26.7 vs. 16.7 g).     
     Average intake of milk and alternatives was consistent with the CCHS data for women       
≤ 50 y (1.4 vs. 1.5 servings/day), however women > 50y reported a mean of 1.9 servings 
compared to 1.3 servings in the CCHS. This apparent difference is reflected in the mean 
calcium intake from foods, which appears to be higher among women >50 y in this sample 
(1032 mg), compared to women in the same age range from the CCHS (740 mg). The mean 




among women in the CCHS (5.1 ug). Current dietary intakes relative to the CCHS data and age 
and gender specific recommended intakes are summarized in table 4.3. 
Table 4.3: Current Dietary Intake Relative to the CCHS (2004) and Age/Gender Specific 
Recommended Intakes  
 
n=28     




Energy (kcals) 1883 (359) 933-2553 1767 1677-2674 b 
Protein (g) 



















Total Fat (g) 









Saturated fat (% energy) 8.9 (2.8) 3.7-13.6 10.2 <10 c 
Fibre (g) 
   All women 
   ≤50 y ** 


















   Dark Green 








Fruit (servings/day) 2.7 (1.5) 0.8-6.6   
Vegetables & Fruit 
(servings/day) 
6.0 (3.1) 1.2-15.0 5.1 7-8 
Milk/Alt. (servings/day) 
   All women 
   ≤50 y 



















   All women 
   ≤50 y  
   >50 y  
Foods + Supplements 
   All women 
   ≤50 y  



































Vitamin D (ug / IU)  
Foods    
Foods + Supplements    
 
  5 (3) / 185 (121) 
19 (16) / 745 (620)  
 
1-12 / 40-492 
1-62 / 40-2492 
 
5 / 185 
 
 
15 / 600 
15 / 600 
* Based on the mean daily intake from 3-day food records  **  ≤50 y (n=17), >50 y (n=11) 
 a Dietary Reference Intakes, Eating Well with Canada’s Food Guide,  b  Range of estimated energy requirement 




     Figures 4.1-4.3 show the percentage of women whose intake of protein, carbohydrate and 




Protein intake was within the AMDR for all women and most women (79%) were within the 
acceptable range for carbohydrates. Similarly, most women were within the recommendation 
for total fat, with 10% of women below and 11% above the AMDR. These findings are 
consistent with the CCHS data for protein, however a larger proportion of women from the 
national survey were below the AMDR for carbohydrates (25.3%) and above the AMDR for 
total fat (25.4%).  
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Figure 4.4 shows that 61% and 39% were below and above the <10% guideline respectively, 
for saturated fat intake as a percentage of total energy.  

















     In the absence of an estimated average requirement (EAR) for dietary fibre, it is not 
possible to determine the prevalence of inadequate intake. However, the median intake (27.1 g) 
for the sample (data not shown) was above the AI for both age groups, suggesting that the 






























































Furthermore, since the Canadian Nutrient File does not contain data on functional fibre (Health 
Canada, 2009), the current analysis reflects naturally occurring fibre only and may therefore 
represent an underestimate of actual fibre intake.   
     Figures 4.5-4.7 show the distribution of vegetables and fruit, dark green vegetable and 
orange vegetable intake. Many women (61%) did not meet the minimum recommendation for 
total vegetables and fruit (7 servings/day), with 36% and 79%, respectively not meeting Health 
Canada’s recommendation (2007) to eat at least one dark green and one orange vegetable each 
day. Twenty-three percent of women in this sample reported less than five total vegetable and 
fruit servings per day, compared to almost 50% of women in the CCHS. 
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     Figure 4.8 shows the distribution of milk and alternative intakes for women ≤ 50 y (n=17) 
and >50 y (n=11), relative to the recommended servings per day, based on Eating Well with 
Canada’s Food Guide. Sixty-five percent of women ≤ 50 y did not meet the recommended 
number of servings (2/day), while 91% of women > 50 y reported less than the recommended 
number of servings for their age group (3/day). These findings are similar to data from the 
CCHS, in which 72 and 80% of women respectively, were below minimum recommendations.  
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     Figure 4.9 shows the distribution of calcium intakes from foods relative to the Dietary 
Reference Intakes for women ≤ 50 y and > 50 y. Based on the EAR cut-point method (Health 
Canada, 2006), the prevalence of inadequate calcium intake from foods alone was high in this 
sample, with 47% of women ≤ 50 y and 55% of women > 50y below the EAR for their age 
group (800 and 1000 mg, respectively). Figure 4.10 shows the distribution of total calcium 
intake from foods and supplements. The prevalence of inadequate intake based on combined 
intake from food and supplements, drops to 18% among women in both age categories.  









* EAR cut-point ≤ 50 y = 800 mg, >50 = 1000 mg 
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     Figures 4.11 and 4.12 show the distribution of vitamin D intakes, with and without 
supplements. Vitamin D intake from foods alone was low across the sample group, with 96% 
of women below the EAR cut-point for adult women (10ug). The prevalence of inadequate 
intake based on combined intake from food and supplements was 36%. It is important to keep 
in mind that vitamin D status is influenced by sun exposure as well, although less so in the 
Canadian climate during the winter months (Health Canada, 2007). The DRIs for vitamin D 
were established assuming minimal sun exposure (National Academy of Sciences, 2010).  










* EAR cut-point = 10 ug 
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     This study describes both self-reported changes in diet among early stage breast cancer 
survivors after diagnosis and current dietary intake, within the first year of completing 
chemotherapy treatment. The majority of women in this sample reported that they had made 
changes to their diet after their breast cancer diagnosis. Most of the changes reported were 
consistent with current guidelines for cancer prevention, including an increase in vegetable and 
fruit intake, decreased meat consumption, increased fish intake and reduced alcohol intake. 
Negative changes were minimal, including an increase in desserts for a small proportion of 
women. Compared to their normal diet before diagnosis, 53% of women reported that they had 
been eating less since the completion of treatment, reflecting residual treatment effects                
(low appetite) in half of these women and weight loss efforts after treatment in others.  
     Based on 3-day food records, protein, carbohydrate and total fat intakes were within the 
AMDR for most women and 61% of women were below the recommendation for saturated fat 
intake. Median fibre intake was above the AI for women ≤ 50 y and > 50 y, suggesting low 
prevalence of inadequate intakes in this sample. Although 75% of women reported an increase 
in vegetable and fruit intake, 61% did not meet the minimum recommendation for total 
vegetables and fruit and many did not meet the minimum recommendation to include at least 
one dark green and one orange vegetable each day. Two-thirds of women ≤ 50 y and most 
women > 50 y did not meet the recommended number of milk and alternative servings for their 
age group. The prevalence of inadequate calcium and vitamin D intake from foods was high 
across the sample, but were substantially lower when total calcium and vitamin D intakes from 




     Compared to the most recent national survey data (CCHS, 2004), mean energy, fibre and 
vegetable and fruit intake appear to be a higher in this sample, while total and saturated fat, as 
a percentage of total energy, are slightly lower. These findings appear to reflect awareness of 
current public health messages around healthy eating for breast cancer survivors (Canadian 
Breast Cancer Foundation, 2012, Canadian Cancer Society, 2012a). While these professional 
associations acknowledge the uncertainty concerning specific foods or dietary components on 
breast cancer risk, both suggest that increasing intake of vegetables and fruit and maintaining a 
healthy body weight may reduce the risk of breast cancer recurrence. These recommendations 
are consistent with key messages from the much publicized American Institute of Cancer 
Research/World Cancer Research Fund report (2007), which may also have caught the 
attention of breast cancer survivors in recent years. Among women > 50 y, the mean milk and 
alternative, calcium and vitamin D intakes were higher than those reported by women of 
similar age in the CCHS. Again, many women in the current study seemed to be aware of the 
importance of adequate calcium and vitamin D for bone health, especially after menopause 
(National Institutes of Health, 2011). Fifty-four percent of women were taking supplemental 
sources of these nutrients at the time of interview, with 32% introducing regular use of these 
supplements since their diagnosis.  
     Comparisons to previous findings in women with breast cancer are challenged by the 
limited number of studies in which dietary changes among breast cancer survivors have been 
reported, as well as differences in dietary assessment methods and timing of the measures 
relative to diagnosis. Energy intake derived from 3-day food records in the current study is 
higher than previous reports in this population. Based on a 114 item FFQ, mean energy intake 




and Lifestyle (HEAL) and Life After Cancer Epidemiology (LACE) studies) of breast cancer 
survivors (stage 0-IIIA), approximately two years after diagnosis (Wayne, Lopez, Butler et al., 
2004; Caan et al., 2005). At a similar time point, based on repeated 24-hr recalls, baseline data 
from the Women’s Healthy Eating and Living (WHEL) study (Pierce, Natarajan, Caan et al., 
2007) (n=3088, stage I-IIIA) revealed a mean energy intake of 1718 kcals; energy intake that is 
similar to mean kcals reported by the Women’s Intervention Nutrition (WINS) study (n=2437, 
stage I-IIIA) (Chlebowski, Blackburn, Thomson et al., 2006).  
     Mean protein intake as a percentage of total energy (17.9%) is similar to that reported in the 
HEAL and LACE studies (16.9-17.1%), while the amount of energy derived from 
carbohydrates is a little higher in the current study (52.2% vs. 47.4-48.6%). Total fat intake 
(28.5%) is consistent with data from the WHEL and WINS studies (28.5-29.6%), but lower 
than estimates from the HEAL and LACE cohorts (33.8-35.5%). Mean fibre intake (26.7 g) 
was high compared to WHEL (21.2 g) and LACE (15.2 g). Finally, total servings of vegetable 
and fruit per day was lower in the current study (6.0) compared to WHEL (7.2-7.4) but higher 
than those reported in LACE and HEAL (3.6-4.1).  
     Current dietary intake in this sample seems to be more closely aligned with baseline data 
from the WINS and WHEL intervention trials, suggesting that the precision of the instruments 
(food records and 24-hr recalls vs. FFQ) may explain some of the apparent differences that 
were observed. Key demographic and clinical characteristics were similar across studies 
(ethnicity, education, clinical stage, baseline BMI), however participants in the current study 
and the WHEL study were, on average, a little younger compared to the HEAL, LACE and 




     Overall, the women participating in the current study seemed to be quite health conscious, 
eager to adopt or maintain lifestyle behaviours that might influence disease recurrence and 
overall health. This is supported by lower fat intake, higher fibre intake and higher mean 
vegetable and fruit servings compared to women in the same age range from the general 
population. Furthermore, the nature of dietary changes reported in the current study are similar 
to those reported in previous studies among breast cancer survivors, however the proportion of 
women reporting dietary changes after diagnosis is higher in this sample.  
     Maunsell et al. (2002) described self-reported dietary changes in 250 women with newly 
diagnosed, non-metastatic breast cancer. In this study, 41% of women reported that they had 
initiated dietary changes in the first year after diagnosis, most common being an increase in 
vegetable and fruit intake and a decrease in meat and desserts. Similarly, in response to global 
interview questions on dietary habits, Wayne et al., (2004) found that 39% of women 
diagnosed with stage 0-IIIA disease (n=260) reported an increase in vegetable and fruit intake 
after diagnosis, while 45% reported a decrease in dietary fat. Self-reported changes in this 
study were consistent with data derived from FFQs one year before and two years after 
diagnosis, however the amount of change estimated by FFQ was small (<0.5 servings), with 
76% of women still eating less than five servings of vegetable and fruits per day (Wayne et al., 
2004). Thomson et al., (2002) asked women recruited to the WHEL study to indicate via 
questionnaire whether they had increased or decreased their intake of several foods after 
diagnosis. In this sample of early stage breast cancer survivors (n=3084), the most frequently 
reported change was an increase in vegetables and fruit (60% and 58%, respectively) followed 
by a decrease in red meat, cheese and other high fat foods (38-61%) and an increase in whole 




with an overall more healthful diet apparent among women reporting these dietary changes 
after diagnosis (Thomson et al., 2002).  
     This research adds to a limited number of studies reporting dietary change in breast cancer 
survivors and to the author’s knowledge is the first to report dietary change, in the context of 
dietary intake in the first 12 months after diagnosis. These findings address an important gap in 
the literature, since understanding dietary habits of women after breast cancer treatment is a 
critical first step in developing effective intervention strategies (Thomson et al., 2002). A few 
studies have evaluated dietary change and/or dietary intake within two to four years of 
diagnosis (Thomson et al., 2002; Wayne et al., 2004, Caan et al., 2005). While these studies 
have provided important insights, it is possible that dietary assessments in this time frame may 
miss changes that are made earlier, and may or may not endure up to four years after diagnosis.   
     Of particular interest was the finding that many women reported having initiated positive 
changes in diet during active treatment. It has been suggested in the literature, and supported 
by the current study, that some women may need time to recover from the turmoil of a cancer 
diagnosis and its treatment before they are ready for dietary change (Thomson et al., 2002).    
Our results demonstrate however, that some women may be willing and able to implement 
positive changes earlier in the treatment trajectory. These women reported some challenges in 
making these changes during treatment, however appeared to have supports in place            
(e.g. cooking, social support) to motivate and reinforce their efforts. This has important 
implications for dietary counseling, suggesting that early intervention may be effective in 
promoting dietary habits that will assist with weight management and overall health.  
     There is some evidence to suggest that a diagnosis of breast cancer may represent a 




promote long-term disease free survival and overall wellness (Demark-Wahnefried, Peterson, 
McBride et al., 2000; McBride, Clipp, Peterson et al., 2000). It appears that many women 
report positive changes in diet that may support weight management, disease remission and 
overall health (Kroenke et al., 2005; Rock, Natarajan, Pu et al., 2009; Kwan et al., 2009; 
Hauner et al., 2011). The amount of change however, is modest (Wayne et al., 2004), with 
many women still below current recommendations for vegetables, fruit and fibre and above the 
guidelines for dietary fat (Wayne et al., 2004; Caan et al., 2005; Pierce et al., 2007). Moreover, 
our findings of high prevalence of inadequate calcium and vitamin D intakes from foods alone 
highlight the need for dietary counseling around food and supplemental sources of these 
nutrients. This is especially important among women who have undergone treatment for breast 
cancer, given that many of these women are postmenopausal at diagnosis (Canadian Cancer 
Statistics, 2012), and many others are expected to become menopausal as a result of treatment 
(Canadian Breast Cancer Foundation, 2012). Treatment-induced menopause could not be 
evaluated in this study (length of time from treatment <12 months), however with the 
Recommended Dietary Allowance linked to loss of calcium from bones at menopause, it is 
likely that the dietary recommendation for calcium for women ≤ 50 y (1000mg) would increase 
to those of women > 50 y (1200 mg), within the first few months of treatment. While “best 
practice” dietary guidelines after a breast cancer diagnosis are not yet known, these findings 
suggest possible targets for dietary intervention in this population.  
     This study has some limitations. First, the survey used to evaluate self-reported changes in 
diet is not a validated research instrument. It is noteworthy however, that data on dietary 
changes appear to be consistent with current dietary intake, with a high proportion of women 




vegetable and fruit servings, compared to national survey data. Moreover, earlier studies have 
reported good concordance between self-reported changes in diet and dietary changes captured 
by FFQ before and after diagnosis (Wayne et al., 2004) and current dietary intake assessed by 
repeated 24-hr recalls (Thomson et al., 2002). This survey has been used with breast cancer 
survivors (Maunsell et al., 2002), thus affording the opportunity to provide direct comparisons.  
     We did not quantify dietary change in this study, however self-reported changes were 
evaluated in the context of current dietary intake estimated from 3-day food records; an 
important link in understanding how these changes impact on the overall quality of the diet. In 
addition, we did not have baseline dietary data, which may have influenced the perception of 
dietary change data. For example, 39% of women reported a reduction in alcohol intake, 
however many others reported that they had consumed little or no alcohol before diagnosis and 
reported no change in alcohol consumption since their diagnosis. Once again, a precise 
measure of current dietary intake provided context for dietary change data.  
     It is possible that self-reported dietary change and dietary intake were subject to the well 
documented limitations of social expectation bias and under-reporting (Hill & Davies, 2001, 
Caan et al., 2000). Energy intake in this sample however, was higher than previous reports in 
breast cancer survivors and women of similar age from the general population, suggesting that 
social desirability and under-reporting may be less pronounced in this study. Two weekdays 
and one weekend day were included in each 3-day record, to control for possible day-of-the-
week effects, but it is possible that seasonal variation in eating patterns may have influenced 
dietary intake. Data collection took place over a 14 month period however, with diet records 
equally dispersed across the summer and winter seasons, suggesting that seasonal variation 




     Lastly, dietary data in the current study may be associated with a self-selection bias, 
reflecting systematic differences in the type of women who might choose to participate in a 
study of this nature, and may not be representative of the population of breast cancer survivors. 
The age distribution of women in this sample appears to be a little younger that the distribution 
of Canadian women who are diagnosed with breast cancer (Canadian Cancer Statistics, 2012). 
This may have had an impact on generalizability of our results, since there is some evidence to 
suggest that younger women are more likely to make dietary changes after a diagnosis of 
breast cancer (Thomson et al., 2002; Wayne et al., 2004). Although many of the women who 
volunteered for this study appeared to have a strong interest in healthy eating and exercise, this 
is consistent with other studies in which breast cancer survivors are described as highly 
motivated to make positive changes in lifestyle. The study sample was part of a larger study, in 
which women were participating in qualitative interviews. In keeping with the in-depth nature 
of qualitative analysis, the sample size was relatively small. 
     In summary, the majority of women in this sample of early stage breast cancer survivors 
reported positive changes in diet since their diagnosis. Dietary changes were largely consistent 
with current recommendations for cancer prevention, however some women were still above 
the recommendations for dietary fat and many were below the minimum recommendation for 
vegetables and fruit, and milk and alternatives. The prevalence of inadequate calcium and 
vitamin D intakes from foods was high in the sample. Our findings add to a limited number of 
studies in which dietary changes among breast cancer survivors have been reported in the 
context of current dietary intake and may serve to guide dietetic practice and nutrition 






CHAPTER 5: FOREWARD 
 
     Chapter 5 presents the findings from study 2 (objectives 1, 2 and 5) and is focused on 
physical and psychological distress (past week), current dietary intake, changes in diet after 
diagnosis, and weight change since the completion of chemotherapy treatment. The data for 
this chapter, with the exception of current dietary intake, were collected in conjunction with the 
qualitative interviews for study 1.   
 
 

































CHAPTER 5: Weight Change, Physical Distress, Psychological Distress and Food Intake 
among Early Stage Breast Cancer Survivors. 
 
The work presented in this chapter will be submitted to the European Journal of Cancer Care: 
 
Vance V, Campbell S, McCargar L, Mourtzakis M and Hanning R. Persistent Treatment 




Objectives: The purpose of this study was to describe weight change; symptoms of physical 
distress, psychological distress and fatigue; diet and dietary change in early stage breast cancer 
survivors within 12 months of completing chemotherapy. Relationships among weight change 
since the completion of treatment and composite scores for physical and psychological distress, 
fatigue, current dietary intake and changes in diet since diagnosis were investigated.   
 
Methods: Symptoms of physical distress, psychological distress and fatigue (past week) were 
assessed in 28 early stage breast cancer survivors, using the Rotterdam Symptom Checklist 
(RSCL), the Distress Thermometer (DT) and the Fatigue Symptom Inventory (FSI). Current 
dietary intake was estimated from 3-day food records. Changes in diet were assessed using a 
self-reported survey in which women identified whether they had introduced, increased, 
decreased or eliminated foods/food groups since their diagnosis. Weight at the end of treatment 
was based on self-report. Current weight was measured at the time of interview. 
 
Results: Weight change since the completion of treatment (mean=6.4±4.4 months) ranged 
from -6.0 kg to +5.2 kg (mean=-0.4±3.2). Among women who gained >2.0 kg (n=6), the mean 
weight gain was 3.5 kg. Psychological distress scores ranged from a low of 0 to a high of 76.1, 
out of 100 (mean=27.1±16.9) and were higher than physical distress scores (17.5±9.0, p<0.01). 
The DT rated the distress level as moderate to severe (≥4, scale=0-10) in 35% of women, 
according to guidelines from the National Comprehensive Cancer Network. Fatigue intensity 
was rated from 0 to 7.5 out of 10 (mean=3.5±2.2), was experienced from 0 to 7 days in the 
previous week (mean=4.5±2.6) and was present for 0 to 50% (mean=28±16%) of the daytime. 
The level of interference associated with fatigue ranged from 0 to 7, out of 10 (mean=2.4±2.0). 
The mean energy intake for the sample was 1883±359 kcals/day. Most women (84%) reported 
dietary changes since diagnosis, most common being an increase in vegetable and fruit intake. 
Fatigue duration (proportion of daytime) was negatively correlated with weight change       
(p=-0.46, p<0.05). No associations were observed between dietary factors and weight change 
during this time frame. Although symptoms were highly variable, the mean levels of physical 
and psychological distress in this sample were similar to previous reports among early stage 
breast cancer patients in active treatment and appear to be markedly higher than previous 
reports of distress among cancer-free adults. Despite relatively high levels of fatigue, 71% of 
women described their quality of life in the past week as “good” or “excellent”. 
 
Conclusions: Symptoms of physical and psychological distress seem to persist for many breast 
cancer survivors in the first year after completing chemotherapy and may associate with weight 
change. These findings may serve to guide dietary counseling within a growing population of 





5.2 Introduction  
 
     Weight gain and unfavourable changes in body composition, including fat gain and loss of 
lean tissue, are common among a growing population of breast cancer survivors (Canadian 
Cancer Statistics, 2011; National Cancer Institute, 2011). These changes have been well 
documented during chemotherapy treatment (see review, Vance et al., 2011), however weight 
gain is also known to be a progressive and persistent problem for many women in the months 
and years after diagnosis (Demark-Wahnefried et al., 1997b; Irwin et al., 2005; Makari-Judson 
et al., 2007). Excessive weight gain, especially an increase in relative adiposity, predisposes 
breast cancer survivors to obesity-related disorders including cardiovascular disease and type II 
diabetes (Brown et al., 1993; Wingo et al., 1998) and may increase the risk of disease 
recurrence (Nichols et al., 2009; Chen et al., 2010; Thivat et al., 2010). Loss of lean tissue 
might further exacerbate the problem of weight gain and combined with gains in adipose tissue 
may lead to adverse metabolic consequences (Robinson & Graham, 2004), decreased strength 
and functional impairment (Prado et al., 2008). Furthermore, weight gain after diagnosis is 
distressing for many breast cancer survivors and may contribute to poor quality of life and loss 
of self-esteem, especially among women who were not overweight before diagnosis (Knobf, 
1986; Halbert et al., 2008).  
     The role of diet in promoting these changes is not yet clear, however it as been suggested 
that behavioural changes affecting energy balance, likely influenced by fatigue and 
psychosocial factors, may play an important etiologic role (Demark-Wahnefried et al., 1993; 
Rock et al., 1999). At this time, little is known about the potential influence of treatment-
related side effects, many of which may persist beyond the period of chemotherapy treatment 




     The purpose of this study was to describe 1) weight change 2) symptoms of physical 
distress, psychological distress and fatigue 3) diet and dietary change in early stage breast 
cancer survivors within 12 months of completing chemotherapy. Relationships among weight 
change since the completion of treatment and composite scores for physical and psychological 
distress, fatigue, current dietary intake and changes in diet since diagnosis were investigated.   
5.3 Participants and Methods 
 5.3.1 Study Sample  
 
     The women in this sample group were participants in a qualitative study designed to explore 
individual experiences of food intake and weight change during chemotherapy. At the time of 
the qualitative interview, women provided survey data and 3-day food records to be used in the 
current analysis. Participants were recruited from the Waterloo, Guelph, Hamilton and London, 
Ontario regions. Eligibility requirements included female breast cancer survivors >18 y, 
clinical stage I-IIIA, within 12 months of completing chemotherapy treatment, able to 
communicate freely in English (oral and written) and capable of providing informed consent. 
 5.3.2 Procedures 
     Participants were made aware of the study by posting a recruitment letter at local events         
(e.g., Canadian Breast Cancer Run for the Cure), businesses and community support programs, 
as well as online through the Waterloo Region Registered Dietitian’s network and the 
Canadian Breast Cancer Network (Bulletin Board and Newsletter). The recruitment letter was 
also posted at the Grand River Regional Cancer Centre, Kitchener, Ontario and the University 
of Waterloo’s Well-Fit Centre (group exercise program for cancer patients) and advertisements 




     Those who were interested in participating were asked to call a local telephone number or to 
contact the researcher via email, at which time they were screened for eligibility and provided 
with a detailed information letter. These women were contacted by the researcher by telephone 
or email within one week of initial contact, to review study details and respond to questions. 
Interviews were scheduled within the next two weeks in the participant’s home or at the 
University of Waterloo, based on participant preference. This research project received ethics 
clearance through the Office of Research Ethics at the University of Waterloo. All women 
provided written consent before participating.  
Measures 
     A demographic and medical questionnaire was completed with the researcher, to collect 
background data on age, marital status, education and employment status, medical and 
treatment information and weight history. Current weight was measured on the same portable 
scale (Tanita, BF680, Arlington Heights, Illinois), calibrated against a standard platform 
balance scale, with participants wearing one light layer of clothing and no shoes. Participants 
were also asked to self-report their weight at the end of treatment and their current weight. In 
the event of uncertainty regarding medical or treatment information, participants referred to 
official medical documents in their possession or consulted with their medical oncologist. 
     Symptoms of physical and psychological distress were assessed using the Rotterdam 
Symptom Checklist (RSCL); a multidimensional tool which has been used and validated in 
breast cancer survivors (deHaes et al., 1996). The RSCL provides sub-scales for physical 
distress, psychological distress and global quality of life (QOL). Using this tool, participants 
were asked to indicate the extent to which they have been bothered by a series of common 




     Symptoms of physical and psychological distress were interspersed, with responses ranging 
from 1 (not at all) to 4 (very much). A single global QOL item asked the participants to 
respond to the question “all things considered, how would you describe your quality of life 
during the past week?”. This item was scored on a 7 point scale ranging from 1 (excellent) to    
7 (extremely poor). The sums of physical and psychological symptom scores were calculated 
to provide a summary estimate (composite score) of overall physical and psychological 
distress, respectively. All raw scores (physical distress, psychological distress, global QOL) 
were transformed ([raw score – minimum raw score / maximum – minimum score] X 100) to 
provide a standardized score on a 100 point scale for each domain (Appendix J). This 
transformation adjusts for differences in the number of items for each sub-scale and allows for 
comparisons of the level of impairment across domains (deHaes et al., 1996). Lower scores 
imply better functioning or well-being. 
     Participants also completed the Distress Thermometer (National Comprehensive Cancer 
Network, 2012). The Distress Thermometer (DT) is a simple self-report measure developed 
and validated for the evaluation of distress in cancer patients (Jacobsen et al., 2005; Hegel et 
al., 2008; Yong et al., 2012), in which participants were asked to circle the number (0-10) on a 
visual scale that best describes the amount of distress they have been experiencing in the past 
week (0 = no distress, 10 = extreme distress). The DT has been reported in recent breast cancer 
survivorship literature (Hegel et al., 2006; Dabrowski et al., 2007; Hegel et al., 2008; Yong et 
al., 2012) and was included to allow for comparisons of findings.    
     The Fatigue Symptom Inventory (FSI) was used to conduct a more comprehensive 
assessment of current fatigue (Hann et al., 1998). The FSI is designed to measure the intensity 




symptom was of particular interest since it is the most commonly reported symptom among 
breast cancer survivors and has been reported to persist for several months (Meeske et al., 
2007). The FSI consists of four items related to intensity, in which participants were asked to 
rate their level of fatigue at its most, least and “on average” in the last week, as well as current 
fatigue, on an 11 point rating scale ranging from 0 (not at all) to 10 (extreme fatigue). 
Participants were also asked to rate how much, in the last week, fatigue had interfered with 
daily living (e.g., general activity, work activity, concentration, relationships) in a 7-item 
subscale, with responses ranging from 0 (no interference) to 10 (extreme interference). Two 
final items related to duration evaluated how many days in the past week participants were 
fatigued for any part of the day (range = 0-7) and how much of the day, “on average” they felt 
fatigued in the past week (range = 0 - none of the day to 10 - the entire day). Single scores 
were reported for most, least, mean and current fatigue (intensity), number of days and how 
much of the day (duration), with a composite score calculated for the level of “interference” 
associated with fatigue (Hann et al., 1998). 
     Current dietary intake (energy, % energy from protein, carbohydrate and fat) was assessed 
using 3-day food records (2 weekdays, 1 weekend day). Detailed verbal and written 
instructions for recording food intake and a “sample day” were provided. Participants were 
encouraged to provide as much detail as possible and to use household measures (teaspoons, 
measuring cups, scales) and food labels to estimate serving sizes. Completed records were 
reviewed with participants, for clarification and completeness. Nutrient analysis was conducted 
using The Food Processor SQL version 10.5.2 (Esha Research, Salem, Oregon), including the 




     Changes in diet after diagnosis were assessed via a questionnaire asking women to identify 
changes in food intake since their diagnosis. Nine food groups or diet components, adapted 
from previous research with breast cancer survivors (Maunsell et al., 2002) and grounded in 
current dietary recommendations for healthy eating (Health Canada, 2007), were evaluated 
including vegetables and fruit, legumes, meat, fish, dairy products, breads/cereals, desserts, 
alcohol and supplements. Participants were asked to indicate whether they had “introduced”, 
“increased”, “decreased” or “eliminated” these items from their diet since their diagnosis. In 
addition, four items were further explored to determine if there had been a “change in type” 
including meat, dairy products, breads/cereals and supplements. Based on the work of 
Maunsell et al. (2002), changes were categorized as positive if intake of vegetables and fruit, 
legumes and fish were reported as increased (or introduced) and if intake of meat, desserts and 
alcohol were reported as decreased (or eliminated). Changes in dairy products or meats, and 
breads/cereals were considered positive if women report consuming products with a lower fat 
content or higher fibre content, respectively.   
5.3.3 Data Analysis 
     Descriptive statistics were used to characterize the sample in terms of demographic, medical 
and treatment background. Weight at end of treatment and current weight were used to 
categorize participants by weight change (weight gain, weight loss, weight stable) since the 
completion of treatment. Given that normal short-term fluctuations in body weight may be as 
high as 2.0 kg in some adults (Groff & Gropper, 2000), weight gain or loss was defined as a 
change in body weight greater than 2.0 kg. Body mass index (BMI) was calculated as       
weight (kg)/height (m2) and used to categorize participants as underweight (BMI<18.5), 




     Descriptive statistics were used to present self-reported symptoms of physical and 
psychological distress, global quality of life, intensity and duration of fatigue and the extent to 
which fatigue interfered with daily activities. Paired t-test was used to compare composite 
scores for physical and psychological distress. The mean scores for individual items on the 
physical distress, psychological distress and fatigue interference sub-scales were calculated in 
order to rank individual items from most to least distressing. Finally, mean scores for physical 
and psychological distress, quality of life, intensity of fatigue (“on average”) and level of 
interference associated with fatigue are presented in the context of normative data, including 
breast cancer patients in active treatment, a comparison group of healthy women and a random 
sample of cancer-free adults from the general population (deHaes et al., 1996; Hann et al. 
1998; Hegel et al., 2006; Yong et al., 2011).  
     Current dietary intakes are presented as means, standard deviations and ranges. Descriptive 
statistics were used to identify the nature and extent of self-reported changes in diet since 
diagnosis.  
     Pearson’s correlations were used to investigate relationships between weight change (kg) 
since the completion of treatment and composite scores for physical and psychological distress, 
intensity of fatigue, duration of fatigue, level of interference associated with fatigue, current 
dietary intake (energy, macronutrients) and the number of positive changes in diet since 
diagnosis. In order to identify women more likely to gain weight since the completion of 
treatment, crude odds ratios compared women who gained weight to those who were weight 
stable or lost weight, on the basis of physical and psychological distress, fatigue, current 




     Statistical analysis was conducted using the Statistical Package for the Social Sciences 
(SPSS version 20 IBM, Armonk, New York). Statistical significance was set at p< 0.05.   
5.4 Results 
  
 5.4.1 Sample Characteristics 
 
     A total of 28 women consented to participate, over a 14 month recruitment period between 
Oct, 2010 and Nov, 2011. The mean time from completing treatment was 6.4±4.4 months. 
Demographic, clinical and treatment characteristics are summarized in Table 5.1.      
Table 5.1: Demographic, Clinical and Treatment Characteristics of the Participants 
Characteristic (n=28) Mean (SD) Range n (%) 
Demographic    
Age (yrs) 49.8±8.5  33-69  
Ethnicity                       White 
                                      Black, Asian, West Asian 
 
 
 25 (89%) 
  3 (11%) 
Marital Status                Married 
                                      Single 
                                      Divorced 
  18 (64%) 
  4 (14%) 
  6 (22%) 
Education Completed   High School 
                                      College 
                                      University 
    6 (21%) 
  7 (25%) 
15 (54%) 
Employment Status       Employed 
                                      Leave of Absence 
                                      Unemployed/Retired 
  10 (36%) 
  7 (25%) 
11 (39%) 
Living Arrangements    Lives with Significant Others 
                                      Lives alone 
  20 (72%) 
  8 (28%) 
Clinical History    
Clinical Stage                I 
                                      II 
                                      IIIA 
    3 (11%) 
15 (53%) 
10 (36%) 
Menopause Status        Premenopausal 
 (at diagnosis)               Postmenopausal 
  19 (68%) 
  9 (32%) 
Treatment History    
Surgery Type                Lumpectomy 
                                      Mastectomy 
                                      Planned (Mastectomy)  
  15 (53%) 
10 (36%) 
  3 (11%) 
Chemotherapy              Number of Cycles 
                                     Duration of Treatment (weeks) 








Radiation Therapy        Yes 
                                      No 
                                      Planned 
  16 (57%) 
  5 (18%) 
  7 (25%) 
Hormone Therapy        Tamoxifen 
                                     Aromatase Inhibitor     










     The mean BMI at the end of treatment was 26.2±5.5 kg/m2, with 11 women (39.3%) in the 
normal weight category and 16 (57.1%) classified as overweight or obese. The mean weight 
change since the completion of treatment was -0.4± 3.2 kg (range = -6.0 - +5.2). Among 
women who gained >2.0 kg (n=6), the mean weight gain was 3.5±1.0 kg. Seven women lost an 
average of 5.1±0.8 kg during this time frame. At the time of interview, the mean BMI was 
26.1±5.7 kg/m2 with 11 women (39.3%) in the normal weight category and 15 (53.5%) 
classified as overweight or obese. Weight history is summarized in table 5.2. 
Table 5.2: Weight History 
 
Weight History (n=28) Mean (SD) Range n (%) 
Weight Status (end of treatment)    
Body Weight (kg) 72.9 (14.6)  48.2-101.8  
BMI (kg/m2)   26.2 (5.5)    17.1-36.7  
Body Weight Classification  Underweight (BMI < 18.5) 
                                               Normal Weight (BMI 18.5-24.9) 
                                               Overweight (BMI 25-29.9) 
                                               Obese (BMI ≥30) 
      1 (3.6%) 
11 (39.3%) 
  9 (32.1%) 
  7 (25.0%) 
Weight Change After Treatment     
All participants (kg) 
Women Who Gained Weight (kg)  
Women Who Lost Weight (kg) 
  - 0.4 (3.2) 
 + 3.5 (1.0)  
 -5.1 (0.8) 
  -6.0 - +5.2 
+ 3.1 - +5.2 
- 3.5 - - 6.0 
 
 6 (21.4%) 
    7 (25%) 
Weight Status (current)    
Body Weight (kg) 72.5 (15.1)  49.5-103.4  
BMI (kg/m2)   26.1 (5.7)    17.4-37.0  
Body Weight Classification  Underweight (BMI < 18.5) 
                                               Normal Weight (BMI 18.5-24.9) 
                                               Overweight (BMI 25-29.9) 
                                               Obese (BMI ≥30) 
      2 (7.2%) 
11 (39.3%) 
  9 (32.1%) 
  6 (21.4%) 
 
 
 5.4.2 Symptoms of Physical and Psychological Distress 
 
     The mean scores for physical and psychological distress (past week), based on the RSCL 
were 17.5±9.0 (range = 5.8-37.7) and 27.1±16.9 (range = 0-76.1), respectively. Based on these 
standardized scores, the level of psychological distress in this sample of women, at the time of 




     Figures 5.1 and 5.2 show the distribution of scores for physical and psychological distress 
across the sample group. These figures highlight the degree of variability in physical and 
psychological symptoms experienced by breast cancer survivors, in the first 12 months after 
completing chemotherapy treatment.  
* Note: All RSCL results (physical distress, psychological distress and QOL) represent the 
standardized scores (100 point scale), for ease of comparison across domains. 
 
Figure 5.1: Physical Distress among Early Stage Breast Cancer Survivors in the First 

















* CV = Coefficient of Variation 
 
Figure 5.2: Psychological Distress among Early Stage Breast Cancer Survivors in the 
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     Based on the mean scores across participants for individual items on the physical distress 
scale, symptoms rated as most distressing included difficulty sleeping, decreased sexual 
interest, tiredness and difficulty concentrating (Table 5.3). The scores for psychological 
distress reflect a high level of burden reported for “worrying”, “irritability” and “despairing 
about the future” in particular (Table 5.4). * Scores range from 1 (not at all) to 4 (very much). 
Table 5.3: Ranking of RSCL Physical Symptoms by Mean from Most to Least Distressing 
among Early Stage Breast Cancer Survivors in the First Year after Completing 
Chemotherapy Treatment.  
  
Symptoms of Physical Distress (n=28) Mean (SD) 
Difficulty Sleeping 2.20 0.91 
Decreased Sexual Interest 2.18 0.98 
Tiredness 2.16 0.58 
Difficulty Concentrating 2.09 0.82 
Tingling Hands or Feet 1.95 1.09 
Lack of Energy 1.91 0.61 
Sore Muscles 1.86 0.76 
Shivering 1.68 0.82 
Low Back Pain 1.52 0.79 
Dry Mouth 1.50 0.64 
Constipation 1.46 0.74 
Burning/Sore Eyes 1.39 0.57 
Lack of Appetite 1.36 0.68 
Headaches 1.36 0.68 
Acid Indigestion 1.29 0.60 
Dizziness 1.25 0.44 
Abdominal (Stomach) Aches 1.25 0.44 
Diarrhea 1.21 0.50 
Shortness of Breath 1.21 0.42 
Nausea 1.11 0.32 
Loss of Hair 1.11 0.57 
Vomiting 1.04 0.19 
Sore Mouth/Pain when Swallowing 1.00 0.00 
                      
Table 5.4: Ranking of RSCL Psychological Symptoms by Mean from Most to Least 
Distressing among Early Stage Breast Cancer Survivors in the First Year after 
Completing Chemotherapy Treatment.   
 
Symptoms of Psychological Distress (n=28) Mean (SD) 
Worrying 2.07 0.66 
Irritability 1.86 0.65 
Despairing About the Future 1.86 0.59 
Tension 1.82 0.82 
Anxiety 1.82 0.72 
Depressed Mood 1.70 0.90 




     The mean score for QOL (past week) was 19.6±20.3 (range = 0-83). Variability in this 
measure was high across the sample group, with 20 women (71%) describing their QOL in the 
past week as “good” or “excellent”, 4 (14%) as “moderately good” and 3 (11%) as “neither 
good nor bad”. One participant rated their quality of life as “poor” (Figure 5.3).      
Figure 5.3: Self-reported Quality of Life among Early Stage Breast Cancer Survivors in 













    The mean score on the Distress Thermometer (past week) was 3.1±2.9 (range = 0-9.5). The 
DT was added to the study protocol after recruitment was initiated and was completed by 26 of 
28 participants. Nine of these women (35%) rated their distress level as moderate to severe 
(≥4), according to the National Comprehensive Cancer Network guidelines (2012). 
Figure 5.4: Distress Thermometer Scores among Early Stage Breast Cancer Survivors in 
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Mean = 19.6 
CV = 104% 
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     The mean score for intensity of fatigue (“on average”) was 3.5±2.2 (range = 0-7.5), with 
fatigue reported across a mean of 4.5±2.6 days (range = 0-7) in the previous week. On a scale 
of 0 (none of the day) to 10 (the entire day), the mean score for the proportion of the daytime 
“on average” participants reported feeling fatigued was 28±16% (range=0-50%). Figures 5.5-
5.7 show the distribution of scores for intensity and duration of fatigue (past week), 
highlighting wide variability in measures of fatigue across the sample group.  
Figure 5.5: Intensity of Fatigue among Early Stage Breast Cancer Survivors in the First 













                                             * 0 = not at all fatigued, 10 = extreme fatigue 
 
Figure 5.6: Duration of Fatigue (number of days/past week) among Early Stage Breast 
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Figure 5.7: Duration of Fatigue (proportion of daytime) among Early Stage Breast 














     The mean level of interference associated with fatigue was 2.4±2.0 (range=0-6.9). Figure 
5.8 shows the distribution of scores across participants. This sample of women reported higher 
levels of interference for “general activity”, “ability to concentrate” and “mood” (Table 5.5). 
Figure 5.8: Level of Interference Associated with Fatigue * among Early Stage Breast 














Table 5.5: Ranking of RSCL Fatigue Interference Sub-scale Items * by Mean from Most 
to Least Amount of Interference among Early Stage Breast Cancer Survivors (n=28).   
 
Interference with Daily Activities (n=28) Mean (SD) 
General Activity 3.36 2.77 
Ability to Concentrate 3.21 2.90 
Mood 2.86 2.53 
Normal Work Activity 2.57 2.38 
Enjoyment of Life 2.32 2.21 
Relations with Other People 2.29 2.49 
Ability to Bathe and Dress Yourself 0.46 1.23 
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 5.4.3 Symptoms of Physical & Psychological Distress Relative to Previous Findings 
 
     Although true comparisons are not possible, it appears that on average, indicators of 
physical and psychological distress in this sample of early stage breast cancer survivors are 
comparable to reports of breast cancer patients in active treatment and higher than comparison 
groups of healthy adults (de Haes, et al., 1996; Hegel et al., 2006; Yong et al., 2012; Hann et 
al., 1998). Figure 5.9 (a-f) shows the means scores for physical distress, psychological distress, 
quality of life, the distress thermometer and fatigue relative to previous findings among breast 
cancer survivors and normative data from cancer-free adults. (see discussion) 
Figure 5.9: Comparison of Mean Scores for Physical and Psychological Distress 
Indicators Between Early Stage Breast Cancer Survivors Post-treatment and 
Comparison Groups of Breast Cancer or Healthy Individuals from the Literature. 
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 5.4.4 Dietary Intake and Dietary Change 
     Based on 3-day food records, the mean energy intake for the sample was 1883±359 kcals, 
with protein, carbohydrates and fat providing 17.9%, 52.2% and 28.5% of energy, respectively. 
Eighty-four percent of women (n=24) reported that they had made changes to their diet since 
diagnosis, the majority of which were categorized as positive. The most common change was 
an increase in vegetables and fruit (75% of total sample), followed by a decrease in overall 
meat consumption or a change to lower fat options (decreased red meat, increased chicken, 
57.1%), increased intake of fish (46.4%) and reduced alcohol intake (39.3%). Reports of 
negative dietary changes were minimal in this sample, most common among them being an 
increase in desserts (14.3%). Among women reporting any dietary change, the mean number of 
positive changes was 3.88±1.4 (range = 0-6).  
 5.4.5 Relationships between Symptoms of Physical and Psychological Distress, Diet  
               and Weight Gain Since the Completion of Treatment  
 
     Treating weight change (kg) as a continuous variable, there were no significant associations 
between weight change since the completion of treatment and each of physical and 




past week) or level of interference associated with fatigue. Fatigue duration, based on the 
proportion of daytime fatigue was reported, was significantly correlated with weight change 
(r=-0.46, p<0.05), with fatigue over a larger proportion of the day associated with weight loss 
since the completion of treatment. Dietary factors, including current intakes and number of 
positive changes in diet since diagnosis, were not associated with weight change since the 
completion of treatment. Odds ratios comparing women who gained weight to women who did 
not gain weight (loss or stable) after treatment on the basis of treatment-related (physical and 
psychological distress, fatigue) and dietary factors (energy, macronutrients, number of positive 
changes in diet since diagnosis) were non-significant.  
5.5 Discussion 
 
     This study provides an intensive investigation into weight change and symptoms of physical 
distress, psychological distress and fatigue, as reported by early stage breast cancer survivors 
within 12 months of completing chemotherapy treatment. Relationships among physical and 
psychological distress, fatigue, current dietary intake, changes in diet and weight gain since the 
completion of treatment were investigated.  
     Overall weight change in this sample, since the completion of treatment, was minimal. Six 
women (21.4%) however, gained an average of 3.5 kg, while 15 (53.6%) were weight stable 
and 7 (25%) lost weight during this time frame. Based on previous findings (Demark-
Wahnefried et al. 1997a; Makari-Judson et al., 2007; Kutynec et al. 1999), it was expected that 
as many as 50% of women would gain weight in the first 12 months of completing treatment, 
however, the mean time from treatment in this sample was 6.4 months and 32% (n=9) of 
women were within three months. This relatively short follow-up period yielded a narrow 




frame. While this may have limited capacity to detect significant relationships, the removal of 
six participants from the analysis who were  ≤ 1 month from completing chemotherapy did not 
alter our findings and no significant association was observed between weight gain and length 
of time from treatment (data not shown). 
     The current results suggest that levels of both physical and psychological distress associated 
with cancer and its treatment may persist for many breast cancer survivors in the first year after 
completing treatment. Although symptoms were highly variable across the sample group, 
based on the same instrument, the mean levels of physical and psychological distress in these 
women were similar to a large sample of early stage breast cancer patients in active treatment 
(n=653, age < 51 y) and appear to be markedly higher than previous reports of distress among 
a random sample of adults from the general population (n=201, 59% female, mean age = 45 y) 
(de Haes, et al., 1996). The ranking of physical symptoms from most to least distressing is 
consistent with the findings of Stein, Denniston, Baker et al. (2003), who reported consistently 
high ratings for “tiredness”, “lack of energy”, “difficulty sleeping” and “decreased sexual 
interest” among 1005 male and female cancer patients (mean age = 58±14 y), 18% of whom 
were still in active treatment.   
     Comparisons to breast cancer patients in active treatment or cancer-free populations were 
not available, however compared to newly diagnosed breast cancer patients awaiting treatment 
(n=236, stage I-III, mean age = 57 y), the mean DT score in this sample of women appears to 
be lower (Hegel et al., 2006). This finding is consistent with evidence that psychological 
distress may be higher immediately after diagnosis but recedes somewhat once treatment has 
been initiated (deHaes et al., 1996). The mean Distress Thermometer score seems to suggest 




breast cancer survivors (n=150, stage I-II, mean age = 49 y) after treatment (Yong et al., 2012). 
However, since the time frame was not reported in the earlier study, it is possible that the 
comparison sample group was further removed from the completion of treatment, thus 
allowing more time to recover from the residual effects of treatment. 
     The mean intensity of fatigue (“on average”) in this sample, was comparable to the mean 
intensity of fatigue reported by breast cancer patients in active treatment (n=117, mean age      
= 52 y) and appears to be higher than an age-matched comparison group of healthy women 
(n=94) (Hann et al., 1998). Similarly, the extent to which fatigue interfered with daily activities 
was consistent with women in active treatment, but suggested a higher degree of burden 
associated with fatigue, compared to healthy women. Additional findings reported by Hann 
and colleagues (1998) are consistent with our results, in women who have completed 
treatment. Also based on the FSI, Hann et al. (1998) reported a mean intensity of fatigue of 3.4 
(vs. 3.5 in the current study) among 113 women (mean age = 53 y) who were at least three 
months post-treatment for early stage breast cancer. In this sample, the mean duration of 
fatigue was 4.0 (days/week) and 31% (proportion of daytime), respectively compared to 4.5 
and 28% in the current study. The mean score for fatigue “interference” was also comparable 
across studies (2.1 vs. 2.4).  
     Despite relatively high levels of physical and psychological distress at the time of interview, 
71% of women in this sample rated their quality of life in the past week as “good” or 
“excellent” Based on interview responses to the qualitative portion of the larger study, this 
finding seemed to reflect a gradual adjustment to their cancer diagnosis over time, a strong 
sense of relief at having completed treatment and a commonly expressed desire to “seize the 




score for global QOL appears to be comparable to a random sample from the general 
population but lower (implying better QOL) than early stage breast cancer patients in active 
treatment (de Haes, et al., 1996).  
     Scores for physical distress, psychological distress, fatigue and QOL were highly variable 
across the sample group. This finding is supported by previous reports among breast cancer 
survivors, in which the inter-individual variability for indicators of physical and psychological 
distress (CVs=54%-96%) and QOL (CV=67%), at various time points in the cancer trajectory, 
were high (deHaes et al., 1996; Hegel et al., 2006; Yong et al., 2011; Hann et al., 1998). In the 
current sample, scores for these survey variables were not significantly correlated with 
demographic or clinical characteristics, or length of time from treatment (data not shown).  
     Comparisons to previous findings and normative data must be considered within the context 
of similarities and differences in sample characteristics and study design. First, all comparisons 
were based on the same validated instruments and are strengthened by similarities in 
demographic and clinical characteristics of the participants. Breast cancer specific comparisons 
(RSCL, DT, FSI) were drawn from samples of women who were similar in age and stage of 
disease (de Haes, et al., 1996, Hegel et al., 2006; Yong et al., 2011; Hann et al., 1998).  
Cancer-free comparison groups included a sample of healthy women of similar age (Hann et 
al., 1998) and a random sample from the general population, of which 59% of participants 
were female (de Haes, et al., 1996). Differences in the timing of measures (Yong et al., 2011) 
and changes in treatment protocols over time, may however have impacted on the level of 
physical and psychological distress among clinical populations. It should also be noted that 




white, married, well-educated women, suggesting caution in extrapolating the findings to the 
population of breast cancer survivors. 
     It is noteworthy that, without repeated measures in the same sample group, we cannot be 
certain that physical and psychological distress reported at the time of interview actually reflect 
persistent effects of cancer treatment. However, qualitative interviews with the same sample 
group, in which physical and psychological distress and pervasive fatigue were reported during 
treatment, suggest that current symptoms may represent residual effects of cancer and its 
treatment for many women. This is supported by comparisons of current findings to cancer-
free populations, which suggest that the levels of distress in this sample of women were 
substantially higher.   
     Energy intake from 3-day food records (1883±359 kcals) in the current study is higher than 
previous reports in this population. In two large prospective cohorts of early stage breast 
cancer survivors (Health, Eating, Activity and Lifestyle (HEAL) and Life After Cancer 
Epidemiology (LACE) studies), mean energy intake based on a 114 item FFQ was estimated at 
1356-1458 kcals (Wayne et al., 2004; Caan et al., 2005).  Using 24-hr recalls, baseline data 
from the Women’s Healthy Eating and Living (WHEL) study (Pierce, Natarajan, Caan et al., 
2007) (n=3088, stage I-IIIA) revealed a mean energy intake of 1718 kcals; energy intake that is 
similar to mean kcals reported by the Women’s Intervention Nutrition (WINS) study (n=2437, 
stage I-IIIA) (Chlebowski et al., 2006). Mean protein intake as a percentage of total energy 
(17.9%) is similar to that reported in the HEAL and LACE studies (16.9-17.1%). Total fat 
intake (28.5%) is consistent with data from the WHEL and WINS studies (28.5-29.6%), but 
lower than estimates from the HEAL and LACE cohorts (33.8-35.5%).  The amount of energy 




both HEAL and LACE (52.2% vs. 47.4-48.6%). Differences in dietary assessment methods 
and timing of the measures relative to diagnosis may explain apparent differences in dietary 
intake data. Although key demographic and clinical characteristics were similar across studies 
(ethnicity, education, clinical stage, baseline BMI), participants in the current study and the 
WHEL study were, on average, a little younger compared to the HEAL, LACE and WINS 
cohorts, which may help account for differences that were observed  (Thomson et al., 2002; 
Wayne et al., 2004). 
     Our finding that higher scores for fatigue duration (proportion of daytime) were negatively 
correlated with weight change is of interest. This is consistent with findings from an earlier 
qualitative analysis with this sample group, suggesting that extreme and persistent fatigue 
during chemotherapy treatment may associate with reduced food intake and weight loss in 
some women (Chapter 3). In this study, participants who reported unrelenting fatigue between 
cycles, described that they were “too tired to eat”, “couldn’t be bothered” or didn’t have the 
energy to prepare food, especially if they were living alone. Given that fatigue has been shown 
to persist for many breast cancer survivors in the months and years after diagnosis (Meeske et 
al., 2007), the apparent relationship between fatigue and lower food intake may endure for 
some women. These findings contrast with those of Kumar et al. (2004) who found that, based 
on the FSI, duration of fatigue was positively correlated with weight gain in breast cancer 
survivors (n=198, stage I-IIIB) in the six month period after treatment; a relationship that may 
be mediated by lower levels of physical activity during this time (Irwin et al., 2003). Although 
fatigue is common in this population, these results highlight wide inter-individual variation in 




     Beyond the observed association between fatigue duration and weight change, relationships 
between symptoms of physical and psychological distress, current dietary intake, changes in 
diet and weight gain since the completion of treatment were non-significant. There are a 
number of factors which may have influenced these null findings. First, data for this analysis 
were collected in conjunction with a qualitative study designed to explore the recalled 
experiences of food intake and weight change during treatment. In keeping with the in-depth 
nature of qualitative analysis, the sample size was relatively small and may have limited the 
ability to detect significant relationships after treatment. Based on the observed effect size in 
this study (r=.46), and a desired power level of 0.8, it is estimated that a sample size of 38-40 
would be necessary to detect significant correlations between psychosocial and treatment-
related factors and weight gain since the completion of treatment. A longer mean follow-up 
period, based on this sample size, may produce more variability in weight change and 
sufficient statistical power for further study.     
     In addition, this study was limited by the cross-sectional design, as it is not known if the 
level of physical and psychological distress reported at the time of interview (past week) 
accurately reflects the level of distress experienced since the completion of treatment. While 
normative data derived from women with similar characteristics allowed for meaningful 
comparisons to the current findings, and suggested enduring symptoms of physical and 
psychological distress after treatment, these comparisons would be strengthened by repeated 
measures within the same study population, across the cancer trajectory.  
     The current findings point to factors that may influence dietary choices and energy balance 
in the first year after breast cancer treatment. This is an important first step in developing 




and weight management are unlikely to be effective without appropriate supports in place to 
address potential barriers. Evidence of persistent physical and psychological distress among 
breast cancer survivors raises awareness of ongoing challenges that may influence eating 
behaviour after treatment. This is important given that psychological distress in particular, is 
common in cancer survivors but often goes unrecognized (National Comprehensive Cancer 
Network, 2012) and is now endorsed nationally and internationally as the “6th vital sign” 
(Howell & Olsen, 2011). Residual effects of cancer and its treatment, including distress should 
be recognized in the clinical and research settings for their effects on overall health and their 
potential impact on food intake and energy imbalance after treatment.    
     In summary, our results suggest that symptoms of physical and psychological distress may 
persist for many breast cancer survivors in the first 12 months following primary treatment and 
may be associated with weight change. These findings may serve to guide dietary counseling 
within a growing population of breast cancer survivors and to aid in the development of 













CHAPTER 6: GENERAL DISCUSSION 
 
     The purpose of this general discussion is to provide a summary of the overall results of this 
thesis, with an emphasis on the integration of qualitative and quantitative findings and weight 
history across studies 1 (Chapter 3-during treatment) and 2 (Chapters 4 and 5-after treatment). 
Key contributions of these findings toward expanding the field of research are reviewed, 
followed by a discussion of the relevance of these findings for clinical practice and 
recommendations for future research. Finally, some concluding remarks and a “personal post-
script” are included as an effort to capture the depth of involvement offered by the women who 
participated in this study and to provide additional context for the interview process.      
6.1 Overall Findings and Key Contributions 
 
     The purpose of study 1 was to gain an appreciation of the experience of chemotherapy from 
the perspective of breast cancer survivors; to describe the unique challenges related to diet and 
weight management and to investigate possible relationships among psychosocial and 
treatment-related factors, dietary intake and weight change during treatment. Since participants 
were interviewed within 12 months of completing chemotherapy, this timing offered an 
opportunity to explore whether factors that appear to associate with weight change during 
treatment (study 1), might persist in the first year after receiving chemotherapy and continue to 
exert an effect on food intake and energy balance after treatment (study 2). The use of 
qualitative methods, validated surveys and dietary records (at the time of interview) helped to 
overcome some of the methodological limitations associated with dietary assessment during 
breast cancer treatment and provided novel insights into diet and weight change after 




     Qualitative findings (study 1) revealed common themes around food intake and eating 
patterns, and factors associated with changes in diet during treatment. As presented in Figure 
3.1, changes in food intake relative to treatment day, changes in appetite and changes in food 
appeal (food cravings, comfort foods and food aversions) were common concerns in this 
sample of early stage breast cancer survivors. Based on women’s perceptions, fatigue, taste 
changes, gastrointestinal disturbance, family/social support and the emotional impact of cancer 
and its treatment were key factors contributing to changes in food intake and eating patterns 
during treatment (Figure 3.2).  
     While underlying themes were apparent across the sample group, these shared psychosocial 
and treatment-related issues produced a wide range of dietary responses. Taste changes, for 
example, produced both food cravings and food aversions in this sample, while gastrointestinal 
disturbance and emotional distress were associated with increased appetite and increased 
intake of energy dense comfort foods in some women and reduced appetite and lower food 
intake in others. Qualitative analysis, based on the constant comparative method, led to the 
development of two theoretical models. The first model was designed to explain how 
psychosocial factors and treatment-related side effects might influence diet and eating patterns 
in ways that promote weight gain during treatment (Figure 3.3). This model was expanded to 
include factors associated with weight loss during treatment (Figure 3.4), in light of emerging 
evidence that weight fluctuation, both gain and loss, may associate with adverse health effects.  
     The theoretical framework presented in Figure 3.3 shows that increased appetite, food 
cravings and intake of energy dense comfort foods seemed to be more prevalent and persistent 
among women who gained weight during treatment. Vivid recall of the chemotherapy 




central in promoting these dietary responses. These qualitative findings are supported by a 
significant association between self-reported quantity of food intake (compared to usual intake 
before diagnosis) and weight gain during treatment, and the subjective perceptions of women 
concerning behavioural factors affecting energy balance during this time frame.  
     Figure 3.4 highlights possible relationships between treatment effects, food intake and 
weight loss during treatment. Women who lost weight in this sample group tended to report 
more severe and persistent side effects of treatment, leading to a more prolonged reduction in 
food intake after treatment. Fatigue, nausea, constipation and heartburn in particular, seemed to 
endure in these women well into the second and third weeks within cycles, producing 
decreased appetite and irregular eating throughout treatment. In this sample, weight loss also 
appeared to be more common among women who lived alone, perhaps reflecting the level of 
cooking support that was available in the home.  
     Findings from study 2 (Chapters 4 and 5) provide additional support for some of the 
qualitative results presented in study 1. In this sample of women, mean scores for physical 
distress, psychological distress and fatigue at the time of interview (mean = 6.4 months from 
completing treatment), were similar to women in active treatment but appeared to be 
consistently higher than normative data drawn from healthy comparison groups. Based on the 
Distress Thermometer, compared to a large sample of women with newly diagnosed early 
stage breast cancer, the level of distress reported in the current sample appears to be lower. 
This observation is consistent with the experience of women in the current study, with most 
women having reported lower levels of anxiety once a treatment plan was in place and 




     As reported in previous studies, self-reported changes in diet after diagnosis were consistent 
with current dietary recommendations for cancer prevention, with many women reporting an 
increase in vegetable and fruit intake, decreased meat, increased fish and reduced alcohol 
consumption. The proportion of women reporting positive changes in diet after diagnosis was 
quite high in this sample, compared to earlier studies, however based on 3-day food records at 
the time of interview, many women did not meet minimum recommendations for vegetable & 
fruit servings or milk & alternatives and some were above the current guidelines for total and 
saturated fat. The prevalence of inadequate fibre intake appeared to be low. 
     A significant association between fatigue and weight loss in study 2 also lends support to 
qualitative findings from study 1. Based on the Fatigue Symptom Inventory, fatigue duration 
(past week) was negatively correlated with weight change since the completion of treatment. 
This is consistent with an apparent association between extreme fatigue and weight loss during 
active treatment. Associations between other survey variables, current dietary intake, changes 
in diet and weight gain since the completion of treatment were non-significant. These findings 
likely reflect insufficient statistical power, based on sample size and limited variability in 
weight change in the current study, however serve to estimate a required sample size of 38-40 
for future studies.  
     Figure 6.2 (pg. 182) integrates the findings of study 1 and 2, to explain how psychosocial 
factors and treatment-related side effects might influence diet and eating patterns in ways that 
promote weight change after a breast cancer diagnosis. Factors that appear to associate with 
food intake both during and after treatment are bolded. This model suggests that emotional 
distress, fatigue and decreased appetite may persist for some women in the months following 




the RSCL, “tiredness” and “lack of energy” were ranked high on the list of individual 
symptoms of physical distress, at the time of interview. Although “lack of appetite” was ranked 
lower, based on the mean values for most to least distressing (table 5.3), 54% of women (n=15) 
reported that they had been eating less than they would normally eat since the completion of 
treatment, almost half of whom (n=7) attributed lower food intake to early satiety and reduced 
appetite. Five of these women had lost weight since the completion of treatment. Symptoms of 
psychological distress were relatively high in this sample, compared to cancer-free adults, and 
reflected higher scores for “worrying”, “despairing about the future”, “tension” and “anxiety”, 
in particular. Most women reported that other treatment-related factors associated with food 
intake and eating patterns during treatment (taste changes, food cravings/aversions, nausea, 
constipation, heartburn) had largely resolved by the time of interview.  
     Weight change during treatment and since the completion of treatment are provided in the 
results sections of chapters 3 and 5, however a closer look at weight history across the total 
study period (diagnosis to time of interview) may provide additional insights (Figure 6.1). 
Weight gain >2kg was observed in 57.1% of women (n=16) in this sample, during or after 
treatment. One woman gained weight in both of these time periods. Among women who 
gained weight during treatment (n=11), 64% (n=7) were still > 2kg above their baseline body 
weight, at the time of interview. Three additional women, who were weight stable during 
treatment, gained > 2kg since the completion of treatment. Between diagnosis and the time of 
interview, the mean weight change was +0.5±3.9 kg (range = -10.1 - +8.41); supporting the 
variability in weight change that has been observed in breast cancer survivors (Gu et al., 2010; 
Nissen et al., 2011). Among women who gained weight across the total study period (n=10, 




26.1±5.7 kg/m2, compared to 25.9±5.7 kg/m2, at diagnosis, with 53.5% of women (vs. 46.4%) 
now classified as overweight or obese. During this time frame, two women moved from the 
normal weight to overweight category and one woman, who was normal weight at diagnosis, 
was classified as underweight at the time of interview. These findings are consistent with 
earlier studies in which a general trend toward a reduction in overall weight gain in this 
population has been observed (Vance et al., 2011), however underscores that weight gain is 
nonetheless a persistent problem for a sizeable proportion of women.  
     The weight gain reported in this sample, over an average of 15 weeks of treatment (0.8±4.6 
kg) is higher than would be expected in a healthy population (~0.2-0.55 kg/y) (Williamson et 
al, 1991; Guo et al., 1999), and was substantially higher in some women. Weight change 
during treatment, after treatment or across the study period were not associated with BMI at 
diagnosis (p = .20, .29 and .47, respectively); a finding that is supported by some (Goodwin et 
al., 1988; Costa et al., 2001; Lankester et al., 2002; Ingram & Brown, 2004; Irwin et al. 2005; 
Heideman et al., 2009; Tredan et al., 2010; Gordon et al., 2011) but not all (Gu et al., 2010; 
Nissen et al., 2011; Yaw et al., 2011) previous studies.  
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Figure 6.2: Relationships between Psychosocial & Treatment-related Factors, Food Intake and Weight Change in Breast 






     These findings contribute to the current literature in a number of important ways.  
1. Food intake and eating patterns during treatment are influenced by a wide range of 
psychosocial and treatment-related factors that vary across women. 
 
Qualitative methods based on comprehensive interviews with breast cancer survivors provided 
a unique perspective on food intake and weight change during treatment. The exploration of 
food intake and eating patterns, in the context of psychosocial and treatment-related factors, 
identified dietary challenges that women face as they are undergoing chemotherapy treatment. 
Although nutrition-impact symptoms are well documented, the severity and persistence of 
these symptoms vary considerably between women and across the treatment trajectory, leading 
to a broad range of behavioural responses associated with both weight gain and weight loss. 
This data, based on the lived experience of women, will help to design healthy eating and 
weight management strategies that acknowledge and address potential barriers.  
2.  Methodological challenges have limited the ability to detect relationships between food  
     intake and weight change during treatment. 
 
Evidence of marked variability in food intake within cycles and across treatment, highlights the 
difficulty in accurately capturing dietary change and energy balance using quantitative 
assessment methods. A theoretical model based on the current findings supports several 
pathways by which psychosocial factors and treatment-related side effects might influence diet 
and eating patterns in ways that promote weight change during treatment. These findings may 
have important relevance for clinical practice (section 6.2) and future research (section 6.3).  
3.  Many breast cancer survivors may not be meeting current dietary recommendations.  
 
Study 2 adds to a limited body of literature on dietary changes and dietary intake after breast 
cancer. Improving our understanding of dietary habits after diagnosis including dietary changes 




compare to current recommendations, will inform appropriate targets/timing for intervention. 
For example, knowing that the majority of women (84%) are already making dietary changes 
and that many (36%) are making these changes during active treatment helps to direct the 
timing and provision of resources.   
4. Physical and psychological distress appear to persist for many breast cancer survivors in the  
    first 12 months after completing chemotherapy treatment.  
 
This study is the first, to the author’s knowledge, to explore the potential influence of physical 
and psychological distress on diet and weight change after treatment. Further research with a 
larger sample size is needed to confirm relationships between survey variables, dietary data 
and weight change. Nonetheless, the relatively high levels of physical and psychological 
distress reported in this sample of breast cancer survivors, on average 6 months post-treatment, 
is an important finding. Health care providers should be alerted to the role that fatigue and 
emotional distress for example, may play in promoting energy imbalance after treatment.  
6.2 Clinical Applications  
     Qualitative findings from study 1 may help the health care team to identify women who are 
most at risk of weight gain or loss during treatment. Moreover, understanding the unique 
challenges related to diet and weight management in this population may inform the 
development of effective guidelines and diet/weight management interventions after diagnosis.  
     A key lesson to be drawn from the experiences of women who participated in this study is 
an appreciation for the variability in dietary responses to common psychosocial and treatment-
related issues that was evident during treatment. It is clear that the “anticipated” experience of 
early stage breast cancer patients receiving chemotherapy cannot be defined by a single set of 
guidelines. This is supported by wide variation in weight change during and after treatment, 




weight change and associated psychosocial and treatment-related factors regularly throughout 
treatment and refer to the appropriate supportive care personnel for guidance and counseling, 
as required. Dietitians should acknowledge the potential role of taste changes, nausea and 
emotional distress in promoting food cravings, increased appetite and weight gain and provide 
guidance around dietary strategies that will assist in maintaining energy balance during 
treatment. Given that weight loss may be equally concerning in terms of health outcomes, the 
apparent link between extreme fatigue and GI disturbance should be evaluated in the context of 
the level of cooking support that is available in the home, to ensure that women who are 
experiencing persistent symptoms have access to supportive services and adequate nutrition 
throughout treatment.  
     Evidence in the current study that some women may be willing and able to implement 
positive changes in diet during treatment suggests that supportive dietary services may be 
effective early in the cancer trajectory. This is supported by earlier studies in which it has been 
demonstrated that a diagnosis of breast cancer may represent a time when women are open to 
learning about food and nutrition and highly motivated to make lifestyle changes that will 
promote optimal health (Demark-Wahnefried et al., 2000; McBride et al., 2000). Although a 
full analysis is beyond the scope of this thesis, qualitative interviews included a question in 
which participants were asked to discuss their previous knowledge and level of concern about 
weight control during treatment, their use of dietary services and any recommendations they 
had for improving dietary supports after diagnosis. Most women expressed that weight 
management was on their mind during treatment but was a lower priority for them, as they 
coped with their diagnosis and the effects of treatment. Many were not aware that weight gain 




offered by dietitians in the cancer centres where they were treated, but only two received 
individual counseling during this time. Many women expressed that they would have been 
open to meeting with a dietitian early in treatment to discuss food intake and weight 
management issues. Most of these women indicated that practical advice around dietary 
planning, coping with side-effects and foods that might increase or decrease the risk of 
recurrence was of particular interest. These services are in fact available in most major cancer 
centres, however it was apparent that many women were not aware of how to access them or 
were overwhelmed with information and medical appointments, such that attending a class on 
another day was impractical for them. During the study period, the Grand River Regional 
Cancer Centre, where 57% of the study sample were treated, was offering two classes to cancer 
patients; one focused on healthy eating in general, the other providing guidance around 
nutrition and cancer specifically. Individual diet consultations could also be arranged through 
supportive services. Although only two women exercised this option, several others (n=7, 
25%) mentioned that a Registered Dietitian from supportive services had dropped in to see 
them in the chemotherapy suite. These meetings were generally brief, designed to explore how 
patients were coping with nutrition-related side effects of treatment. These findings suggest a 
need for improved integration of dietary support services, within the regular oncology 
schedule.  
      Although a large proportion of women in this study reported positive changes in diet after 
diagnosis, dietary data based on 3-day food records in the first 12 months after diagnosis, 
suggests that vegetable and fruit, milk and alternatives, dietary fat, calcium and vitamin D 
intakes may be targets for nutrition intervention in this population. This is consistent with 




and two randomized trials (Chlebowski et al., 2006; Pierce et al., 2007), evaluating the effects 
of specific foods/nutrients on prognosis, have produced mixed results. Without clear evidence 
for the beneficial effects of individual dietary factors (Robien, Demark-Wahnefried & Rock, 
2011), current findings suggest that a reduced fat, predominantly plant-based diet, that supports 
a healthy body weight will improve overall survival (Kroenke et al., 2005, Kwan et al., 2008) 
and may protect against recurrence (Rock et al., 2009; Hauner et al., 2011). Similarly, an 
association between calcium and vitamin D and breast cancer recurrence is equivocal (Jacobs, 
Thomson, Flatt et al., 2010), however the established role of these micronutrients in protecting 
against osteoporosis after menopause (National Institutes of Health, 2011), supports their place 
in nutrition intervention.  
     Lastly, evidence of progressive weight gain after treatment suggests that continued 
intervention and follow-up is warranted. Dietary supports are needed within the context of 
potential barriers to healthy eating and weight management during and after treatment. 
Relatively high levels of distress in this sample of women, who were on average 6.4 months 
from completing chemotherapy, underscores a need for ongoing cancer care and wellness 
programs across the cancer trajectory. Several women expressed anxiety about being outside 
the “circle of care”, meaning they were no longer seeing their oncologists on a regular basis or 
receiving routine diagnostic tests to monitor their disease. As a result, they were concerned that 
they would not know how to interpret new symptoms and that they would not know if their 
“cancer had come back”. Supporting the results of previous studies, most women were very 
interested in behavioural strategies that might reduce the likelihood of recurrence, once again 
highlighting the need for “rehabilitation” programs that will help patients to fully recover from 




     There are undoubtedly lessons to be drawn from the long standing practices and established 
benefits of cardiac rehabilitation. Cardiac rehab programs aimed at recovery, secondary 
prevention and lifestyle change, have been in place since the 1960’s (Certo, 1985). The 
Cardiac Health Foundation of Canada (2012) defines cardiac rehab as “the enhancement and 
maintenance of cardiovascular health through individualized programs designed to optimize 
physical, psychological, social, vocational and emotional status”. Such programs, focused on 
diet, exercise, smoking cessation and stress management, are known to reduce risk factors 
associated with heart health, decrease pain, reduce the risk of morbidity and mortality and 
improve quality of life (National Institutes of Health, 2012). 
     While there is a critical need for further research to support cancer rehabilitation programs, 
for a growing population of breast cancer survivors, there is also a need to translate the best 
evidence to date into clinical practice. Elevated risk of co-morbid conditions among women 
who have been treated for breast cancer and the known benefits of diet and exercise in 
promoting overall health, support the need for lifestyle intervention in this vulnerable 
population (Robien et al., 2011). The “precautionary principle” endorsed by the Canadian 
Breast Cancer Foundation (2012) suggests that evolving evidence should be applied, with a 
view to “err on the side of caution” and put women’s health first.  
     Table 6.1 summarizes suggestions for caregivers working with women who are undergoing 
chemotherapy treatment for breast cancer. These suggestions are not meant to be exhaustive, or 
to reiterate well-established standards of dietetic practice, but rather represent “lessons” from 
the women who participated in this study that may help to provide guidance around healthy 





Table 6.1: Suggestions for Caregivers Working with Women Undergoing Chemotherapy 
Treatment for Breast Cancer.  
 
Before Treatment 
Inform in Advance About: 
Fatigue • Very common for the first few days after treatments.  
• May persist into the second week and may be cumulative across cycles. 
Changes in Taste • Many foods will likely taste “off” - metallic or chemical taste is common.  
• May experience loss of taste sensation.  
• Taste changes usually present with the first couple of days and may last through 
the first and second week after chemotherapy.  
GI Disturbance • May experience nausea, constipation, diarrhea, heartburn.  
• Reinforce adherence to anti-nausea, laxative and acid reflux medication protocols, 
as prescribed. 
Changes in Appetite • Most women experience lower appetite for the first couple of days.  
• Appetite generally improves in the second and third weeks.  
• Some women experience an increase in appetite within a few days of treatment.  
Food Cravings/ 
Food Aversions 
• Both are common and are often associated with changes in taste.  
• May want to avoid favourite foods around chemotherapy days.  
Mouth Sores  • Reinforce careful oral hygiene and routine use of mouthwashes, as prescribed. 
Planning Ahead • Stock up on easy to prepare, well tolerated foods (e.g. pasta, soups, bananas, 
applesauce, puddings and yogurt).  
• Bring snacks on treatment days in case of long waiting periods and limited 
availability of preferred foods. 
Social Support • Support of family and friends (e.g. treatment companion, food preparation) is 





Fatigue • Rest and daytime naps as required for the first few days.  
• May find it helpful to break down “must do” tasks into smaller increments. 
• Low intensity exercise (walking, yoga) as tolerated, may help to increase energy.  
Changes in Taste • Adding lemon, salt or spices to foods as tolerated, may enhance flavour or mask 
unpleasant tastes. 
GI Disturbance  • Healthy dietary strategies for managing nausea (e.g. soda crackers), constipation 
(e.g. high fibre as tolerated, plenty of fluids), diarrhea (e.g. increase fluids, avoid 
fried foods/caffeine) and heartburn (e.g. avoid eating 3-4 hrs before bedtime).  
Changes in Appetite  • Increased appetite: Lower energy-dense food choices (e.g. fruit, yogurt, eggs). 
• Reduced appetite: High protein, energy-dense food choices (e.g. smoothies, nuts).  
Food Cravings/ 
Food Aversions 
• Nutrient rich, lower energy-dense foods may satisfy cravings for starchy 
carbohydrates and sweets (e.g. whole grain pasta, fruit, yogurt, chocolate milk).   
• Smaller portions of energy-dense cravings. 
• Alternate protein sources for red meat aversions (e.g. fish, eggs, dairy, beans). 
• Cooked vegetables, soups and juices may be tolerated in place of raw vegetables. 
Mouth Sores • Soft foods if mouth sores are present.  
• Cool foods (e.g. applesauce, yogurt) may be especially well tolerated.  
Social Support • Ask about food preparation and level of cooking support.  
• Refer to appropriate supportive services as required. 
Emotional Distress • Refer to appropriate supportive services as required. 
Advice for Family and Friends: 
Social Support • Practical assistance (e.g. accompanying patients to treatments, food preparation, 
childcare) contributes to emotional wellness.  




6.3 Future Research Directions 
 
     Given the adverse consequences of weight gain, fat gain and loss of lean tissue after 
diagnosis, continued efforts to identify the relative contribution of diet in promoting these 
changes are justified. Qualitative methods show promise as an effective means of capturing 
dietary change and associated psychosocial and treatment-related factors across the treatment 
trajectory, however the integrity and transferability of key themes should be tested in breast 
cancer populations representing a wider range of demographic characteristics (age, ethnicity, 
education), treatment protocols and stage of disease. Since multiple days of record keeping are 
problematic and may be impractical during treatment, future energy balance studies should, as 
a minimum, be designed to account for the timing of diet assessment relative to treatment day. 
Intra-individual variation in food intake across treatment is a confounder, however overall 
patterns of dietary intake in this sample suggest that food records or 24 hr recalls in the first, 
second and third weeks after treatment will provide a more accurate picture of dietary change, 
compared to the more common use of before and after measures only.     
     Evidence that both weight gain and weight loss may be associated with poor prognosis 
suggests that underlying metabolic disturbances associated with changes in body composition 
may be responsible for poor health outcomes (Healy, Ryan, Carroll et al., 2010). Since fat gain 
and loss of lean tissue may occur with or without weight gain (Cheney et al., 1997; Kutynec et 
al., 1999), it will be important to measure changes in body composition and to evaluate the 
effect of these changes on intermediate metabolic biomarkers (e.g., insulin, blood lipids).  
     At this time it seems probable that diet and physical activity patterns interact with a range of 
secondary factors (psychosocial, treatment effects, hormonal changes) to promote energy 




during treatment, may continue to exert an effect in the months and years after diagnosis. As 
such, further research is needed to test the efficacy, optimal timing and delivery of combined 
diet and exercise interventions after diagnosis (Robien et al, 2011), along with long-term 
studies designed to examine the effects of these interventions on prognosis and overall health.    
 6.4 Concluding Remarks 
     Although there is more research to be done to evaluate the impact of diet and exercise 
intervention on disease recurrence and survival, I conclude this thesis with a personal testament 
to the benefits of adopting a healthy lifestyle after diagnosis. A cancer diagnosis, and the 
treatment that follows, is clearly a time when patients must relinquish control over many 
aspects of their life. Diet and exercise may help to restore a sense of control and may have a 
significant role to play in overall wellness.   
Valerie: I know that everyone's journey is so very different, but focusing on fitness and 
nutrition is the one thing that had the most positive physical and psychological impact on 
my recovery. It really made me feel strong and in control again - something that cancer 
tries to steal. I also had an incredible network of support that encouraged me to do 
whatever I needed to do to recover, so I felt very fortunate. 
 
    Current dietary advice for patients seems to include a message to “eat whatever you want” 
or to “just get through it”, however, it was suggested by a few women that this was not a very 
positive message.  
         Heather: When you’re in treatment, they just said “eat whatever you want, just eat, you  
         want to have 10 donuts, eat 10 donuts” and I thought, yeah right. 
 
 Ursala: They said, “you eat anything that you want to eat”. That was bad to tell me, you  
         know for when I started feeling better.  
 
 Connie: I didn’t want my weight to go up for sure. I saw it as an opportunity to make 
         some changes that I could carry through after chemo and treatments were done. 
 
     Findings from this study suggest that proactive advice for preventing weight gain during 




they may or may not have been able to adhere to weight management advice in the face of 
treatment-related side effects, they would have appreciated more information at the time. It is 
clear however, that weight management guidelines should be flexible and delivered with a 
sensitivity and respect for the challenges that women face as they are undergoing treatment.  
     In keeping with the constructivist theoretical position adopted for this research, it is 
important to keep in mind that each woman’s experience with chemotherapy will be different.  
While there were common themes around diet and eating patterns and factors associated with 
food intake during treatment, there were many different perspectives and behavioral responses, 
reflecting individual reactions to cancer and its treatment. Moreover, with much variability in 
psychosocial and treatment-related factors affecting food intake, it was apparent that a priori 
“sensitizing concepts” should be held lightly, to ensure that the theoretical framework that was 
generated was grounded in the reality that breast cancer survivors “construct” for themselves. 
Personal Post-Script 
 
     The women who participated in this study appeared to be wholly invested in the research, 
exhibiting a level of commitment that I believe influenced the quantity and quality of the data 
that were obtained. The opportunity for “kitchen table” conversation, where I often had the 
privilege of meeting significant others and children, and their willingness to openly share their 
personal stories, provided an atmosphere for comfortable discussion and rich context. 
     Most of the participants seemed very eager to provide as much information as possible. It is 
noteworthy that many women appeared to be more at ease discussing how unwell they felt 
during treatment as the interviews progressed, suggesting the importance of developing a 
comfortable rapport. The interviews usually approached or exceeded the 90 minute target, with 




their personal diaries from the treatment period, in the event that additional information 
contained there would assist with the research. Food records were very detailed, often 
accompanied by food labels and/or personal recipes.  
     In the days and weeks following the interviews, I received several follow-up emails 
indicating how much they had enjoyed the opportunity to participate, and expressing interest in 
hearing about the results. In one case, I received an email update (with pictures) from a 
participant who wanted to share that she had accomplished a major lifestyle goal she had set 
for herself during treatment. This high level of interest and commitment to provide quality data 
reflected a strong motivation to “give back” in a way that might assist future breast cancer 
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Appendix A – Pilot Study Overview and Preliminary Findings 
Information Letter: Overview of Methods and Procedures 
 
Nutrition and Metabolic Evaluation of Breast Cancer Patients 
Principal Investigator:         Dr. Marina Mourtzakis 
    Department of Kinesiology, University of Waterloo 
519-884-4567 Ext. x38459 
 
Co-Investigators:   Dr. Rhona Hanning, University of Waterloo  
Dr. Mala Bahl, Grand River Hospital 
Ms. Caryl Russell, University of Waterloo 
 
 
Student Investigators           Megan Bedbrook, University of Waterloo 
    Vivienne Vance, University of Waterloo 
 
Purpose of Study: 
 
There are several changes that occur in your body when you are receiving treatment for breast 
cancer. You have been asked to take part in a research study designed to evaluate the nutrition 
and metabolic changes that occur with exercise training in breast cancer patients. Patients with 
breast cancer who receive chemotherapy tend to gain fat and lose lean mass. These changes 
may increase your risk of cardiovascular disease and diabetes. Exercise can reduce the risk 
factors leading to these diseases. Many breast cancer patients exercise to reduce fatigue and 
enhance their quality of life; however, the metabolic benefits of exercise in breast cancer 
patients are not known. During the time that you are receiving treatment, we will evaluate the 
changes that take place in your nutrition and metabolism. We will be studying 20 breast cancer 
patients who are receiving chemotherapy. Of these 20 patients, 10 will undergo exercise 
training for 16 weeks while 10 will be studied in the same way without undergoing an exercise 
program. You have an equal chance of being in either the exercise training or non-exercise 
training group. If you are in the non-exercise group, you will have the option, at the end of the 
study, to receive a similar exercise training program through the Well-Fit Centre at the 
University of Waterloo that will be 12 weeks long and be customized to activities that you 
enjoy. The information from this study will help us design future studies to better understand 
the benefits of nutrition and exercise for patients with breast cancer. 
 
Procedures Involved in this Study for All Participants: 
 
If you participate in this study, regardless of whether you are in the exercise or non-exercise 
group, you will be scheduled for nutrition, blood and fitness   
evaluations at the University of Waterloo at 3 different times over the 16-week duration of 




Procedure Week 0 Week 8 Week 16 
 (beginning   
 of the study)   
3-Day Food Diary X X X 
Physical Activity Surveys X X X 
Blood Test X X X 
Oral Glucose Tolerance Test X X X 
Snack X X X 
Incremental Exercise Test X X X 
Strength Test X X X 
 
On each of the 3 occasions (Weeks 0, 8, and 16), the total time that the evaluation will 
require at the Well-Fit Centre is 4.5 hours as well as 2 hours for the completion of the 3-
Day Food Diary and Physical Activity Surveys prior to your evaluation at wks 0, 8 and 16. 
 
If you are in the exercise group, you will also participate in a 16-week exercise training 
program (3 sessions / week for 1 to 1 ½ hours each session) and you will be supervised by an 
exercise physiologist at each session at the Well-Fit Centre at the University of Waterloo. 
 
Explanation of Procedures and Risks for All Participants: 
 
For the evaluations at Weeks 0, 8, and 16, you will be asked to come to the Well-  
Fit Centre at the University of Waterloo (See attached brochure or go to 
www.uwfitness.uwaterloo.ca) after an overnight fast (about 8 hours without food or drink 
except water). You will be able to take your usual medication in the morning. Upon arrival at 
the Well-Fit Centre, you will be asked if you have taken any medications that morning and 
then one of our personnel will take your weight and height (without shoes). The amount of fat 
in your body will also be estimated using skin-fold test with callipers and girth measurements. 
 
3-Day Food Diary & Nutritional Consult (~30 minutes per day): 
 
The purpose of the dietary analysis is to examine the quality and quantity of nutrients that are 
you eating or drinking. You will be provided with instructions and material to complete a 3-
day food diary (~30 minutes per day). To complete the food diary, you will be asked to record 
everything you eat and drink for a period of 3 days (2 weekdays, 1 weekend day). You will 
also need to indicate the medications, vitamins and supplements that you are taking. It is 
important that you do not try to alter your diet during this period of time. You should eat as 
you would normally do if you were not recording your nutritional intake. 
 
 A sample day is provided with the instructions so that you can see the amount of detail 
needed in filling out the diary. During the time that you are completing the dietary record, we 
will contact you by telephone to check if you have any questions about the food diary. After 
you have completed the document, you will be asked to bring it with you to your next 




Physical Activity Surveys (30 minutes): 
 
You will be asked to complete 2 physical activity surveys to provide us with information 
about your level of activity during the time that you are recording information for your food 
diary. This will allow us to understand the amount of energy you use compared to the 
amount of food energy you take in. Please do not alter your activity during this period of 
time. After you have completed the document, you will be asked to bring it with you to your 
next scheduled visit at the University of Waterloo. 
 
Blood Tests and Oral Glucose Tolerance Test (about 3 hours 30 minutes): 
 
You will be asked to arrive at the Well-Fit Centre after an overnight fast (about 8 hours 
without food or drink except water). We encourage you to drink water the morning of these 
tests. You may take your medications the morning of the tests but please inform us of the 
medications that you are taking. You will have your finger pricked to attain a small amount of 
blood (a couple of drops) for a quick measure of your blood glucose. If your fasting blood 
glucose is above 7.0mM, we will not be able to carry out the study and we will also notify your 
physician of this result. If your fasting blood glucose is above 6.0mM, but less than 7.0mM, 
you will still be able to participate in the study, but we will make your doctor aware of your 
results. After the finger prick, a catheter attached to saline will be inserted by someone who is 
certified to draw blood for a series of blood samples. The catheter will be inserted into a 
suitable vein in the forearm. A blood sample (~20 mL which is about 1.5 tablespoons) will be 
taken for the analysis of several different compounds that are not routinely measured at the 
cancer clinic. The sample will provide us with information about how your metabolism is 
changing during treatment. After this initial blood sample, a second sample will be taken 30 
minutes later (about 5 mL or 1 teaspoon) and this will be the baseline for the oral glucose 
tolerance test. An oral glucose tolerance test will allow us to determine how sensitive your 
body is to sugar. You will then ingest a drink (orange- flavoured) that contains 75g of sugar. 
For this test, a blood sample of about 5 mL  
(1 teaspoon) will be taken at 8 additional time points over a 3 hour period. The insertion of a 
catheter may, on occasion, result in some bruising or discomfort at the site of insertion. 
 
Snack Break (15 minutes): 
 
A small snack will be provided to you after you have completed the blood tests and prior to 
the exercise tests. One of our personnel will meet with you to review your food diary. When a 
food diary is completed in detail, valuable information is obtained and appropriate 
recommendations for changes in your diet can be made. 
 
Incremental Exercise Test (20 minutes): 
 
The risks of doing incremental exercise to your functional limit are very similar to the risks of 
doing heavy voluntary exercise. There is a very slight chance that an apparently healthy 
individual will have a cardiovascular complication that has not been previously detected 





Heart Rate – Heart rate will be continuously monitored by an electrocardiograph (ECG) by 
placing 3 spot electrodes on the skin surface. The electrodes are normally placed in the lower 
portion of the chest. This procedure is entirely safe. In a very small group of individuals, a 
skin rash might occur due to the adhesive on the electrodes. There is no way of knowing this 
ahead of time. The rash, if it develops, will resolve itself within a day or so. However, you are 
asked to avoid scratching any rash and to keep it clean. 
 
Oxygen Uptake – We measure the amount of oxygen you take from the air you are breathing 
by having you breathe through a face mask. Attached to the face mask will be a sensor to 
determine the volume of air that moves into and out of your lungs, and a sample line that 
takes a small quantity of the air to a gas analyzer system. The facemask and the volume 
measurement device are sterilized before each person’s use to eliminate any risk of spread of 
infection. If you are allergic to rubbing alcohol, then you should not participate in this study. 
 
Incremental Exercise – This test will begin with a four-minute warm-up period in which you 
will pedal against a very low resistance. The work rate will then increase progressively but 
you will not be asked to reach your maximal effort.  
Instead, 2-3 submaximal efforts will be recorded. The total test duration will be approximately 
10-15 minutes. For participants who will be in the exercise training program, this test will 
allow us to design an exercise program and to evaluate your progress over 16 weeks. 
 
Incremental exercise does have some risk. We will not include individuals who have high 
blood pressure (resting diastolic pressure over 90 mmHg during a measurement in our 
lab) or who have been told by their doctor that they have some form of cardiovascular 
disease. It is impossible to predict whether apparently healthy individuals might have 
some previously undetected cardiovascular disease that might cause a heart attack or 
arrhythmia (irregular heart beat) during strenuous exercise. The Well-Fit  Centre is 
equipped with an Automated External Defibrillator on site. In the case of a medical emergency, 
all researchers and Well-Fit Centre staff have First Aid training. 
 
The sensation of fatigue that you experience during incremental exercise will probably be 
similar to that experienced previously during some voluntary activities. The sensation of 
fatigue should quickly disappear after the test. 
 
Stopping the Exercise Session: 
 
If you experience any sensation that appears to be unusual to you (i.e. not what you would 
expect during voluntary maximal exertion), then you can stop the exercise and inform the 
researchers of this. 
 
Strength Test (about 25 minutes): 
 
This test will begin after your muscles have warmed up following your incremental exercise 
test. We will test the muscles of your upper-body and lower- body for their maximal strength. 
You will be shown how to perform each exercise safely. You will start with a relatively low 
weight that you can easily and safely lift one time (based on your reported activity levels). You 




time, correctly and safely. You may experience some soreness and fatigue in the muscles that 
were tested, but this will disappear within a couple of days after the test. This information will 




When you see your doctor at the Grand River Hospital for your routine follow-up 
appointment while you are receiving chemotherapy, your doctor will ask you a series of 
questions and will also provide us with your blood analysis from your treatment evaluation. 
 
Explanation of Procedures and Risks for Participants in the Exercise Training 
Group 
 
Exercise Training (1 - 1 ½ hours per session; 3 sessions per week): 
 
The exercise training program will take place 3 times / week and will consist of 30 minutes of 
cardiovascular exercise (either bike or treadmill depending on your preference) at 60% of your 
maximal performance. The rest of the exercise session will consist of lifting weights at 60% of 
your maximal strength (3 sets of  
10 repetitions for each exercise with 1-2 minute break between sets). If you experience any 
sensation that appears to be unusual to you, then you can stop the exercise and inform the 
researchers of this. You may feel some soreness in your muscles for the first week of this 
exercise program, but this will be less or may disappear entirely after the first 2 weeks of 
the program. 
 
Heart rate will be monitored by chest band heart rate monitor for the duration of the exercise 
training protocol. The band is placed in the lower portion of the chest. This procedure is 
entirely safe. The band is sterilized between uses. In the case of a medical emergency, all 
researchers and Well-Fit Centre staff have First Aid training. 
 
Personal Benefits of Participation: 
 
Participation in this study may or may not be of personal benefit to you. Exercise has been 
shown to reduce fatigue while receiving chemotherapy. Based on the evaluations done in this 
study, we will provide you with personalized nutritional information that may or may not be 
helpful in managing your dietary intake and weight. However, based on the results of this 




• Participants are asked to refrain from drinking alcohol in the 24-hour period 
immediately prior to scheduled evaluations at Weeks 0, 8 and 16.  
• For the blood test and oral glucose tolerance test, please arrive following an overnight 
fast (about 8 hours without food or drink except water). We encourage you to drink 
water the morning of these tests. You may take your medications the morning of the 




• The 3-Day Food Diary should include 2 weekdays and 1 weekend day.   
Please record everything you eat and drink as precisely as possible.   
• The Physical Activity Surveys should be completed during the time that you 
complete your 3-Day Food Diary.   
• Regardless of which group you are in (exercise or non-exercise group), for your 
evaluations at Weeks 0, 8 and 16, please wear comfortable pants/shorts, a short sleeve 
shirt and running shoes. If you are part of the exercise training group, you will also be 
asked to wear comfortable pants/shorts, a short sleeve shirt and running shoes for each 
of your training sessions.  
 
Medical Screening Form: 
 
This questionnaire asks some questions about your health status. This information is used to 
guide us with your entry into the study. Contraindications to participation in this study include 
any injury that makes exercise uncomfortable,  any kidney problems, known diabetes, or any 
cardiovascular diseases including bleeding disorders, or any respiratory diseases. 
 
Participation in the study: 
 
You may choose not to participate in this study. Choosing not to participate in this study 
will not compromise the medical care that you receive from your doctor. 
 
You may withdraw from this study at any time without penalty. You may be asked why you 
have chosen to withdraw so that the researchers have an understanding of how to improve 
enrolment in this study. To withdraw from the study, indicate this to the researcher or one of 
the research assistants by saying, "I no longer wish to participate in this study". Withdrawing 
from the study will not compromise the medical care that you receive from your doctor. 
 
Confidentiality and Security of Data: 
 
Identifying health information will be collected during this study. Information from your 
medical records including: date of birth, cancer diagnosis, current medications, treatments and 
blood analysis done as part of your routine medical care for the duration of this study. This 
information may be used by the researchers who are carrying out this study, and may be 
disclosed to others as described below. 
 
Direct access to your identifiable health information collected for this study will be restricted 
to the researchers who are directly involved in this study except in the following 
circumstances. 
 
Your identifiable health information may need to be inspected from time to time for quality 
assurance (to make sure the information being used in the study is accurate) and for data 
analysis (to do statistical analysis that will not identify you). The following organizations 
may do this inspection:  
• Tri-Hospital Research Ethics Board   




     To ensure the confidentiality of individuals’ data, each participant will be identified by a 
participant identification code known only to the principal investigator and her research 
assistants. If we identify abnormal results from your blood glucose and lipid tests, we will 
contact your doctor to make him or her aware of these results. Any publications or reports that 
result from this study will be presented as group data. In the case where individual data is 
presented and data that is analyzed by students, your information will not be identifiable. Your 
information will be stored in Dr. Marina Mourtzakis’ locked office (BMH building at the 
University of Waterloo) and secure computer. The information will be stored for an indefinite 
time but the links that identify you will be destroyed after 10 years. 
     Although absolute confidentiality can never be guaranteed, we will make every effort to 
keep your identifiable health information confidential, and to follow the ethical and legal 
rules about collecting, using and disclosing this information. 
     As a participant of this study, you have the right to ask the researchers about the data being 
collected about you for the study and the purpose of this data. You also have the right to ask 
the study doctor to let you see your personal information and to make any necessary 




After the study is completed, you will be provided with a feedback sheet that will include a 
summary of your dietary intake and exercise results. We will discuss your nutrition and 
exercise results and provide recommendations for your nutritional and activity needs. 
 
Remuneration: 
Your participation in this study is greatly appreciated and while monetary 
remuneration will not be provided, we will cover: 
 
• the cost of parking for your scheduled visits to the University of Waterloo,   
• the cost of a nutrition and exercise consult  
 
For patients who were in the non-exercising group, they will be offered a similar exercise 
program when the study is completed. This program will be 12 weeks long and suited to the 
activities that the patients enjoy at the Well-Fit Centre. 
 
Contact Information: 
If you have any questions about the study at any time, please contact Dr. Marina Mourtzakis at 
her office 519-888-4567 ext. 38459. 
 
Concerns about Your Participation: 
 
I would like to assure you that this study has been reviewed and received ethics clearance 
through the Office of Research Ethics at the University of Waterloo and the Tri-Hospital 
Research Ethics Board. Please be aware that you may contact the Director, Office of Research 
Ethics at the University of Waterloo, Dr. Susan Sykes at 519-888-4567 ext. 36005 or the Chair 
of the Tri-Hospital Research Ethics Board, Dr. Michael Coughlin at 519-749-4300 ext. 5367. 



















































Appendix B - Chemotherapy Protocols for Early Stage Breast Cancer 
 
Classification of Chemotherapy Drugs Used to Treat Breast Cancer 
 
Class                              Mode of Action                                              Examples 
Alkylating Agents 
 
damages the proteins that control growth 
in the genes of the tumor cell 
cyclophosphamide 
Antimetabolites acts as false building blocks in the genes of 
cancer cells, causing cell death as it 
prepares to divide 
5-florouracil 
gemcitabine 
Anthracyclines inhibits gene replication doxorubicin, epirubicin 
Antimiotic Agents prevents genes from reproducing 
themselves during cell division 
vincristine, vinorelbine 




Common Chemotherapy Combinations Used to Treat Breast Cancer 
 
AC – doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan, Procytox) 
• usually given every 21 days for 4 cycles 
• treatment lasts ~3-4 months 
 
AC + T – doxorubicin, cyclophosphamide + paclitaxel (Taxol) or docetaxel (Taxotere) 
• usually given every 21 days – 4 cycles of AC, followed by 4 cycles of paclitaxel or in the case 
of docetaxel, every 21 days for 6 cycles  
• Note: AC with docetaxel often requires colony-stimulating factor drugs (i.e. filgrastim 
(Neupogen) treatment lasts ~ 4-6 months  
 
FAC (or CAF) – cyclophosphamide (orally or IV), doxorubicin and 5-florouracil (5-FU, Adrucil) 
• usually given every 21 days for 6 cycles 
• treatment lasts ~4-6 months 
• Note: when cyclophsophamide is given orally, FAC is usually given every 28 days for 6 cycles 
 
CEF – cyclophosphamide (orally), epirubicin (Ellence) and 5-florouracil 
• usually given every 28 days for 6 cycles 
• treatment lasts ~ 4-6 months 
 
FEC - 5-florouracil, epirubicin and cyclophosphamide (IV) 
• usually given every 21 days for 6 cycles 
• treatment lasts ~ 4-6 months 
 
CMF – cycophosphamide (orally or IV), methotrexate and 5-fluorouracil  
• usually given every 28 days for 6 cycles 
• treatment last ~ 6 months 
• Note: this protocol is now used rarely 
 
In some cases, single drugs including vinorelbine (Navelbine), capecitabine (Zeloda), paclitaxel 
(Taxol), docetaxel (Taxotere) or gemcitabine (Gemzar) are used to treat metastatic or recurrent disease  
 









RESEARCH IN NUTRITION  
AMONG WOMEN WITH BREAST CANCER 
 
ARE YOU A BREAST CANCER SURVIVOR? 
 
Have you completed CHEMOTHERAPY 
TREATMENTS within the LAST 12 MONTHS? 
 
 As a participant in this study, you would be asked to: 
 
• Participate in an individual interview (approximately 60-80 minutes) to discuss 
the unique challenges associated with chemotherapy treatment in relation to 
food intake and weight management.  
 
• Complete 2 questionnaires related to ongoing side effects of treatment.  
 
• Record your food intake for 3 days. 
 
 
Participants will receive a personal nutritional assessment,  $30.00 honorarium 
and a breast cancer bracelet in appreciation for your time 
 
For more information or to volunteer for this study, please contact: 
 
Vivienne Vance, R.N., MSc, PhD (Candidate) 
 Department of Health Studies & Gerontology 
University of Waterloo 
Telephone: (519) 654-2538 
Email: vavance@uwaterloo.ca 
 
This study has been reviewed and received clearance through the 















































Appendix F– Information Letter  
                                                                                      
 
 
Relationships among Psychosocial Factors, Treatment-Related Side Effects,  
Dietary Intake and Weight Gain in Women Treated with Adjuvant Chemotherapy for 
Early Stage Breast Cancer 
 
Principal Investigator:    Dr. Rhona Hanning 
                                           Department of Health Studies and Gerontology, University of 
Waterloo  
                                           (519) 888-4567, ext 35685 - rhanning@uwaterloo.ca   
                                            
Co-Investigators:             Dr. Marina Mourtzakis, University of Waterloo 
                                           Dr. Sharon Campbell, University of Waterloo 
                                           Dr. Linda McCargar, University of Alberta 
 
Student Investigator:      Vivienne Vance, MSc., PhD (Candidate) 
                                           Department of Health Studies and Gerontology, University of 
Waterloo 
                                           (519) 654-2538 - vavance@uwaterloo.ca  
 
Purpose of Study: 
 
   Weight gain is a common problem for many breast cancer survivors during treatment and in 
the months and years after diagnosis. Weight gain is distressing for most women and may lead 
to an increased risk of heart disease, diabetes and disease recurrence. Although it appears that 
many women experience changes in diet during and after treatment, we do not know if these 
changes play a role in weight gain after diagnosis. We are very interested in gaining a better 
understanding of the unique challenges associated with chemotherapy in relation to nutrition 
and weight management in breast cancer survivors.   
   You have been asked to participate in a research study designed to investigate changes in 
your food intake and eating patterns during and after treatment and to identify factors that may 
have influenced these changes. We will be interviewing approximately 30 breast cancer 
survivors within 12 months of completing chemotherapy treatment, including those who have 
gained weight and those who have not gained weight, since diagnosis. The information from 
this study will help us to develop nutrition guidelines and programs to support healthy eating 
and weight management during and after treatment.   
 
Procedures Involved in this Study: 
 
   If you participate in this study, you will be scheduled for a 60-80 minute individual interview 




Waterloo, based on your personal preference. In this interview, you will be asked to discuss 
your experience of chemotherapy, in terms of food intake and eating patterns and to identify 
factors which may have influenced changes in your diet during treatment. You will also be 
asked to complete two brief questionnaires related to quality of life and ongoing side effects of 
treatment. The first questionnaire will ask you to indicate the extent to which you have been 
bothered by 30 common physical and emotional symptoms in the past week. For example: 
“Have you been bothered in the past week by lack of appetite, nausea, difficulty sleeping, 
irritability, anxiety - not at all, a little, quite a bit or very much”. The second questionnaire will 
ask you to rate the intensity and duration of fatigue and how much fatigue has interfered with 
your daily activities, during the previous week. In addition, you will be asked to identify any 
changes in diet that you have made since the completion of treatment and to discuss changes in 
physical activity and any concerns you have regarding weight management since diagnosis. A 
brief background questionnaire will collect information on age, marital status, education and 
employment, as well as medical (date & age at diagnosis), treatment (surgery, chemotherapy, 
radiation, other medications) and weight history (weight change since diagnosis). Current 
weight will be measured at the time of interview. You may choose to not answer any interview 
question or questionnaire item, at your discretion.   
   At the completion of the interview you will be provided with a diet record and asked to 
record everything you eat and drink for a period of 3 days (2 weekdays, 1 weekend day). The 
purpose of the diet record is to examine the quality and quantity of nutrients in your current 
diet. Each day of recording is expected to take about 30 minutes in total. Detailed written 
instructions and a “sample day” will be provided. It is important that you do not alter your diet 
during the recording period – simply eat as you would normally eat. Arrangements will be 
made for your completed diet record to be picked up at your home, within one week. During 
the time that you are recording your food intake, we will contact you by telephone to see if you 
have any questions or concerns.  
 
Follow-Up Contact:  
 
   Once your personal information is analyzed, we may re-contact you to clarify any 
information and ensure that our interpretation of your interview responses accurately reflects 
your experience. You may choose at that time to participate or not participate in further 
discussion. 
 
Explanation of Benefits and Risks: 
 
   Participation in this study may or may not be of personal benefit to you. During the 
interview, you will have opportunity to discuss any concerns you have about your current diet 
and exercise patterns and written resources on healthy eating and exercise will be provided, at 
your request. Based on your 3-day food record, we will provide you with a personalized 
nutrition assessment and a summary of the research findings at the end of the study, which may 
be helpful in managing a healthy diet and a healthy body weight. It is hoped that the findings 
from this study will improve patient care in the future. We do not anticipate any risks 






Confidentiality and Security of Data: 
   
   Personal health information will be collected during this study. Direct access to this 
information will be restricted to the researchers who are directly involved in the study. To 
ensure the confidentiality of personal data, each participant will be identified by a participant 
identification code, known only to the listed investigators. Any publications or reports that 
result from this study will be presented as group data and your personal information will not be 
identifiable. Your information will be stored in a locked cabinet and secure computer. The 
information will be stored for an indefinite time but the links that identify you will be 
destroyed after 10 years. As a participant in this study, you have the right to ask the researchers 
about the data being collected about you for the study and the purpose of this data. You also 
have the right to ask the student investigator to see your personal information and to make any 
necessary corrections to it. 
 
Withdrawal from the Study: 
 
   You may withdraw from this study at any time without penalty. You may be asked why you 
have chosen to withdraw so that the researchers have an understanding of how to improve 
enrolment in this study. To withdraw from the study, please indicate this to the researcher by 




   At the completion of the study, you will be provided with a personalized nutritional 
assessment, based on your 3-day food record, and a summary of the research findings.  
   
Remuneration: 
 
   All participants in this study will receive a small honorarium of $30 and a breast cancer 
bracelet, as a token of appreciation. The cost of parking ($4) will be covered, for those opting 




   If you have any questions or concerns about the study at any time, please contact: 
• Vivienne Vance (519) 654-2538 - vavance@uwaterloo.ca or 
• Dr. Rhona Hanning (519) 888-4567 ext. 35685 - rhanning@uwaterloo.ca 
 
Ethics Review:  
 
   This study has been reviewed and received ethics clearance through the Office of Research 
Ethics at the University of Waterloo. Please be aware that you may also contact the Director, 
Office of Research Ethics, University of Waterloo Dr. Susan Sykes (519) 888-4567 ext. 36005 










I agree to participate in a research study being conducted by Vivienne Vance, PhD 
(Candidate) under the direction and supervision of Dr. Rhona Hanning, Dr. Marina 
Mourtzakis and Dr. Sharon Campbell of the University of Waterloo and Dr. Linda McCargar 






I have made this decision based on the information I have read in the information letter.   
All of the procedures and any risks and benefits have been explained to me. I have had the 
opportunity to ask any questions related to this study, to receive satisfactory answers to my 
questions, and any additional details I wanted. I am aware that I may withdraw from the 
study or decline answering any interview question or questionnaire item without penalty at 
any time by advising the researcher of this decision. 
 
This project has been reviewed and received ethics clearance by the Office of Research 
Ethics at the University of Waterloo. I am aware that I may contact the Director, Office of 
Research Ethics at the University of Waterloo, Dr. Susan Sykes at 519-888-4567, ext. 36005  
or  Dr. Rhona Hanning of the Department of Health Studies and Gerontology 
(519-888-4567, ext 35685) if I have any questions or concerns resulting from my 
involvement in this study. 
 
 
Printed Name of Participant           Signature of Participant                   Date 
 
_______________________     ___________________________      ____________________ 
 
 
Printed Name of Witness              Signature of Witness                         Date 
 
______________________       ___________________________      ____________________ 
 
 
Printed Name of Investigator      Signature of Investigator                    Date 
 


































































Appendix L – 3-Day Food Record  
3-DAY FOOD DIARY 
 
Participant #:____________________________  
 
Phone Number: _______________________ 
 
Record Dates: ___________ (DD/MM/YY) 
  ___________ (DD/MM/YY) 
  ___________ (DD/MM/YY) 
 
Your Most Recent Treatment Date: ___________ (DD/MM/YY) 
 
 
University of Waterloo 













FOOD AND BEVERAGE ITEMS DESCRIPTION OF ITEM UNIT OF MEASURE NO. OF 
UNITS 
Enter all foods and beverages consumed.  For 
combination foods, please include detailed 
information on each item. 
Include a detailed description of each food and drink item 
consumed including: 
- Brand name 
- Flavour 
- Method of cooking 
- All other relevant information on food/drink label 
(e.g. fortified, low fat, 1%, 2% milk fat, 100% juice) 
Enter unit of measure: 
for example: cup, 





Spaghetti with tomato/meat sauce:    
Pasta Spaghetti, cooked Cup 2 
Tomato sauce Hunt’s canned sauce, roasted garlic flavor Cup 1 
Meat balls  Made with extra lean ground beef Number (1 oz/ball) 5 
Parmesan cheese, grated Kraft, 30% Milk Fat (M.F.) Tablespoon 1 
Garlic Bread:    
Italian Bread Toasted Piece (large slice) 3 
Garlic Butter  Teaspoon 3 
Caesar salad:    
Lettuce Romaine Cup 1 
Croutons Safeway brand, garlic flavor Tablespoon 2 
Bacon bits Simulated flavour, No Name Brand Tablespoon 2 
Caesar salad dressing Kraft, Fat free Tablespoon 2 
Milk 1% Cup 1 
Tiramisu Sarah Lee  Slice 1 
Coffee Black Cup 1 
Fill in blanks: Time of meal/snack: 6:00 pm Location meal/snack was consumed:  at 
home________________                    




Day 1 – Morning Meal 
FOOD AND BEVERAGE ITEMS 
 
DESCRIPTION OF ITEM UNIT OF MEASURE NO. OF 
UNITS 
Enter all foods and beverages consumed.  For 
combination foods, please include detailed 
information on each item. 
 
Include a detailed description of each food and drink item 
consumed including: 
- Brand name 
- Flavour 
- Method of cooking 
- All other relevant information on food/drink label 
(e.g. fortified, low fat, 1%, 2% milk fat, 100% juice) 
Enter unit of measure: 
for example: cup, 





    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Fill in blanks: Time of meal/snack:____ Location meal/snack was consumed:  ___________________________                    





Day 1 – Mid-Morning Snack 
FOOD AND BEVERAGE ITEMS 
 
DESCRIPTION OF ITEM UNIT OF MEASURE NO. OF 
UNITS 
Enter all foods and beverages consumed.  For 
combination foods, please include detailed 
information on each item. 
 
Include a detailed description of each food and drink item 
consumed including: 
- Brand name 
- Flavour 
- Method of cooking 
- All other relevant information on food/drink label 
(e.g. fortified, low fat, 1%, 2% milk fat, 100% juice) 
Enter unit of measure: 
for example: cup, 





    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Fill in blanks: Time of meal/snack:____ Location meal/snack was consumed:  ___________________________                    





Day 1 – Mid-day Meal (lunch) 
FOOD AND BEVERAGE ITEMS 
 
DESCRIPTION OF ITEM UNIT OF MEASURE NO. OF 
UNITS 
Enter all foods and beverages consumed.  For 
combination foods, please include detailed 
information on each item. 
 
Include a detailed description of each food and drink item 
consumed including: 
- Brand name 
- Flavour 
- Method of cooking 
- All other relevant information on food/drink label 
(e.g. fortified, low fat, 1%, 2% milk fat, 100% juice) 
Enter unit of measure: 
for example: cup, 





    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Fill in blanks: Time of meal/snack:____ Location meal/snack was consumed:  ___________________________                    





Day 1 – Mid-Afternoon Snack 
FOOD AND BEVERAGE ITEMS 
 
DESCRIPTION OF ITEM UNIT OF MEASURE NO. OF 
UNITS 
Enter all foods and beverages consumed.  For 
combination foods, please include detailed 
information on each item. 
 
Include a detailed description of each food and drink item 
consumed including: 
- Brand name 
- Flavour 
- Method of cooking 
- All other relevant information on food/drink label 
(e.g. fortified, low fat, 1%, 2% milk fat, 100% juice) 
Enter unit of measure: 
for example: cup, 





    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Fill in blanks: Time of meal/snack:____ Location meal/snack was consumed:  ___________________________                    





Day 1 – Evening Meal 
FOOD AND BEVERAGE ITEMS 
 
DESCRIPTION OF ITEM UNIT OF MEASURE NO. OF 
UNITS 
Enter all foods and beverages consumed.  For 
combination foods, please include detailed 
information on each item. 
 
Include a detailed description of each food and drink item 
consumed including: 
- Brand name 
- Flavour 
- Method of cooking 
- All other relevant information on food/drink label 
(e.g. fortified, low fat, 1%, 2% milk fat, 100% juice) 
Enter unit of measure: 
for example: cup, 





    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Fill in blanks: Time of meal/snack:____ Location meal/snack was consumed:  ___________________________                    





Day 1 – Evening Snack  
FOOD AND BEVERAGE ITEMS 
 
DESCRIPTION OF ITEM UNIT OF MEASURE NO. OF 
UNITS 
Enter all foods and beverages consumed.  For 
combination foods, please include detailed 
information on each item. 
 
Include a detailed description of each food and drink item 
consumed including: 
- Brand name 
- Flavour 
- Method of cooking 
- All other relevant information on food/drink label 
(e.g. fortified, low fat, 1%, 2% milk fat, 100% juice) 
Enter unit of measure: 
for example: cup, 





    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Fill in blanks: Time of meal/snack:____ Location meal/snack was consumed:  ___________________________                    





Day 1 Meals 
 
 
NOTE: Compared to my “normal” diet refers to how you have been eating over the last couple of weeks.  

















PILLS PER DAY 
DAYS PILLS WERE TAKEN 
(EXAMPLE: DAY 1, 2 OR 3) 
    
    
    
    
    
    
    
    
    
    
    
    
    
































Dear                  , 
   Thank you for participating in our study, designed to investigate the unique challenges 
associated with chemotherapy in relation to nutrition and weight management in breast cancer 
survivors. This study will help us to develop nutrition guidelines and programs to support 
healthy eating and weight management during and after treatment. It is hoped that the findings 
from this study will improve patient care in the future. 
    
   I am attaching a summary and personal nutritional assessment based on your 3-day food 
record. We have identified areas of nutrition in which you are doing well and pointed out some 
areas that could be improved. We hope this information will be helpful in planning a healthy 
diet. Some additional resources are provided at the end of your personal assessment. If you 
have any questions or concerns, please feel free to contact me using the email or telephone 
number listed at the bottom of the page. The full study is expected to be completed by 
December 2011, at which time I will be pleased to send you a summary of the research 
findings.   
    
   Please be assured that your results are identified by a specific code, known only to the 
investigators and will be kept confidential. Direct access to this information will be restricted 
to the researchers who are directly involved in the study. Any publications or reports that result 
from this study will be presented as group data and your personal information will not be 
identifiable.  
    
   As with all University of Waterloo projects involving human participants, this project was 
reviewed by and received ethics clearance through the Office of Research Ethics at the 
University of Waterloo.  Should you have any comments or concerns resulting from your 
participation in this study, please contact Dr. Susan Sykes in the Office of Research Ethics at 
519-888-4567, Ext., 36005 or ssykes@uwaterloo.ca. 
 






Department of Health Studies and Gerontology, University of Waterloo 





Appendix O – Personal Nutritional Assessment 
 
PERSONAL NUTRITIONAL ASSESSMENT 
 
Name:                                                                   Date:                                        
 
Height:       
 
Weight:        
 
Weight Change:  
 
Body Mass Index (BMI):  
 
Body mass index is a basic measure of body size based on your height and weight. 
The normal range for BMI is between 18.5 and 24.9.  
 
Current BMI:     
 
BMI Status:  
 
Nutrition Summary 
Estimated Daily Calorie Requirement:  
 
Actual Daily Caloric Intake (based on your 3-day food record):  
Daily Caloric Intake Status:  
 
 
Estimated Daily Protein Requirement: 0.8 g/kg (~   /day), 10-35% of total calories 
 
Actual Daily Protein Intake (based on your 3-day food record):  
Grams:  
% of total calories:  
 
Your current intake…..  
 
Protein is a source of calories that is important for cell growth, repair, and maintaining a 
healthy immune system. Ensuring adequate protein intake will help to protect against loss of 
lean tissue after treatment. Try to include a little protein at each meal/snack (low fat milk, 
cheese or yogurt, eggs, lean meats, fish, poultry, legumes, tofu, nuts & seeds). Protein also 
helps to create and maintain a feeling of “fullness” and stabilizes blood sugar for longer 




Estimated Daily Carbohydrate Requirement:  minimum of 130 g/day, 45-65% of total 
calories 
 
Actual Daily Carbohydrate Intake (based on your 3-day food record):  
 
Grams:  
% total calories:  
 
Your current intake ….. 
 
Dietary carbohydrates provide the body with energy and in their less processed forms, come 
packed with important nutrients including fibre, vitamins and minerals.   
 
A carbohydrate rich diet includes plenty of whole grains, fruits, vegetables, legumes and low 
fat dairy. Eating Well with Canada’s Food Guide provides an excellent resource for serving 
sizes and healthy ways to incorporate these food groups into your daily diet.   
 
Estimated Daily Fat Requirement:  total fat: 20-35% of total calories, saturated fats < 10% 
 
Actual Daily Fat Intake (based on your 3-day food record):  
 
Total fat:  
Saturated fat:  
 
Your current intake of total fat and saturated fat…..   
 
Some fat in the diet is critical for good health. Dietary fats provide the body with energy, 
insulation and protection for vital organs. Fat is also needed for the absorption and use of fat-
soluble vitamins, structure of cell membranes and to make several important body compounds.  
 
Current guidelines suggest that we should increase our intake of heart healthy fats (vegetable 
oils, fatty fish, nuts & seeds) and limit our intake of saturated fats (red meats, whole milk, 
cream, butter, cheese, coconut and palm oils) and trans fats (processed and deep-fried foods, 
cakes, cookies, pastries, imitation cheese, some margarines)  
 




























Reminder: a balanced diet means eating a variety of foods from each of the four food groups 
every day and enjoying “extras” or other foods in moderation. Be sure to adjust your total 
calorie intake according to your activity level for the day. e.g.) eat a little lighter on days when 





Guelph and Wellington Breast Cancer Support Group 
http://communitylinks.cioc.ca/record/GCL0512 
 
Canadian Breast Cancer Network www.cbcn.ca 
 
Canadian Breast Cancer Foundation www.cbcf.org 
 
BC Cancer Agency: A Nutrition Guide for Women with Breast Cancer 
http://www.bccancer.bc.ca/PPI/TypesofCancer/Breast/breastcakit.htm 
 
Nutrition and Breast Cancer: What You Need to Know (2007).  Canadian Cancer Society 
www.cancer.ca 
 
Good Nutrition: A Guide for People with Cancer (2007).  Canadian Cancer Society 
 



















Dear “name of participant”, 
 
   Thank you once again for participating in our study on nutrition, weight change and chemotherapy in 
breast cancer survivors. All of the data for this study have now been collected and analyzed. Below is a 
summary of the research findings: 
 
1. A total of 28 women participated in this study. Weight change during chemotherapy was highly 
variable ranging from a loss of ~12 kg (27lbs) to a gain of ~9 kg (20 lbs).  
2. Food intake was highly responsive to the day of treatment, with most women reporting lower 
food intake and irregular eating patterns for the first few days after chemotherapy.  
3. Participants who lost weight tended to report more severe and persistent side effects of 
treatment, leading to a more prolonged reduction of food intake after each cycle.  
4. Increased appetite, food cravings and intake of calorie dense comfort foods seemed to be more 
common among women who gained weight during treatment. These dietary changes were 
associated with changes in taste, nausea and emotional distress. 
5. Most women reported a reduction in physical activity during treatment.  
6. Weight change after treatment was also quite variable (range = -6 kg to + 5 kg). 
7. Most women (84%) reported changes in diet after diagnosis. Most changes were positive (e.g. ↑ 
veggies/fruit) and consistent with current recommendations for cancer prevention.  
8. Despite these changes, some women were still above the guidelines for total fat and saturated 
fat and many were below recommendations for vegetables/fruit and milk/alternatives. Many 
women were not receiving adequate calcium and vitamin D from foods alone, however intakes 
were improved considerably through the use of supplemental sources of these nutrients.  
9. Based on survey responses, symptoms of physical and psychological distress after treatment 
(including fatigue) were highly variable across women, however “on average” scores were 
similar to previous reports of women in active treatment and higher than women who have not 
been treated for breast cancer.  
10. These findings suggest that changes in food intake and eating patterns may play an important 
role in weight change after a breast cancer diagnosis.  
11. Comprehensive interviews with breast cancer survivors provided a unique perspective on food 
intake and weight change during treatment, helping to advance our understanding of dietary 
challenges that women face as they are undergoing treatment.  
12. A key lesson drawn from your personal stories is an appreciation for the fact that each woman’s 
experience with chemotherapy is different. This finding, combined with data on dietary habits 
of women after breast cancer and evidence of persistent treatment effects in the first year after 
completing chemotherapy, will help to guide future research and to design effective healthy 
eating and weight management programs.   
 
We sincerely appreciate your contribution to this research and hope that it was an interesting experience 
for you. Please feel free to contact me if you have any questions or concerns, using the email or 





School of Public Health and Health Systems, University of Waterloo 




Appendix Q – Weight Gain in Breast Cancer Survivors 
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